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CHAPTER 1
Introduction
Essential fatty acids
More than sixty years ago, Burr and Burr (I ) described that rats, who had received a
fat-free diet for several months, developed symptoms like growth retardation, scaly
dermatitis, increased trans-epidermal loss of water and reproductive failure.
Supplementation with small amounts of polyunsaturated fatty acids of the (n-6) and
(n-3) family improved the deficiency symptoms (1,2). This study demonstrated that
these so-called essential fatty acids (EFAs) are not only a source of energy but have
other essential functions as well.
Since men, in contrast to plants, lack A-12- and A-15-desaturase, they cannot
synthesize the fatty acids linoleic acid (18:2(n-6)O , LA) and a-linolenic acid
(18:3(n-3), LnA) <fe novo. Therefore, LA and LnA must be derived from the diet (3).
Once in the body, these parent EFAs can be desaturated and elongated to longer chain,
more unsaturated derived EFAs of the (n-6) and (n-3) family, respectively (see figure
1 ). For the synthesis of long chain polyenes (polyunsaturated fatty acid with 20 or
more carbon atoms and at least one more double bond than their parent essential fatty
acid, LCPs), the activity of A-6-desaturase is rate limiting. The substrate affinity of
this enzyme is in the order 18:3(n-3)>18:2(n-6)>18:l(n-9). In addition, the activity of
A-6 desaturation is influenced by the concentration of the reaction substrate as well as
product. This latter also applies to the A-5-desaturase activity (4,5). In mammals, there
is no interconversion between the fatty acids of the different families.
Fatty acids of the (n-3) and (n-6) family are found especially in membrane
phospholipids, where they serve important functions. Linoleic acid is essential in
maintaining the epidermal water barrier (6,7). In addition, LA is the precursor of
dihomo-y-linolenic acid (20:3(n-6), DHGL) and arachidonic acid (20:4(n-6), AA),
which are substrates for the production of the eicosanoids of the 1 - and 2-series,
respectively (8,9). AA is also an important structural fatty acid in the brain (10,11).
Evidence for a specific function for 18:3(n-3) other than being a precursor of (n-3)
long chain polyenes has not yet been reported (12). The most important fatty acids
derived from LnA are timnodonic acid (20:5(n-3), TA) and cervonic acid (22:6(n-3),
• " The nomenclature used for fatty acids is as follows: the number of carbon atoms, followed by a colon and
the number of double bonds: between brackets the fatty acid family is indicated by designation of the position
of the first double bond from the methyl end of the carbon chain.
CA)(2) . TA is the precursor of eicosanoids of the 3-serie (13). CA is found in very
high levels in neural and retinal cells (10,11,14), where it performs an array of
membrane associated functions.
Since essential fatty acids are important constituents of all cell membranes, they are of
specific significance during fetal life, when processes like brain development and
organogenesis are taking place in a limited time interval (15). Fatty acid analyses of
total lipids from fetal brain tissues showed that during the last trimester of pregnancy
the quantitative accretion of total (n-3) and (n-6) fatty acids increases progressively as
gestation progresses (16,17). For fetal liver tissue a lineair increase was observed (18).
These data indicate that the fetal demand for (n-3) and (n-6) fatty acids is high during
intra-uterine development.
If insufficient essential fatty acids (EFAs) are available to meet the EFA requirement,
the body starts to synthesize "surrogate" fatty acids. The presence of these fatty acids
thus indicates a shortage of EFAs. One of the best known essential fatty acid
deficiency markers is Mead acid (20:3(n-9), MA). This fatty acid is derived from oleic
acid (18: l(n-9), 01 A) and is synthesized when there are not enough EFAs to "occupy"
the A-6 desaturase (see also figure I ). Because an adequate supply of either LA, LnA
or their derived LCPs prevents synthesis of MA, the presence of MA indicates a
general shortage of all parent and derived essential fatty acids. The ratio
triene/tetraene (MA/AA) is often used as an essential fatty acid deficiency marker
(19).
Another essential fatty acid deficiency marker is Osmond acid (22:5(n-6), OA). If
there is an isolated shortage of cervonic acid, the production of OA increases, which
is the "surrogate" fatty acid for cervonic acid. Since the synthesis of OA also depends
on the availability of its precursor, adrenic acid (22:4(n-6), AdA), the ratio 22:5(n-
6)/22:4(n-6) (Cervonic acid deficiency index, CADI) is considered a reliable marker
of a cervonic acid deficiency (20).
The essential fatty acid status of pregnant women and their newborns
Differences in the concentration of plasma lipids between pregnant women and their
infants at birth were recognized as early as 1912 by Hermann and Newmann (21). It
was. however, not until the early sixties that differences in plasma levels between the
mother and her newborn infant for fatty acids were reported. The fatty acid
composition of the newborn was characterized by lower levels of linoleic acid
(18:2(n-6), LA) and a-linolenic acid (18:3(n-3). LnA) and higher levels of
arachidonic acid (20:4(n-6), AA) and cervonic acid (22:6(n-3), CA) (22-26).
Crawford et al (26) demonstrated with guinea pigs that in the phospholipids the
concentrations of LA and LnA diminished and those of their derived long chain
polyenes (LCPs) increased from the maternal liver, to placenta, fetal liver and finally
<*> In the literature, nmnodomc acid and cervonic acid are frequently referred to as eicosapentaenoic acid
(EPA) and docosahexacnoic acid (DHA). respectively.
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the brain. Observations in man suggested a similar trend: the proportion of LA and
LnA decreased and of the (n-6) and (n-3) LCPs increased in the phospholipids from
maternal blood, cord blood, fetal liver and fetal brain. The term "biomagnification"
(26) has been used to describe this increase in (n-6) and (n-3) LCPs. It is, however,
not exactly known in which way the fetus does obtain its essential fatty acids (12,27).
The fetus can derive them from the maternal circulation by passage across the
placenta, by metabolism within the placenta, or by synthesis in fetal liver. Because the
fetus cannot synthesize the parent EFAs ( LA and LnA), these fatty acids must be
derived from the maternal circulation. Since fatty acid synthesis in human placenta
and fetal tissue is probably rather low (28-31), it is likely that most of the fetal (n-6)
and (n-3) LCPs are derived from the maternal circulation by placental transfer.
Fatty acids are transported in blood either as free fatty acids, or in the form of
triglycérides, phospholipids or cholesterol-esters. The relative importance of each of
the potential sources to the total transfer of (n-6) and (n-3) fatty acids is not known
(for a review: see ref. 12). It has been shown that free fatty acids may cross the
placenta in either direction but that the movement of phospholipids and triglycérides
may be restricted or absent (12,27,29,32,33). This may be important in light of the
biomagnification process. One hypothesis to explain the concentration gradient of (n-
6) and (n-3) LCPs (biomagnification process) is that at the fetal side of the placenta
the (n-6) and (n-3) LCPs are compartmentalized in a lipid fraction which cannot
recross the placental barrier and will, therefore, be preserved to ensure an appropriate
fetal development (31,34,35).
Hornstra et al (36) determined the fatty acid composition of the walls of umbilical
vein and arteries. Since these blood vessels do not have vasa vasorum, they receive
their EFAs from the blood they contain and, consequently, the vascular wall fatty acid
composition may be considered a longer term reflection of the EFA status of the fetal
supply (vein) and return (arteries). Relatively high amounts of Mead acid (20:3(n-9),
MA) were observed in vessel wall phospholipids from cord arteries, in contrast to the
fatty acid composition of adult colonie arteries which did hardly contain MA. This led
to the suggestion that the EFA status of neonates may not be adequate. Moreover, the
ratio between 22:5(n-6) and 22:4(n-6) (CADI) was found to be much higher in
umbilical cord than in adult colonie vessel walls, suggesting a fetal shortage of
cervonic acid as well (36). These observations may imply that the essential fatty acid
requirement of the fetus is not adequately covered. Crawford et al (37,38) observed
the highest concentration of MA and 22:5(n-6)/22:4(n-6) ratio in the umbilical artery
of the lowest birht weight baby and suggested that there was more than a
physiological demand at stake. To further elucidate these findings, more information
has to be obtained on the maternal EFA status, because the developing fetus depends
on the mother for an adequate supply of EFAs.
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Outline of the thesis
The aim of this thesis is to investigate the EFA composition of the maternal diet and
the maternal EFA status in relation to the neonatal EFA status and the outcome of
pregnancy. First, the neonatal EFA status in relation to the maternal HFA status at
delivery was studied (Chapter 2). For the assessment of the EFA status, the fatly acid
composition of phospholipids (PLs) from plasma, blood cells, placental tissue and/or
umbilical cord vessel walls was determined. Since, in general, PLs have a slower
turnover than free fatty acids, triglycérides and cholesterolesters. the EFA profile of
PLs is considered suitable to document the overall EFA status of a given individual
(39,40).
In situations where the placenta function is impaired, the transfer of nutrients from
mother to fetus may be insufficient. To what extent the neonatal EFA status was
affected by such an event was studied in cases with pregnancy-induced hypertension
(P1H), which is, in a high percentage, characterized by a reduced uteroplaccntal
perfusion and function (41 ) (Chapter 3).
The results of these two initial studies led to the main study of this thesis, which is
described in the following Chapters.
Hardly any information is available on the maternal EFA status throughout normal
pregnancy. Rosing et al (42) described the fatty acid composition of serum lecithin
from twenty pregnant women in the second half of normal pregnancy. Although most
of the (n-6) and (n-3) fatty acids remained constant between 24 and 36 weeks of
pregnancy (linoleic acid showed a slight decrease till the end of gestation) it cannot be
excluded that in the first half of pregnancy major changes took place. Moreover, no
data were available on the nutrient intake of these women. As it has been shown that
fatty acid metabolism is under influence of dietary factors (4), changes in maternal
diet can have an effect on the fatty acid composition of serum lipids. Furthermore, it is
important to know how the plasma fatty acid levels of pregnant women are related to
their fatty acid intake during pregnancy. In Chapter 4 the EFA composition of the
maternal diet throughout normal pregnancy is described. Because the Netherlands
Nutrient Databank (43) provides only data on one essential fatty acid, linoleic acid,
the analyses are restricted to total fat, saturated fat, monounsaturaled fat,
polyunsaturated fat and linoleic acid. More detailed information on the course of the
maternal EFA status during normal pregnancy is reported in Chapter 5. In that study,
from 110 pregnant women a blood sample was taken regularly from the 10th week of
gestation until delivery. A subsample of 43 women gave also a blood sample
approximately six months after delivery. In addition, data on the neonatal EFA status
was collected. The results confirmed again the marginal EFA status of newborn
infants.
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As is shown in Chapter 3 and by others (44-46), PIH is associated with alterations in
the maternal EFA status. However, these studies share the disadvantage that they are
retrospective case-control studies with small number of subjects and using material
collected in late pregnancy or post-partum. As a consequence, no information is
available whether the alteration of the EFA status took place èe/ore or a/fer the
development of PIH. Therefore, a prospective longitudinal study was started to
investigate the relationship between the EFA status of mother and child and the
occurrence of PIH. The results of this study are given in Chapter 6.
To study if maternal supplementation during pregnancy with linoleic acid (18:2(n-6),
LA) could be useful in improving the fetal EFA status, pregnant women were
supplemented with approximately 10 gram LA per day from the 20th week of
gestation, until delivery. The results are described in Chapter 7 and compared with
two control groups, in which no intervention took place. One control group consisted
of pregnant women with habitual low plasma LA levels and the other of pregnant
women with habitual high plasma LA levels.
Finally, the overall conclusions and the implications for further research are discussed
in Chapter 8.
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CHAPTER 2
Biochemical EFA status of mothers and their
neonates after normal pregnancy
Monique DM. AI, Gerard Homstra.Yvonne T. van der Schouw, Marèse T.E.W.
Bulstra-Ramakers and Henk J. Huisjes
Human Deve/opmenf 7990; 24:239-246
ABSTRACT
The essential fatty acid (EFA) status of neonates was compared with that of their
mothers by determining the fatty acid compositions of phospholipids (PL), isolated
from umbilical arterial and venous tissue, blood cells (BC) and plasma, from maternal
venous plasma and BC, and from non-infarcted placenta! tissue.
The PL of umbilical arterial tissue (efferent fetal vessels) contained fewer fatty acids
of the (n-6) family and more of the (n-9) family than umbilical venous tissue (afferent
fetal vessel). The relative amounts of (n-6) and (n-3) fatty acids were less in arterial
than in venous plasma. Mead acid, 20:3(n-9), the presence of which indicates a poor
EFA status, was 5 times higher in the efferent than in afferent cord vessels. In
neonatal plasma and BC it was twice as high as compared with maternal levels. In
general, the fatty acid composition of the placenta PL showed a comparable pattern as
neonatal venous plasma PL.
These findings demonstrate that the biochemical EFA status of neonates after a
normal pregnancy is not optimal. The significant correlations between neonatal and
maternal EFAs indicate that the neonatal EFA status depends on the EFA content of
the maternal diet.
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INTRODUCTION *
During the last trimester of pregnancy, fetal demands for long-chain polyunsaturated
fatty acids (LCPs), especially 20:4(n-6) (arachidonic acid, AA) and 22:6(n-3)
(cervonic acid, CA) are high ( 1 ). AA and CA are the chain-elongated and desaturated
products of the essential fatty acids (EFAs) 18:2(n-6) (linoleic acid, LA) and 18:3(n-3)
(a-linolenic acid), respectively. Since man is unable to synthesize these essential fatty
acids, fetal EFAs and their long chain derivatives are ultimately derived from the
maternal diet.
LCPs of the (n-3) and (n-6) families comprise 20-25% of the brain fatty acids, largely
as constituents of cellular membranes (2,3). Brain growth takes mainly place before
birth and, therefore, it is important that the availability of essential fatty acids and
their longer chain, more unsaturated derivatives is guaranteed during the development
of the human fetus.
In an earlier study (4) we demonstrated that under normal conditions the EFA status
of neonates may be marginal. The phospholipids of the umbilical arteries (efferent
fetal vessels) were shown to contain significantly less fatty acids of the linoleic (n-6)
and linolenic acid (n-3) families and more of the oleic acid (n-9) family than the
umbilical vein (afferent fetal vessel). Elevated levels of (n-9) fatty acids in
combination with reduced amounts of LA and AA indicate a possible EFA deficiency
(5.6).
The aim of the present investigation is not only to verify our earlier results which
were based on a relatively small set of samples and restricted to cord tissue only, but
mainly to extend our knowledge about the fetal EFA status and its relation to the
maternal EFA status. Therefore, we also determined the relative fatty acid
composition of phospholipids (PL), isolated from umbilical venous and arterial
plasma and blood cells (BC), from non-infarcted placental tissue and from maternal
venous plasma and BC.
MATERIAL AND METHODS
The study group comprised 15 healthy women and their neonates (8 girls and 7 boys).
The mean age of the mothers was 27 years (range 20-33 years). All mothers gave their
informed consent. Umbilical vessel walls and placentas were obtained from 13
persons only. The two other placentas and umbilical vessel walls had to be sent to the
pathological-anatomical laboratory for examination, because one mother had a manual
placenta removal and the other had an extra placenta. All pregnancies were
uncomplicated and the infants were all born or term (mean 40 weeks, range 38-41
weeks) after vaginal delivery. The mean birthweight was 3451 g (range 3125-4185 g).
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There were no differences between the birthweight of boys and girls. The Apgar score
1 minute after birth was 9 (range 6-10) and 3 minutes after birth 10 (range 9-10).
Maternal blood was taken under nearly fasting conditions (mothers had not been
eating and almost did not drink during labor). Umbilical venous and arterial blood was
collected separately, immediately after the cord had been clamped. Shortly after birth,
placentas and cord vessels were rinsed with cold saline and frozen at -30° C until
further treatment. In a small subset of 5 mothers, venous plasma and BC were also
collected approximately ten days before delivery (this blood was taken under
conditions of complete fasting). Fatty acid compositions were compared with those
just after delivery, to investigate possible fatty acid changes due to labor. There were
no significant differences observed.
All material was collected at the Department of Obstetrics and Gynaecology, State
University of Groningen, The Netherlands and transported to Maastricht.
ana/yrer
The plasma was separated from the blood cells by centrifugation and after plasma
collection, the BC were washed with physiological saline. Plasma and BC were frozen
and stored at -30° C until lipid extraction.
The placentas were cut into pieces for homogenization. An EDTA/NaCl-solution
(NJU-EDTA-2HJO 28.64 g, NaCl 7.00 g, HJO 1000.0 ml) was added to the placentas
(w/v=l/l), after which they were homogenized in a blender. Umbilical cord vessels
were homogenized according to the method described earlier (4).
Total lipid extraction was performed as described by Bligh and Dyer (7). The PL
fraction was separated by thin layer chromatography according to van der Vusse et al
(8). The PL fraction was hydrolyzed and the fatty acids were methylated with boron-
trifluoride. The fatty acid composition of the PL was then determined by gas liquid
chromatography, as described by Rand et al (9).
Sfa/J^nca/ ana/yses
Wilcoxon's signed rank test was used for statistical analyses. The relation between the
fatty acids of maternal and umbilical venous plasma or umbilical vessel wall
phospholipids was studied by linear regression analyses, and Pearson's correlation
coefficients were calculated.
RESULTS
Fatty acid composition data (area % of total fatty acids) are given in Tables 1 and 2.
For clarity, data are mainly presented for those fatty acids or fatty acid combinations
which reflect the EFA status.
The results of cord vessels walls (Table 1) largely confirm earlier data (4): the
umbilical arteries (UA) contained relatively fewer fatty acids of the essential (n-6)
family and more of the non-essential (n-7) and (n-9) families than the umbilical vein
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aurf vein
Fatty acifl
2O:5(n-3)
22:5(n-3)#
22:6(n-3)(CA)
Z(n-3)
I8:2(n-6)(LA)
20:3(n-6)
20:4(n-6) (AA)
22:4(n-6)
22:5(n-6)(OA)
I(n-6)
I (n-6) LCPs
20:3(n-9) (MA)
22:3(n-9)
I [(n-7)+(n-9)]
IPUFA
IMUFA
I SAFA
EFA dcf. index
CADI
tiA
(n=13)
nd§
0.4 1 0.22
4.7 10.19
5.2 10.28
1.910.06
1.510.10
11.410.47
3.110.20
3.510.15
21.510.76
19.610.72
3.310.25
1.510.11
28.1 10.85
31.510.60
23.4 1 0.55
40.3 10.32
0.3 10.03
1.210.07
UV
(n=13)
nd
0.6 1 0.08*
4.5 + 0.18
5.3 10.20
2.810.16b
2.0 1 0.06b
15.9lO.5O*>
5.2 1 0.35b
3.3 10.17
29.2 1 0.57b
26.4 1 0.53b
0.7 10.08b
0.4 1 0.06b
19.41 0.36b
36.1 10.55b
17.9 10.27b
41.510.35»
0.041 0.0 lb
0.7 1 0.06b
BC(A)
(n=15)
0.2 1 0.03
1.810.37
4.710.27
7.0 1 0.48
5.910.57
2.1 10.16
14.010.71
4.0 1 0.27
1.410.07
27.510.87
21.61 1.06
0.6 1 0.06
0.3 1 0.05
19.410.85
35.611.06
18.310.85
41.910.64
0.04+0.01
0.4 1 0.03
1: (n-6) LCPs. (n-6) long chain polyunsaturatcd fatty acids; SAFA. saturated fatty acids;
MUFA. monounsaturatcd fatty acids; PUFA. polyunsaturated fatty acids; EFA def. index,
20:3(n-9)/20:4(n-6); CADI. Ccrvonic acid deficiency index: 22:5(n-6)/22:4(n-6).
§: nd. not detectable.
tt: plus 24:2(n-6) as a minor component.
•: significant difference from arterial values 0.01 < p < 0.05; b: significant difference from
arterial values 0.001 < p < 0.01.
(UV). The proportions of Mead acid (MA) and of its elongation product dihomo-
Mead acid in the UA PL. the presence of which in adults indicates EFA deficiency,
were four to five times that in the UV PL, whereas the proportion of arachidonic acid
(AA) was lower. Consequently, the ratio MA:AA, the EFA deficiency index, was
eight times that in the vein, indicating a considerable deficiency of EFA in the arterial
wall. The cervonic acid deficiency index (CADI), given by the ratio of the proportion
of the Osmond acid (OA) to its immediate precursor, was also raised in UA wall PL
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Fatty acidi
20:5{n-3)
22:5(n-3)*
22:6(n-3) (CA)
I(n-3)
18:2(n-6)(LA)
20:3(n-6)
20:4(n-6)
22:4(n-6)
22:5(n-6) (OA)
X(n-6)
I (n-6) LCPs
20:3(n-9) (MA)
I [(n-7)+(n-9)]
XPUFA
IMUFA
ISAFA
EFA def. index
CADI
PA
(n=!5)
0.7 ± 0.23
I.I ±0.09
6.1 ±0.39
7.9 ± 0.39
7.5 ±0.42
4.4 ± 0.29
18.6 ±0.48
1.9 ±0.36
1.4 ±0.12
34.1 ±0.76
26.6 ±0.81
0.9 ±0.11
15.3 + 0.47
43.2 ± 0.90
14.0 ±0.37
42.4 ± 0.87
0.05± 0.01
1.0 ± 0.16
PV
(n=l5)
0.5 ±0.14
1.4 ±0.17
6.7 ±0.41
8.6 ± 0.40»
7.8 ± 0.30
4.9 ±0.31»
19.8 ±0.52*
1.4 ±0.12
1.3 ±0.13
35.6 + 0.82
27.7 ±0.69
0.9 ±0.13
15.2 ±0.56
45.6 ± 0.97»
13.7 ±0.46
40.4 ± 0.96
0.05±0.01
I.I ±0.17
Placenta
(n=l3)
0.1 ±0.02
1.3 ±0.06
4.8 ± 0.26
6.3 ± 0.28
9.5 ± 0.29
4.3 ±0.25
21.1 ±0.34
1.6 ±0.10
1.0 ±0.06
37.6 ±0.35
28.1 ±0.38
0.2 ± 0.03
12.1 ±0.26
44.4 ± 0.28
11.6 ± 0.26
39.4 ± 0.28
0.01 ±0.00
0.6 ± 0.04
PM
(n=l5)
0.5 ± 0.04
0.7 ±0.03
3.9 ±0.23
5.7 ±0.22
23.1 ±0.55
2.9 ± 0.20
9.4 ± 0.46
0.5 ± 0.03
0.7 ± 0.06
36.8 ± 0.66
13.6 ±0.58
0.5 ±0.12
15.7 ±0.42
43.5 ±0.77
14.7 ±0.45
41.3 ± 1.17
0.06± 0.01
1.4 ±0.13
compared to that in the vein. In contrast, there was no significant difference in the
fatty acid composition of PL from the cells (BC) of UV and UA blood (data for
BC(V) not shown), and, as shown in Table 1, this was closer to that of the UV wall
than that of the arteries. The differences between UA and UV plasma were also small
(Table 2) and the proportions of individual acids were, in general, of the same order as
in the PL of non-infarcted placental tissue. However, as shown in Table 2 and Figure
1, the fatty acid composition of PL from maternal plasma was very different from that
in the fetus. The relative amount of linoleic acid (LA) was three times that in cord
plasma PL, whereas those of AA, cervonic acid (CA) and its precursor were only half
the fetal levels (P < 0.001). As expected, the proportion of MA, and hence the EFA
deficiency index, were low in maternal plasma PL.
On examing results from individual pregnancies, it was clear that the composition of
the fetal plasma PL varied with that of the maternal plasma PL. Not only were there
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significant positive correlations (P < 0.01) between mother and fetus for the sum of
the (n-3) and (n-6) fatty acids (Figure 2), but also for some specific saturated and
mono-unsaturated fatty acids and for CA, LA and OA (results not shown).
DISCUSSION
The present investigation confirms and extends the results of our previous study (4),
in which evidence was obtained for a marginal EFA status of the newborn. The
efferent blood vessel walls have lower proportions of LA and AA and higher relative
amounts of 20:3(n-9) (Mead acid, MA) and its elongation product 22:3(n-9) than the
afferent blood vessel wall.
Ongari et al (10) also observed MA in the umbilical artery. MA was rarely observed
in adult blood vessels and 22:3(n-9) was not observed at all (4). Because the various
fatty acids compete for the same enzymic elongation-desaturation system, the amounts
of linoleic and a-linolenic acid were apparently insufficient to occupy the A-6-
desaturase, which allows oleic acid to become converted to Mead acid (20:3(n-9),
MA). Therefore Mead acid and its elongation product 22:3(n-9) are considered
reliable markers of an essential fatty acid deficiency (6).
It should be realized that all our data refer to relative fatty acid compositions;
consequently, an increase of one fatty acid inevitably means a decrease of at least one
other fatty acid. Such errors can be magnified enormously when ratios are used, if the
numerator and denominator are affected in opposite directions. Therefore, all ratios
presented have to be seen in this light. For further studies, absolute fatty acid
composition measurements are required to understand more about placental transfer
and fetal uptake of EFAs and their metabolites.
The classical biochemical indicator of a borderline EFA status is the EFA deficiency
index, given by the ratio between Mead acid and arachidonic acid (MA/AA ratio). A
value of 0.2 or more in human serum PL is considered as the upper limit of normality
(11). The EFA deficiency index in arterial tissue is 0.3 (Table 1 ), which supports the
idea that the neonatal EFA status is poor indeed, from a biochemical point of view.
The EFA deficiency indeces in fetal BC (Table 1) and plasma (Table 2) do not
indicate an EFA deficiency. This seems in contrast to the findings for umbilical
arterial tissue, but it should be realized that during each passage of the placenta, the
fetal blood will take up new maternal EFAs. Consequently, only small arterio-vcnous
differences are to be expected in the EFA status of circulating blood. This applies to
phospholipids in particular, the turn-over rate of which is much lower as compared to
free fatty acids. Since the walls of umbilical arteries are exclusively in contact with
arterial (efferent) blood, any minor deviation from an optimal fatty acid composition
in the blood will be "added up" in the arterial walls and, consequently, this tissue
gives a more reliable and longer-term reflection of the average EFA status of the
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arterial blood than the post-partum blood itself. This consideration, and the fact that
the MA content of fetal plasma and BC phospholipids is almost twice as high as the
maternal levels (Figure 1 ) suggests that the biochemical EFA status of the fetus is not
optimal indeed.
The presence of these EFA deficiency indicators do not necessarily reflect a shortage
of EFAs, however. An alternative explanation may be that the high proportions of
20:3(n-9) and 22:3(n-9) in umbilical arterial tissue may simply reflect a high
desaturase activity in arterial vessel compared to venous vessel walls. However, the
ratio between total (n-6) long chain polyenes (LCPs) and LA (this ratio is an indicator
of total desaturase activity) in the umbilical arteries (10.4 ± 0.29) is not significantly
different from that in the umbilical vein (9.9 ± 0.59), whereas MA is about five times
higher in the arteries. This suggests that this higher MA content in umbilical arteries
does not simply result from a high desaturase activity. It should be mentioned that the
ratio between (n-6) LCPs and LA, as used here, does not represent the true desaturase
activity. In further studies this activity needs to be measured more precisely.
Another reason for the poor apparent EFA status could be the specific selection by the
placenta for incorporation and transfer of the 20 and 22 carbon chain polyunsaturated
fatty acids at the expense of linoleic acid, to satisfy the demand for (n-3) and (n-6)
LCPs for fetal brain growth (3,12,13). Consequently, there is less substrate available
for the enzyme A-6-desaturase and some switching to oleic acid desaturation might be
expected. However, this can only partly, explain the elevated levels of MA, because
the activity of A-6-desaturase is also controlled by a feed-back mechanism; higher
amounts of arachidonic acid reduce A-6-desaturation (14).
The relative amounts of 22:5(n-6) are slightly higher in PL of umbilical arterial tissue
than in umbilical venous tissue, whereas most other (n-6) fatty acids are significantly
lower (Table 1 ). Moreover, the ratio between 22:5(n-6) and its direct precursor
22:4(n-6) is significantly higher in the arteries as compared to the vein (P < 0.01, see
Table 1). This ratio has been used as the Cervonic Acid Deficiency Index (CADI) and,
therefore, the present finding may point to a relative shortage of fetal CA also (15,16).
The CADI value for maternal plasma PL (1.4 ± 0.13) is significantly higher than that
for fetal venous plasma PL (1.1 ± 0.17, p = 0.03). Since the adult and fetal CA
requirements may differ from one another, this higher maternal CADI value does not
necessarily imply that the CA status of the mother is insufficient. It may reflect,
nonetheless, an increased maternal CA requirement to improve fetal CA supply.
In conclusion, the biochemical LA status of neonates after a normal pregnancy does
not seem to be optimal. In addition, the fetus seems to have a high CA requirement.
Since not all the data invariably indicate a marginal EFA status of the fetus, the
situation is not that serious. It may become problematic, however, if there is a
disturbed maternal-to-fetal fatty acid transfer. Crawford et al (12) observed the highest
concentration of MA and its elongation product 22:3(n-9) in the umbilical artery of
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the lowest birthweight baby. Therefore, in further studies the fetal EFA status should
be measured after conditions associated with impaired placental circulation (e.g. intra
uterine growth retardation, pre-eclampsia, etc.) Since we demonstrated a close
association between the maternal and fetal (n-3) and (n-6) fatty acids (Figure 2), it
may be possible to improve the fetal/neonatal EFA status by increasing the maternal
EFA intake during pregnancy.
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CHAPTER 3
Fatty acid composition of serum lipids of mothers
and their babies after normal and hypertensive
pregnancies
Yvonne T. van der Schouw, Monique DM. AI, Gerard Hornstra, Marèse T.E.W.
Bulstra-Ramakers and Henk J Huisjes
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ABSTRACT
The biochemical essential fatty acid (EFA) status of neonates born after normal and
hypertensive pregnancies (PIH) and that of their mothers was assessed by measuring
the fatty acid composition of phospholipids (PL), triglycérides (TG) and cholesterol
esters (CE) of umbilical cord serum and maternal serum, respectively.
Relative contents of linoleic acid of serum PL and CE were significantly lower in
mothers with PIH compared to normal pregnancies. Most other (n-6) polyenes in PL
tended to be higher under hypertensive conditions. Total maternal (n-3) polyenes of
serum PL were significantly higher in PIH, mainly due to clupanodonic acid, 22:5(n-
3), and cervonic acid, 22:6(n-3). Total maternal (n-7) and (n-9) fatty acids were also
significantly higher in PIH (PL and CE).
The results indicate that PIH is associated with a relative increased unsaturation of
maternal serum PL, which might facilitate the placental transfer of long-chain,
polyunsaturated fatty acids. As a result, the neonatal EFA status after PIH only
slightly differs from normal.
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INTRODUCTION
The essential fatty acid (EFA) status of normal neonates seems marginal, if not
insufficient. This applies to linoleic acid, 18:2(n-6), and cervonic acid, 22:6(n-3), in
particular (1,2). Linoleic acid is the ultimate dietary precursor of arachidonic acid,
20:4(n-6), which, together with cervonic acid, is of essential importance in fetal brain
development.
Although the marginal EFA status of normal neonates is unlikely to have pathological
consequences, the situation may become more serious under conditions where the
placental perfusion is compromized. This may be the case in the most frequent
medical complication of pregnancy, hypertensive pregnancy, which syndrome is
associated with elevated activation of blood platelets, spiral artery thrombosis and
placental infarction (3).
In the present study we investigated whether pregnancy induced hypertension (PIH)
affects the neonatal EFA status in any significant way.
POPULATION, MATERIALS AND METHODS
The EFA status of mothers and their newborn babies was assessed by measuring the
relative fatty acid composition of the total phospholipids isolated from serum prepared
from venous blood, taken immediately upon vaginal delivery from both a forearm
vein (mother) and the umbilical vein (child). The blood was taken under almost
fasting conditions (mothers had not been eating and almost did not drink during
labor). Fifteen sets of samples were collected after normal pregnancy and fourteen
were obtained after pregnancy complicated with PIH, defined as: "a first diastolic
blood pressure below 90 mmHg, a subsequent increase of at least 25 mmHg, and a
maximum reading of at least 90 mmHg" (4). Multiple pregnancies were not included.
All women with PIH were hospitalized for this syndrome. None of them used any
anti-hypertensive medication. One maternal sample of the last group got lost during
transportation.
To investigate any influence of labor on the post-partum EFA status, five additional
sets of samples were collected after Caesarean sections, performed for anatomical
reasons.
All deliveries took place at the Department of Obstetrics and Gynaecology, State
University, Groningen, The Netherlands and all mothers gave their informed consent.
ZfrocAe mica/ a/ici/y.v»
in all serum samples the relative fatty acid composition of the phospholipids was
measured. Additionally, fatty acid composition of triglycérides and cholesterol esters
was measured in ten sets of normal and ten sets of pregnancies complicated with PIH.
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Age (years)
Number of pnmiparac
Gestational age (weeks)
Birth weight (grams)
Apgar score ( 1 minute)
Apgar score (3 minutes)
Normal
(n=l5)
26.2 ± 1.13
8
39.5 ±0.19
33771 110
8.610.21
9.610.16
PIH
(n=l4)
28.51 1.68
5 . ,:
38.7 1 0.44"
2966 1 236
7.4 1 O.53*>
9.0 1 0.30*
.id), .is
a: tendency for difference. 0.05 < p < 0.10; b: significant difference. 0.01 < p < 0.05.
TaWe 2. Ae/arive /a/fy acid" com/xwirion f%q/' fo/a/ /âfr>' acia^ q/^  venous serum /?flo.vp/io/i/>;di q/
mofners a/fer Caesarian secrto ana" vagina/ tfWi'verv ^ (nean ± s.e.m./
Fatty acid
20:5(n-3)
22:5(n-3)*
22:6(n-3)
18:2(n-6)
20:3(n-6)
20:4(n-6)
22:4(n-6)
22:5(n-6)
l6:l(n-7)
18:l(n-9)
20:l(n-9)
20:2(n-9)*
20:3(n-9)
22:l(n-9)
24:l(n-9)
16:0
17K)
18:0
20:0
21:0
22:0
23:0
24:0
Caesarian section
(n=5)
0.3 1 0.03
0.9 1 0.08
4.0 1 0.39
21.510.88
3.210.27
8.810.62
0.3 i 0.09
0.7 1 0.08
1.8 10.22
11.4 10.24
0.3 10.18
0.410.12
0.3 10.18
tr
1.8 ±0.08
30.1 ±0.53
0.1 ±0.09
8.7 1 0.40
0.5 10.04
0.2 1 0.05
1.1 ±0.20
0.3 ± 0.05
0.910.13
Vaginal
(n=!5)
0.4 ± 0.06
0.8 1 0.04
4.5 ± 0.22
21.710.66
3.1 10.13
8.7 10.37
0.4 1 0.03
0.7 ± 0.04
1.7 10.09
11.910.43
0.210.02b
0.I10.04C
0.6 1 0.08"
0.1 10.03»
1.6 ±0.07
29.8 ±0.31
0.5 1 0.02
9.110.14
0.5 1 0.03
0.3 1 0.03
1.3 ±0.09
0.3 10.03
0.6 1 0.03*
#: plus 24:2(n-6) as a minor component; V: tentative identification; tr: trace.
a: tendency for difference. 0.05 < p < 0.10; b: significant difference. 0.01 < p < 0.05;
c: significant difference, p < 0.01.
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The serum samples were stored for about one to 12 months at -60 °C before the
biochemical analyses were performed at the Department of Human Biology, State
University Limburg, The Netherlands. Lipids were extracted according to the method
of Bligh and Dyer (5). Phospholipids (PL), cholesterol esters (CE) and triglycérides
(TG) were separated by thin layer chromatography as described by Van der Vusse et
al. (6). The different lipid fractions were hydrolyzed and the fatty acids were methy-
lated with methanolic boron-trifiuoride. Fatty acid composition of the lipid fractions
was analyzed using gas liquid chromatography as described by Rand et al. (7).
Samples of mothers and their neonates were always analyzed in the same analytical
series.
Because the relative concentrations of a number of the various fatty acids were not
normally distributed, differences between pregnancy groups and mother-child
differences were tested with the non-parametric two-sided Wilcoxon-Mann-Whitney
two-sample test. The relation between the sum of the (n-6) long chain polyenes
([20:3(n-6)+20:4(n-6)+22:4(n-6)+22:5(n-6)J, (n-6)LCPs) and linoleic acid was inves-
tigated using linear regression analysis. Regression coefficients were tested with a
two-sided F-test.
RESULTS
Table 1 summarizes the relevant clinical information on the study population. No
differences were seen between women with normal pregnancies and pregnancies
complicated with P1H for maternal age and number of pregnancies. Gestational age
tended to be higher in the normal group. No statistically significant difference
between the groups was found for birth weight of the children. Apgar score one
minute after birth was significantly lower in the neonates from mothers with PIH
compared to the normal neonates. Apgar score three minutes after birth showed the
same tendency; however, the difference was no longer significant.
There were no important differences in the fatty acid composition of serum PL
between mothers after normal delivery as compared with Caesarean section (Table 2).
Therefore, any significant interference of labor on maternal fatty acid composition of
serum lipids can be excluded. This is also observed by Ruyle et al. (8).
In Tables 3, 4 and S the fatty acid compositions of the serum lipid fractions of
neonatal and maternal serum are given.
In the neonatal serum PL, TG and CE, hardly any differences were observed between
normal pregnancies and pregnancies complicated by PIH for any of the essential fatty
acids (Tables 3,4, 5).
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Fatty acidi
20:5(n-3)
22:5(n-3)*
22:6(n-3)
I (n-3)
18:2(n-6)
20:3(n-6)
20:4(n-6)
22:4(n-6)
22:5(n-6)
I (n-6)
I (n-6) LCPs
16:l(n-7)
18:l(n-9)
20:l(n-9)
20:2(n-9)*
20:3(n-9)
22:l(n-9)
24:l(n-9)
I[(n-7Hn-9)]
16:0
17:0
18:0
20:0
21:0
22:0
23:0
24:0
IPUFA
I MUFA
I SAFA
Neonates
normal
(n=!5)
0.4 ± 0.06
1.9 ± 0.12
7.4 ±0.41
9.7 ±0.39
7.4 ± 0.45
5.7 ± 0.35
18.4 ±0.49
1.1 ±0.05
I.I ±0.06
33.8 ± 0.86
26.4 ± 0.66
1.3 ±0.05
8.9 ±0.41
0.1 ± 0.02
0.1 ±0.03
0.6 ± 0.05
0.4 ±0.10
2.6 ±0.11
14.0 ±0.90
27.0 ± 0.45
0.3 ± 0.06
11.9 ±0.41
tr
0.5 ±0.11
1.5 ±0.05
tr
0.8 ± 0.08
44.1 ±0.87
13.3 ±0.37
41.9 ±0.79
PIH
(n=14)
0.5 ±0.08
1.9*0.19
7.7 ± 0.68
10 1 ±0.82
7.5 ± 0.45
5.5 ±0.33
18.7 ±0.62
1.2 ±0.07
1.0 * 0.12
33.8 ± 1.06
26.3 ±0.81
1.6±0.09C
11.2 ±0.77»
0.1 ±0.02
0.1 ± 0.02
0.5 ±0.10
0.4 ±0.10
2.4 ± 0.08
16.3 ±1.20
27.0 ±0.64
0.3 ± 0.07
10.6 ±0.54
tr
0.5 ±0.11
l.3±0.10*>
tr
0.7 ± 0.07
44.4 ± 1.15
I5.7±1.18
40.4 ± 1.19
Mothers,
normal
(n=!5)
0.4 ±0.06
0.8 ± 0.04
4.5 ±0.22
6.1 ±0.26
2l.7±0.66
3.1 ±0.13
8.7 ±0.37
0.4 ± 0.03
0.7 ±0.04
34.8 ± 0.48
13.1 ±0.38
1.7 ±0.09
11.9 ±0.43
0.2 ± 0.02
0.1 ± 0.04
0.6 ± 0.08
0.1 ±0.03
1.6 ±0.07
16.3 ±0.52
29.8 ±0.31
0.5 ±0.02
9.1 ±0.14
0.5 ±0.03
0.3 ±0.03
1.3 ±0.09
0.3 ± 0.03
0.6 ± 0.03
41.2±0.54
15.6 ±0.53
42.5 ±0.25
RH
(n=l3)
0.5 ± 0.06"
1.0 ± 0.06&
5.4 ± 0.33^
7.4 ± 0.36»>
I8.2±O.68C
3.5 ±0.16»
9.1 ±0.43
0.5 ±0.04
0.8 ± 0.05
32.1 ±0.92C
14.0 ± 0.43»
1.9 ± 0.10
I3.4±O.4O^
0.2 ± 0.02
0.1 ±0.03
0.8 ±0.08
0.1 ±0.03
l.9±0.1l»
18.4 ±0.52*>
30.0 ± 0.50
0.4 ±0.06
8.9 ±0.24
0.5 ±0.03
0.4 ± 0.05
1.1 ±0.06l>
0.3 ± 0.03
0.5 * 0.04
40.0 ± 1.05
17.5 ±0.50»'
42.1 ±0.43
1: (n-6)LCPs, (n-6) long chain polyenes; SAFA. saturated fatty acids; MUFA, monounsaturated fatty
acids; PUFA, polyunsaturated fatty acids.
#: plus 24:2(n-6) as a minor component.¥: tentative identification, tr: trace,
a: tendency for difference, 0.05 < p < 0.10; b: significant difference, 0.01 < p < 0.05;
c: significant difference, p < 0.01.
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In mothers, a significant difference between normal pregnancies and pregnancies
complicated with PIH was found (Tables 3 and 5) for linoleic acid, 18:2(n-6), (PL,
CE); the linoleic acid status of mothers with PIH appeared significantly reduced
compared to that of mothers with uncomplicated pregnancies. Also, significant
differences for the non-essential fatty acids of the (n-7) and (n-9) family were
observed (PL, CE). In the PL of maternal serum, timnodonic acid, 20:5(n-3), tended
to be higher and clupanodonic acid, 22:5(n-3). and cervonic acid, 22:6(n-3), were
significantly higher, which resulted in a significantly higher amount of total (n-3)
polyenes in PIH compared to normal pregnancies. These differences were not
observed for TG and CE (Tables 4 and 5).
Striking differences exist between the maternal and neonatal fatty acid composition of
the serum Iipid fractions. This is shown in Tables 3, 4 and 5. Differences are
particularly pronounced for linoleic acid (PL, CE), which is much higher in maternal
than in neonatal serum, and for arachidonic acid, 20:4(n-6) (PL, TG, CE), for which
the opposite is true. Mead acid, 20:3(n-9), the marker of a combined linoleic and ct-
linolenic acid deficiency, is higher in neonatal than in maternal serum (TG, CE). In
general, the shorter chain and/or the less unsaturated fatty acids are higher in mothers
than in their children, whereas the reverse is true for the longer chain and/or more
unsaturated fatty acids (PL, TG, CE).
The maternal-neonatal differences are not always consistent for the various Iipid
fractions. In some cases the differences were even in opposite directions. Consistent
differences were found for 20:3(n-6), 20:4(n-6) and 22:6(n-3) only (neonatal values
significantly higher than maternal values). In most cases the patterns observed were
essentially similar for normal pregnancies and those complicated by PIH, although
occasionally significant differences occurred (data not shown, but available on
request).
DISCUSSION
The results of this study indicate that the linoleic acid status of mothers with PIH is
reduced as compared with that of mothers after normal pregnancies. The sum of the
fatty acids of the (n-7) and (n-9) families was significantly higher after pregnancies
complicated by PIH, which also indicates a suboptimal linoleic acid status (9,10).
Theoretically, the lower linoleic acid status in PIH may be the result of a lower dietary
intake of linoleic acid. If this is true, a supplementary consumption of about seven
grams of linoleic acid per day could possibly overcome the difference between normal
mothers and mothers with PIH. This can be estimated by extrapolation of the
regression equation for the relation between linoleic acid intake and the linoleic acid
amount in serum TG, as calculated by Houwelingen et al. (11).
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and mo/Aers a//trr norma/ on</ nvperftwn* pregmi/iciw (m«jn ±
Fatty ackfl
l8:3(n-3)
22:5(n-3)*
22:6(n-3)
I(n-3)
l8:2(n-6)
!8:3(n-6)
20:3(n-6)
20:4(n-6)
22:4(n-6)
22:5(n-6)
Z(n-6)
I (n-6) LCPs
16:l(n-7)
l8:l(n-9)
20:l(n-9)
20:2(n-9)*
20:3(n-9)
Z[(n-7)-Kn-9)]
16:0
17:0
18:0
21:0
IPUFA
IMUFA
ZSAFA
UfifiOttS
normal
(n=10)
1.6 ±0.66
0.3 ± 0.06
2.8 ± 0.32
4.6 ± 0.76
13.8 ±0.95
1.3 ±0.28
1.1*0.15
3.5 ±0.33
0.8 ± 0.05
1.2 * 0.13
21.4 ± 1.41
7.6 ± 0.68
7.7 ±0.64
33.4 ± 1.19
0.5 ±0.13
tr
0.8±0.15
42.4 ± 1.04
22.9 ± 0.99
1.3 ±0.36
3.7 ±0.38
0.8 ±0.21
26.9 ±1.78
41.7 ±0.94
28.6 ± 1.36
PIH
(n=8)
10 ±0.16
tr b
3.2 ±0.52
4.4 ±0.68
13.2 ±0.78
1.0 ±0.17»
I.I ±0.12
3.0 ±0.39
0.7 ±0.04
0.9 ±0.15
20.0 ± 1.26
6.7 * 0.83
7.9 * 0.43
32.8 ± 1.68
0.4 ± 0.09
tr
0.8 ±0.18
41 9 ± 1.88
25.8 ±0.85»
1.5 ±0.38
4.4 ± 0.53
0.8 ±0.21
25.3 ±1.78
41.1 ± 1.85
32.4 ± 0.58b
Mothers
normal
(n=10)
1.3*0.11
0.3 ± 0.06
0.2*0.04
1.6*0.11
14 6 ±0.91
0.3 ± 0.04
0.3 ± 0.03
0.5 ±0.06
0.1 ±0.01
O.I ±0.02
16.0 ±0.95
1.3*0.13
6.4 * 0.28
36.8 ± 0.95
0.9 ± 0.08
0.4 ± 0.03
0.3 ± 0.06
44.8 ± 1.02
29.1 ±0.60
1.7*0.14
3.2 ± 0.26
tr
18.2 ±1.02
44.1 * 1.02
34.1 ±0.68
PIH
(n=8)
1.2*0.11
tr b
0.2 ± 0.06
1.5 ±: 0.10
11.5± 1 50
0.3 ±0.04
0.2 ±0.04
0.4 ± 0.06
tr b
0.1 ± 0 02
12.5 ± 1.58
I.I ±0.12
6.8 * 0.47
37.6* 1.24
0.7 ± 0.09
0.3 ±0.04
0.2 ± 0.03
45.6± 111
31.5± 1.58
1.7 ±0.22
3.1 ±0.12
O.I ± 0.04b
14.6 ± 1.71
45 1 ± 1.15
36.5*1.51
For abbrevations sec Table 3
The lower linoleic acid status of mothers with PIH may also result from a higher fetal
demand for more desaturated and/or more elongated (n-6) fatty acids [(n-6)LCPs], as
a result of which more of the available linoleic acid is used for conversion. Indeed, the
ratio between the (n-6)LCPs and their precursor linoleic acid in maternal PL is signifi-
cantly higher in PIH (0.8 ± 0.03 versus 0.6 ± 0.04, p = 0.002). This suggests more
active elongation and desaturation processes during PIH, possibly to meet an
increased demand for polyenes in this situation. To investigate this in more detail,
linear regression equations were calculated with (n-6)LCPs as the dependent (Y) and
33
TaWe 5. /te/af/Ve./â/fy acia" composi/ion f% o//ofa/./ii/f>' aciasy o/venous .senwn cAo/es/ero/ esters
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Fatty acidl
18:3(n-3)
20:5(n-3)
22:6(n-3)
I(n-3)
18:2(n-6)
I8:3(n-6)
20:3(n-6)
20:4(n-6)
Kn-6)
I (n-6) LCPs
16:l(n-7)
l8:l(n-9)
20:3(n-9)
I[(n-7)+(n-9)]
16:0
17:0
18:0
24:0
IPUFA
IMUFA
ISAFA
Nconatcs
normal
(n=IO)
tr
0.2 ±0.06
0.8 ±0.15
1.0 ±0.20
19.0 ±0.60
0.6 ±0.07
1.0 ± 0.19
11.7± 111
32.4 ± 1.55
13.3 ± 1.21
8.8 ±0.50
32.9 ±0.95
0.2 ± 0.06
41.9 ±0.90
19.5 ± 1.12
0.4 ±0.11
2.9 ±0.41
0.2 ±0.13
33.6 ± 1.74
41.7 ±0.89
23.1 ± 1.44
PIH
(n=8)
tr
0.4 ±0.11
1.1 ±0.13
1.6 ±0.15"
20.6 ± 0.90*
0.7 ±0.10
1.4±O.I7b
12.3 ± 1.30
36.5 ±1.72»
15.4 ± 1.24
8.5 ±0.45
30.7 ± 1.28b
0.2 ±0.06
39.4 ± 1.05b
19.6 ±0.85
0.7 ±0.18
2.0 ± 0.32
0.1 ± 0.04b
38.3 ± 1.75a
39.2 ± 1.02b
22.4 ± 111
Mothers
normal
(n=10)
0.9 ± 0.09
0.2 ± 0.06
0.2 ± 0.03
1.4 ± 0.13
49.7 ± 1.78
0.5 ±0.05
0.5 ± 0.08
3.7 ±0.30
54.4 ± 1.82
4.7 ±0.37
6.2 ±0.65
22.7 ± 1.09
tr
28.8 ± 1.60
12.8 ±0.34
0.4 ± 0.05
0.6 ±0.06
tr
55.9 ± 1.83
28.8 ± 1.60
13.8 ±0.42
PIH
(n=8)
1.0 ±0.05
0.3 ± 0.05
0.3 ± 0.06
1.5 ±0.11
42.9 ± 2.28b
0.6 ±0.08
0.5 ±0.08
3.3 ±0.20
47.4 ± 2.22b
4.5 ±0.17
8.4 ±1.25
26.5 ± 0.92b
tr
34.9 ± 1.94b
13.2 ±0.42
0.4 ± 0.04
0.9± 1.19
tr
48.9 ± 2.19b
34.9 ± 1.94b
14.5 ± 0.60
For abbrcvations sec Table 3
linoleic acid as the independent (X) variable. In normal pregnancy the regression
equation is Y = 21.8 - 0.4X, (r = -0.71, n = 15, p = 0.003). In pregnancies complicated
by PIH this relation tends to be positive, Y = 10.2 + 0.2X, (r = 0.32, n = 13, p =
0.280). The slopes of the two regression lines differ significantly (p = 0.001), which,
together with the switch of the sign of the regression coefficient, is an indication for
more active elongation and desaturation in PIH. Consequently, the lower linoleic acid
status in mothers with PIH may be of metabolic rather than of dietary origin. The
more active desaturation and elongation of linoleic acid may reflect a maternal
attempt to compensate for a less efficient placental transfer of (n-6)LCPs, possibly
resulting from the fact that in PIH the placenta is partially infarcted (3).
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Total (n-3) poiyenes are also significantly higher in maternal plasma PL after
pregnancies complicated by P1H than after normal pregnancies, which is mainly
caused by clupanodonic acid and cervonic acid. Theoretically, this could be an
indication of an increased maternal dietary intake of these (n-3) polyenes, for example
a higher fish consumption (10). However, the lack of difference for (n-3) LCP
amounts in TG and CE does not support the theory of an increased cervonic acid
intake. A more likely explanation for the higher amounts of (n-3) polyenes in serum
PL of mothers with P1H could be an increased mobilization from maternal stores.
These higher amounts of (n-3) polyenes may serve to increase the maternal-fetal (n-3)
gradient, which would compensate for the P1H associated reduction in placental
transfer area.
Because of these adaptation mechanisms, the neonatal EFA status after PIH does not
differ significantly from normal. Whether or not the fetus is involved in the generation
of a signal to stimulate maternal linoleic acid conversion or (n-3) polyenes
mobilization from maternal stores remains a challenging question.
This study indicates that maternal EFA metabolism is altered in hypertensive
pregnancy; linoleic acid seems to be more actively desaturated and elongated and (n-
3) polyenes are possibly mobilized from maternal stores. The resulting higher levels
of (n-3) and (n-6)LCPs could compensate for a impaired placental transfer of these
fatty acids, as a result of which the neonatal EFA status after PIH hardly differs from
normal. Whether or not maternal EFA supply will be benificial in the prevention or
treatment of PIH needs to be studied.
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CHAPTER 4 *
Nutrient intake of women during normal pregnancy
with special emphasis on fat intake
Monique DM AI, Anita Badart-Smook, AdrianaC. v. Houwelingen, Tom H.M.
Hasaart and Gerard Hornstra
Based on: Far /nfafce o/ women dunng norma/ pregnancy: ne/af/onsn/p tvrtn neonafa/
£F>\ s/afus, suom/tfed tor puW/caf/on
ABSTRACT
As part of an-going study on the essential fatty acid status during pregnancy in
relation to the outcome of pregnancy, the nutrient intake of 176 women throughout
normal pregnancy was studied with special emphasis on the amount and type of fat
consumed. The subjects completed a food frequency questionnaire (FFQ) before 13, at
22, and at 32 weeks of gestation. At 22 weeks of gestation a diet history (DH) was
carried out and a maternal blood sample was taken. No significant changes in the
mean daily intake of total fat, saturated fat, mono-unsaturated fat, polyunsaturated fat.
and linoleic acid during pregnancy were observed. Less than 30 % of the women met
the recommendations for amount and type of dietary fat. The intakes of linoleic acid
and polyunsaturated fatty acids (% of total fat intake) of pregnant women assessed
with the FFQ and DH correlated well with the amounts of these fatty acids in plasma
phospholipids. It is concluded that the fat content and composition of the maternal diet
does not change during a normal pregnancy. In addition, the individual dietary
composition with respect to these nutrients seems consistent during gestation.
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INTRODUCTION r 1
A large number of papers has been published on nutritional aspects related to pregnan-
cy (see for reviews: ref. 1-3). However, most studies have focussed on the intake of
energy, protein, vitamins and minerals, without considering the intake of
polyunsaturated fatty acids (PUFAs). It is well known that PUFAs play a major role
during fetal development (4). In addition, some of them are important in human
parturition as precursors of prostaglandins (5). Moreover, PUFAs and their
metabolites are increasingly being linked to the incidence of pregnancy-induced
hypertension (6-9). Therefore, PUFAs and specifically essential fatty acids may be of
great importance in the diet of pregnant women. However, so far no prospective
studies have been reported on this issue. To prepare for such a study, we decided to
investigate the nutrient intake of a group of Dutch pregnant women in each trimester
of their (normal) pregnancy, with special emphasis on the intake of fat. Dietary
intakes were recorded to assess the fat content and composition of the maternal diet
and as a biological marker a blood sample was taken to determine the fatty acid
composition of plasma phospholipids.
SUBJECTS AND METHODS
S/uflfy
Pregnant women were asked to participate in the study at their first antenatal medical
visit. The selection criteria for entering the study were a gestational age less than 13
weeks at entry, and a diastolic blood pressure below 90 mm Hg. Women suffering
from any metabolic, cardiovascular, neurological or renal disorder were excluded. Out
of the 302 women who were willing to participate, 78 women experienced complicati-
ons during pregnancy, and 48 women had an incomplete data set. Finally, 176 Dutch
women (78.6 % of the eligible population) with normal singleton pregnancies were
studied. The mean (s.d.) age of the mothers was 28.8 (4.1) years. The number of
primipara was 113 and of multipara 63. All infants were born a; term (280.1 ± 8.03
days), and the birthweight (3347 ± 391 gram) was appropriate for gestational age (>
Percentile 2.3 and < Percentile 97.7) based on the Dutch intrauterine growth curves,
making allowance for sex and parity (10). One-hundred-five boys and seventy-one
girls were born. The protocol was approved by the Ethics Committee of the University
Hospital and written consent was obtained from each participant.
Dietary
The dietary intake of products rich in fat was investigated each trimester by using a
self-administered semi-quantitative food frequency questionnaire (FFQ) that asked
about the intakes of the previous two months. The FFQ was specifically designed to
collect data on the fat consumption of the participating women. With the help of an
experienced dietitian (AB-S), the foods included in the questionnaire were selected
according to their contribution to the mean daily fat consumption of pregnant women
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(11) and according to their fat content (12). Appendix A shows the seven main food
groups with most of their foods. Frequency of consumption had to be recorded and the
amount eaten had to be indicated in household units or grams for some typical
individual serving size (e.g. meat). In total, three FFQs (first trimester, before 13
weeks of gestation - FFQ1; second trimester, at 22 weeks -FFQ2; third trimester, at 32
weeks - FFQ3) were sent to the participants. The returned questionnaires were
checked for completeness by the dietitian and, if necessary, corrected after a telephone
interview with the participant concerned.
At mid pregnancy, just after FFQ2 had been filled in, a cross-check diet history (13)
was carried out to collect extended dietary data. The participants were visited at home
by the dietitian and questioned about their usual food consumption of the previous two
months. During this interview, food quantities were specified in household measures.
Usual portion sizes were estimated with the aid of food models or replicates; portions
of foods frequently consumed were weighed on a balance having a precision of O.S
gram. All foods and drinks were coded according to the system of the Netherlands
Nutrient Databank (NEVO), developed in the Netherlands and converted into energy
and nutrients by using the extended computerized version of the Netherlands Food
Table (12).
fi/oorf co//ecrion
Within two weeks before or after the diet history was carried out, a venous blood
sample was collected from 80 of the participating pregnant women into disodium
EDTA containing tubes. Plasma was separated from the erythrocytes by centrifugation
and stored at -80° C until fatty acid analysis.
Preparation of a total lipid extract from 100 ul plasma was performed with a modified
Folch extraction by the addition of 3 ml methanolxhloroform (1:2, vol:vol) (14, 15).
L-a-dinonadecanoyl was used as an internal standard. Aminopropyl bonded phase
columns were used to separate phospholipids from the total lipid extract (16). The
fatty acid (FA) constituents of the phospholipids were transmethylated to the
corresponding methylesters (FAME) by reaction with 14% BF3 in methanol at 100° C
for one hour (17). Temperature-programmed GC-FID (Gas Chromatograph-Flame
Ionisation Detector) on a 50m x 0.25 mm CP-Sil 5 CB, df = 0.12 um column (Chrom-
pack®, Middelburg, The Netherlands) with N2 as carrier gas was used for the analysis
of fatty acid methyl esters. In total 39 fatty acids were identified and the following
fatty acids are reported: ZSAFA (sum of the saturated fatty acids 14:0, 15:0, 16:0,
18:0, 20:0, 22:0, 23:0 and 24:0), IMUFA (sum of the mono-unsaturated fatty acids
16:l(n-7), 18:l(n-7), 20:l(n-7), 18:l(n-9), 20:l(n-9), 22:l(n-9) and 24:l(n-9)), I
PUFA (sum of the poly-unsaturated fatty acids 18:3(n-3), 2O:3(n-3), 20:4(n-3),
20:5(n-3), 22:3(n-3), 22:5(n-3), 22:6(n-3), 18:2(n-6), 18:3(n-6), 20:2(n-6), 20:3(n-6),
20:4(n-6), 22:2(n-6), 22:4(n-6), 22:5(n-6), 24:2(n-6), 18:2(n-9), 20:3(n-9) and 22:3(n-
9)) and linoleic acid (18:2(n-6), LA).
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/. /va/ fl/irf /af/y ac/V/ /n/ate fë/doy,* rfuri/ig preg/w/icy, measured *>>• /ôorf
± s.</.. n =
Nutrient^] 1st trimester 2nd trimester 3rd trimester diet history
TF
SAF
MUF
PUF
LA
92.7 ±
38.1±
35.7 ±
18.1 ±
15.41
33.1
12.8
12.1
11.5
10.3
88.1
36.7
34.3
16.5
14.0
1
1
1
1
1
31.3
13.3
12.5
8.0
7.1
88.6 ±
36.91
34.01
16.91
14.31
39.0
14.3
13.7
15.5
13.6
99.51
41.51
38.1 1
19.01
16.2 +
33.2»
13.9»
13.2»
8.2»
7.5»
*: No significant differences at the 0.05 level in nutrient intake between trimesters.
ft TF, total fat; SAF. saturated fat; MUF.mono-unsaturatcd fat; PUF. polyunsaturated fat; LA,
linolcic acid,
a: significant difference between FFQ2 and DH (p < 0.0001 ).
Because the quantitative amounts (g/day) of the intake of total fat, saturated fat,
monounsaturated fat, polyunsaturated fat and linoleic acid were not normally
distributed, these variables were analyzed by non-parametric methods. Differences
between two groups were tested using the Wilcoxon's signed-rank test for paired
observations and the Mann-Whitney test for unpaired observations. The Kruskal
Wallis test was used to investigate differences between more than two groups.
Spearman rank correla-tion coefficients between intakes at three trimesters for total
fat, saturated fat, monounsaturated fat, polyunsaturated fat and linoleic acid were
calculated to assess relative changes in dietary composition within persons.
The effect of parity, smoking and education of the mother on nutrient intake estimated
by diet history (DH), was tested by means of the Student's t-test (two groups) or
Tukey (more than two groups) for the normally distributed variables. Otherwise non-
parametric tests were used (see above).
Although it was not the purpose of the study, the study design made it possible to
assess the validity of the food frequency questionnaire (FFQ). Therefore, several tests
were performed (18): the difference in intake between FFQ2 and DH was tested with
the Wilcoxon's signed-rank test; Spearman rank correlation coefficients were calcula-
ted between nutrient intakes according to FFQ2 and the diet history; furthermore, the
joint classification of nutrient intakes assessed by FFQ2 and DH was investigated with
the aid of contingency tables. The women were divided into quintiles according to the
nutrient intake by FFQ2 and DH. Subjects were grossly misclassified when they were
classified from one extreme category to the other extreme category. Finally, Pearson
correlation coefficients were calculated between the intake of saturated fat,
monounsaturated fat. polyunsaturated fat and linoleic acid intake (% of total fat) on
the one hand and their relative amounts (% of total fatty acids) in plasma
phospholipids on the other.
The statistical analyses were performed by use of the SPSS-PC program (19).
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2. Mifrieitr ùuaAr per da> «K/HOV ges/a/ion. i*nsiimf 6v fA* *>/ Aurorv f««wi A i.rf,.
Nutrient!
Energy (MJ)
Protein
Carbohydrate
TF
SAF
MUF
PUF
LA
Cholesterol (mg/MJ)
Calcium (mg)
Mean ± s.d.
9.8 ± 2.54
14.9 ±2.75
47.9 ± 5.76
38.1 ±5.56
15.9 ±2.51
14.6 ± 2.45
7.3 ±2.13
6.2 ± 2.04
27.2 ± 7.29
1237 ±502
RDA§-*
9J
10-15
50-55
30-35
S 10
10
10
5 33
800-1000
1: TF. total fat; SAF. saturated fat; MUF. mono-unsaturatcd fat; PUF. polyunsaturatcd fat; LA.
linoleic acid.
§: RDA. recommended daily amount.
#: The RDA for total fat intake should be between 30 and 35 % of energy intake and for SAF intake
maximal 10 % of energy intake. For the MUF and PUF intake no recommendations have been
made. However, under ideal circumstances this will be 10 % of energy intake (Netherlands
Nutrition Council 1989. ref. 20).
RESULTS
The mean daily intake of total fat (TF), saturated fat (SAF), monounsaturatcd fat
(MUF), polyunsaturated fat (PUF) and linoleic acid (LA), according to the three
FFQs and diet history (DH) of 176 women, is shown in Table 1. Between the three
trimesters, no significant differences in TF, SAF, MUF, PUF and LA consumption
were observed. The mean nutrient intakes of TF, SAF, MUF, PUF and LA according
to the questionnaire were significantly (p < 0.0001) lower than according to the diet
history (Table 1).
Nutrient intakes assessed with the diet history method are shown in Table 2, and
compared with the Dutch (20) recommended daily amounts (RDA) for pregnant
women. The mean daily intake of total energy (MJ), TF (% of energy intake), SAF (%
of energy intake) and MUF (% of energy intake) was above the RDA's; the mean
daily intake of carbohydrates (% of energy intake) and polyunsaturated fat (% of
energy intake) was below the RDA's. About 27 percent of the women met the goal for
fat intake (5 35 % of energy intake), 2 percent of the women for SAF intake (£ 10 %
of energy intake) and 82 percent for cholesterol (S 33 mg/MJ). About 26 percent of
the subjects had a carbohydrate intake between 50 and 55 % of energy intake.
Although the mean calcium intake was above the RDA, 20 percent of the women had
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i. Spearman rani corre/afzon coe/Ticze/rts Tor nufrienr /nra/œ 6eftvee/i a7/7êrenf sfagKS o /
Nutrient^ I vs II I vs III II vs III II vs DH
TF(g)
SAF(g)
MUF(g)
PUF (g)
LA(g)
0.52
0.49
0.53
0.65
0.69
0.42
0.44
0.44
0.57
0.58
0.61
0.58
0.62
0.66
0.67
0.64
0.61
0.6S
0.66
0.67
I, FFQ-lst trimester; II. FFQ-2nd trimester; III. FFQ-3rd trimester; DH, Diet History.
p < 0.001 for all correlation coefficients presented.
TF.total fat; SAF, saturated fat; MUF, mono-unsaturated fat; PUF. polyunsaturated fat; LA,
linolcic acid.
7aWe 4.
around 20 wee*.* o^gesra/ion fa = #0J ana" f/ie corre/afion coe/ftaem tvif/i /arry acù/ /«fate ^% o /
Fatty acidU plasma PLs FFQ2 DH
mean ± s.d. r (95% CI) r(95%CI)
ISAFA 42 .511 .40 -0.10 (-0.31 to 0.13) -0.02 (-0.24 to 0.20)
IMUFA 12.2 ± 1.42 -0.00 (-0.22 to 0.22) -0.02 (-0.24 to 0.20)
IPUFA 41.1 ±1.62 0.35 (0.14 to 0.53)» 0.45 (0.26 to 0.61 )<=
18:2(n-6) 21 .612.91 0.37 (0.16 to 0.5S)b 0.43 (0.23 to 0.59)C
t ISAFA. sum of saturated fatty acids; ZMUFA. sum of the mono-unsaturated fatty acids; Z
PUF A. sum of the polyunsaturated fatty acids; 18:2(n-6). linolcic acid,
a: p < 0.002; b; p < 0.001; c: p < 0.0001. FFQ: food frequency questionnaire. DH: diet history.
a calcium intake below 800 mg. Approximately 55 percent of the women did not
consume any alcohol. Only 2 persons consumed more than 10 gram (corresponds with
one alcoholic consumption) alcohol a day.
No significant differences were observed for the nutrient intakes between smokers (n
= 42) and non-smokers (n = 134) and between nullipara and primi/multipara. Women
with the highest education (university and higher vocational education, n=36) had
significantly (p < 0.05) lower mean intake of MUF (13.7 vs 15.3 % of energy intake)
and higher mean intake of protein (15.8 vs 13.9 % of energy intake) and calcium
(1454 vs 1134 mg) compared to the mean intake of women with the lowest education
(primary school and lower vocational education. n=39).
In Table 3, Spearman rank correlation coefficients for the intake of TF, SAF, MUF,
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PUF and LA between the different trimesters and between FFQ2 and DH are
summarized. All correlations were highly significant (p < 0.001). The correlations
between the first trimester and the other two were not as strong as between the second
and third trimester. The Spearman correlation coefficient between FFQ2 and DH
ranged from 0.61 (95% CI: 0.51-0.70) for SAF to 0.67 (95% Cl: 0.58-0.74) for LA.
When comparing the classification of nutrient intake, assessed by FFQ2. with the
classification according to DH, 2 women (1.1 %) were grossly misclassified for the
intake of TF and SAF, 1 woman (0.6 %) for PUF. no women for MUF and LA. At
least 75 percent of the women were classified in the same or an adjacent category. For
the intake of MUF and LA it was even 80 percent.
In Table 4 the fatty acid composition of the maternal plasma phospholipids and its
correlation coefficients with the intake assessed by the FFQ2 and DH arc shown.
Significant correlations between dietary intake (% of total fat) and the relative amount
in plasma phospholipids (% of total fatty acids) were observed for PUF and for LA.
No significant correlations were found for SAF and MUF.
DISCUSSION
This study shows that there was no measurable change in the mean daily intake of
total fat (TF), saturated fat (SAF), monounsaturated fat (MUF), polyunsaturatcd fat
(PUF) and linoleic acid (LA) of Dutch women during normal pregnancy. In addition,
the significant correlations between the different trimesters for the intakes of TF, SAF,
MUF, PUF and LA indicate that the individual dietary composition, with respect to
the fat intake, is rather stable during pregnancy.
Berg and Bruinse (3) observed a consistent dietary behavior in 67 healthy Dutch
gravidae, too. However, they found a significantly lower fat intake in the third
trimester compared to the first, assessed with the diet history method. A reduced fat
intake in late pregnancy was also reported by other investigators (21,22). Using the 7-
day weighed dietary record, Doyle e/ a/. (23) observed the lowest fat intake in the first
trimester; it has to be noticed, however, that 95 % of the women participating in that
study had an energy intake below the recommended dietary allowances in all three
trimesters. This inconsistency in result could be due to the different methods used to
assess nutrient intake. In a recent study among 50 American pregnant women, in
which a food frequency questionnaire was used also, no differences in nutrient intake
were observed between trie second and third trimester (24).
Each method to assess dietary intake has specific advantages and disadvantages
(25,26). The method to be preferred in nutrition surveys depends on the purpose of the
study, the accuracy of the methods, the target group and the availability of resources
(27). We have chosen for a combination of two methods, the FFQ and the diet history
(DH). The food frequency questionnaire represents a cheap, simple and quick method
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since it can be completed by the subjects themselves, without special training (27).
The FFQ used in this study, was specially developed to collect data on the fat con-
sumption of the participating women in the course of pregnancy. To estimate the total
energy intake and other dietary components of the pregnant women, the diet history
method was carried out, mid gestation.
The FFQ and DH methods both have a strong subjective component. The information
collected by the interviewer is based entirely on an individual's memory and report
(27). An advantage of our study is that only one dietitian was involved, so observer
differences can be excluded. It is, however, important to know the validity of both
methods used. Because there is no gold standard for the assessment of dietary intake,
only the relative validity can be determined. The DH is considered to be a reliable
method (27) and the results of the diet history in our study were in agreement with the
mean nutrient intake of pregnant women reported by a nationwide dietary survey
carried out in the Netherlands recently (11). Together with the significant positive
correlation between intake of PUF and LA and their relative amounts in plasma
phospholipids, this implies that the results of the DH are reliable.
The relative validity of the FFQ was evaluated by comparison with the results of the
DH and with a biological marker. The mean daily intake of TF, SAF, MUF, PUF and
LA according to FFQ2 was lower than the intake according to the diet history. This
may be due to the fact that the number of food items listed in the FFQ was not
exhaustive and the diet history method yields higher values in general (28). However,
the FFQ was designed to classify individuals by their intake of fat. The FFQ was able
to classify more than 75 percent of the women correctly. Less than 2 percent was
grossly misclassified. These percentages are comparable with those reported by others
(29,30). In addition, significant positive correlations were observed between FFQ2
and the diet history for the intake of TF, SAF, MUF, PUF and LA (Table 3) and
between the LA and PUF intake and their concentrations in plasma phospholipids. So,
the FFQ used in this study seems to be a valid method to rank participants adequately
according to their dietary intake of TF, SAF, MUF, PUF and LA. However, according
to our own experience and that of others (24,30), training the study population in how
to use a FFQ may even further improve the validity of the results derived from the
FFQ.
A difference was observed between the intake of MUF (% of energy intake), protein
(% of energy intake) and calcium of women with the highest educational level
compared with the lowest. However, compared to the RDAs these differences were
not disturbing. This in contrast to the small part of the women who met the goals for
total fat intake (27 °o) and SAF intake (2 %), according to the Dutch quidelines for a
healthy diet. Although all women had a normal pregnancy, it is possible that a
suboptimal maternal diet during gestation may affect the post-natal development of
the child, since evidence is now emerging that maternal nutrition, and fetal and infant
growth, may have an imprinting effect on the risk of cardiovascular disease in adult
life (31).
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In conclusion, no change was observed throughout uncomplicated pregnancy for the
mean daily intake of total, saturated, monounsaturated and polyunsaturated fat and of
linoleic acid of Dutch women. In addition, the individual dietary composition with
respect to these nutrients seems consistent during normal gestation. Finally, the FFQ
used in this study is able to reasonably rank subjects adequately according to the
intake of the nutrients investigated. This allows us to use this FFQ for a future
comparison between uncomplicated and complicated pregnancies.
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CHAPTERS
Maternal essential fatty acid patterns during normal
pregnancy and its relationship with the neonatal
essential fatty acid status
Monique DM. AI, Adriana C. v. Houwelingen, Arnold DM. Kester, Tom H.M.
Hasaart, Andre E.P. de Jong and Gerard Hornstra
ABSTRACT
Although essential fatty acids (EFAs) and their longer-chain, more unsaturatcd
derivatives play a major role during pregnancy, hardly any information is available
with respect to the course of the maternal EFA status during an uncomplicated
pregnancy and its relationship with the neonatal EFA status. Therefore, a longitudinal
study was started in which 110 pregnant women gave repeatedly a blood sample from
the 10th week of gestation until delivery. After birth, a blood sample from the
umbilical vein and a maternal venous sample were collected as well, and six months
after delivery, a final blood sample from the mother was taken (n=43). The absolute
(mg/L) and relative (% of total fatty acids) amounts of the fatty acids in plasma
phospholipids were determined. The total amounts of fatty acids increased
significantly during pregnancy. This pattern was similar for the individual fatty acids
and fatty acid families. The relative amounts of linoleic acid [18:2(n-6)] did not
change during pregnancy, whereas the relative amounts of arachidonic acid [20:4(n-
6)] decreased. Despite a maternal mobilization of cervonic acid (22:6(n-3), CA),
suggested by a temporarily increase in the CA status until 18 weeks of gestation, the
CA status steadily declined thereafter. This was associated with a progressive increase
of the cervonic acid deficiency index in maternal blood throughout pregnancy and
resulted in a sub-optimal neonatal CA status. The overall maternal EFA status steadily
declined during pregnancy also. Therefore, to ensure an adequate EFA status of
mother and fetus during gestation, it may be advisable to supplement pregnant women
with EFA, CA in particular.
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INTRODUCTION >• ,
Essential fatty acids (EFAs) and their longer-chain, more unsaturated derivatives play
a major role during pregnancy. They provide the precursors for prostaglandins and
leukotrienes and they are important constituents of all cell membranes, especially
those in the brain, and in the nervous and vascular systems. During the third trimester
of pregnancy, rapid synthesis of brain tissue occurs (1) and the quantitative accretion
in the human brain of the long chain polyenes arachidonic acid (20:4(n-6), AA) and
cervonic acid (22:6(n-3), CA) increases steadily with gestation (2,3). CA plays an
important role in the visual process and the amount of CA in the human retina also
increases with maturation (4). Evidence is growing that CA is essential for a normal
development of brain and retina (5-7).
Recently, it has been suggested that fish-oil, rich in fatty acids of the (n-3) family,
might reduce the occurrence of obstetric complications such as preterm delivery (8)
and pregnancy induced hypertension (9-13). But not only (n-3) fatty acids seem to be
important to establish a normal pregnancy, because decreased maternal levels of
linoleic acid (18:2(n-6), LA) have been observed in pregnancy-induced hypertension
(14,15) and intra-uterine growth retardation (16). Therefore, fatty acids like LA, AA
and CA may be of great importance in the diet of pregnant women. However, most
studies relating pregnancy complications to EFA status are based on retrospective
case-control designs, using material collected in late pregnancy or post-partum.
Therefore, these studies do not allow any conclusion with respect to a possible cause
and effect relationship. Such a conclusion would require prospective longitudinal
monitoring of the maternal EFA status and the comparison of the maternal EFA
courses during normal and complicated pregnancies. Hardly any information is
presently available with respect to the course of the maternal EFA status during
uncomplicated pregnancy. Therefore, we performed a longitudinal study to investigate
the EFA status of women during normal pregnancy. In addition, the relationship
between maternal and neonatal EFA status was investigated.
SUBJECTS, MATERIALS AND METHODS
At their first antenatal medical visit, pregnant women were asked to participate in the
study. The selection criteria for entering the study were a gestational age less than 16
weeks, singleton pregnancy, Caucasian race, diastolic blood pressure below 90 mm
Hg, and the absence of any metabolic, cardiovascular, neurological or renal disorder.
In total 140 women entered the study. Excluded were women who developed
pregnancy-induced hypertension (n=ll) or gestational diabetes (n=2), women who
delivered their babies before 37 weeks of gestation (n=8) or after 42 weeks (n=5), and
women whose babies were not appropriate for gestational age (<P2.3 (n=3) and
>P97.7 (n=l)). Finally, 110 women with an uncomplicated pregnancy met the
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Variable
Age mother (yr)
Gestational age (wks)
Birthwcight (g)
Apgar score (S min)
Parity at entry (n) 0
1
2
3
Sex (n) male
female
29.5
40.4
3403
10
47
46
14
3
62
48
19-43
37-42
2130-4410
6-10
J: Mean and range (minimum-maximum) given, except for parity and sex.
inclusion criteria. Their relevant clinical information is summarized in Table I.
Maternal venous blood samples were collected into HDTA-tubes at 10 weeks of
gestation (n=45), at 14 weeks (n=98), at 18 weeks (n=101), at 22 weeks (n=97), at 26
weeks (n=98), at 30 weeks (n=105), at 32 weeks (n=103), at 34 weeks (n=l00), at 36
weeks (n=101), at 38 weeks (n=86) and at 40 weeks (n=39). Immediately after
delivery, a blood sample from the umbilical vein (n=98) and a maternal venous blood
sample (n=95) were collected also. At least six months post-partum, 43 women gave a
blood sample once more. The protocol was approved by the Ethics Committee of the
University and written consent was obtained from each participant.
Plasma was separated from the erythrocytes by centrifugation and stored at -80° C
until fatty acid analysis. Fatty acid composition of the phospholipid fraction was
performed using 100 ul plasma samples. A total lipid extract was prepared via a
modified Folch extraction (17,18). Before lipid extraction, 50 ul of an internal
standard (IS) solution was added. The IS solution consisted of 62 mg
l,2,dinonadecanoyl-5«-glycero-3-phosphocholine (PC( 19:0)2), 40 mg 10-
heptadecenoic acid (C17:l) to check carry over of free fatty acids during the
phospholipid separation procedure (see below), and 100 mg BHT, dissolved in 100
ml MeOH. Aminopropyl bonded silica columns (500 mg) were used to separate
phospholipids from the total lipid extract (19). The phospholipids were saponified and
the fatty acids (FA) transmethylated to the corresponding methylesters (FAME) by
reaction with 14% BF3 in methanol at 100° C for one hour (20). The FAMEs were
separated and quantified by using a HP 5890 II gas chromatograph, fitted with a 50 m
CP Sil5 CB non-polar capillary column with 0.25 mm ID and 0.12 urn film thickness
(Chrompack®, Middelburg, The Netherlands) and a split ratio of 1:40. The injection
temperature was 250° C and the detector temperature 300° C. The starting
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temperature of the column was 160° C. After 2 minutes, the temperature increased up
to 220° C with a rate of 2° C/min and finally to 280° C with a rate of 6° C/min. The
flow rate of the carrier gas (N2) was 35 ml/min. A standard FAME mixture was used
to identify the fatty acid methylesters by means of the retention times. Quantifying the
amount of FAMEs was based on the ratio between the peak area 19:0 and the peak
area of the fatty acid methylesters in the sample multiplied by the amount of 19:0
present in the internal standard solution. The results were expressed in absolute
amounts (mg/L plasma) as well as in relative amounts (% of total fatty acids).
Two indices were calculated to describe the essential fatty acid status of the mother
and her newborn. The cervonic acid deficiency index (CADI) (21,22), defined as the
ratio between 22:5(n-6) and 22:4(n-6), was used because a deficit of 22:6(n-3) is
accompanied by an increase in the conversion of 22:4(n-6) to 22:5(n-6), resulting in
higher CADI values (6). The other index was the essential fatty acid status (EFA
status) (22), defined as the ratio between the sum of the (n-3) and (n-6) fatty acids and
the sum of the (n-7) and (n-9) fatty acids. In general, if the supply of (n-3) and (n-6)
fatty acids is sufficient, the desaturation of oleic acid to the long chain polyenes of the
(n-9) family is limited, leading to higher EFA status values. The EFA status was used
instead of the classic tnene tetraenc ratio (an indicator or an c^cniia) faiiy acid
deficiency) (23), because this ratio does not account for changes in delta-5-desaturase
activity (24).
During the gestational period (10 weeks through 40 weeks), it was not always possible
to take all blood samples at exactly the intended days. Since we wanted to analyze
values at specified gestational ages, the values of the fatty acid amounts and
percentages at those days were estimated by lineair interpolation between the days
when blood had been sampled. For blood samples taken within one week before or
after the intended sampling day, interpolation was considered unnecessary. Because of
remaining missing data, means were estimated with adjustment for missing data using
the repeated measures analysis program BMDP 5V (25,26). This program adjusts the
means using the correlations between measurement times.
Using a model with a quadratic dependence of the fatty acid parameter on time, we
tested whether a lineair or quadratic course was present. Data from blood samples at
10 weeks of gestation, immediately post-partum (pp), 6 months after delivery (ad),
and from the umbilical vein (uv) were analysed in a similar model. The data from
weeks 22-32 were included in this analysis to take full advantage of the missing data
adjustment. Comparison of pp, ad. uv, and week 10 was done by the Wald test (26).
Pearson correlation were used to correlate maternal with neonatal values at delivery
and to relate the parameters gestational age. birthweight, head circumference and
placenta! weight and size with maternal values early in pregnancy (week 10, 14 and
18) and maternal and neonatal fatty acid values at delivery. Correlation coefficients
were calculated for the CADI and EFA status and for the absolute and relative
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amounts of ISAFA, IMUFA, In-3, In-6. 18:2(n-6). 20:4(n-6) and 22:6(n-3).
Multiple regression was performed to adjust for the potential confounding variables
parity, maternal height, weight and age, smoking habits and educational level of the
mother and sex of the newborn for the relationship between gestational age and fatty
acid values. When studying the association between size of the newborn, placenta!
weight and placenta! size and fatty acid levels, gestational age was also included as a
potential confounder.
When groups were compared. Student's t-test was performed.
RESULTS
Plasma fatty acids of chain lenghts ranging from 14 to 24 carbon atoms were
identified; however only the three major essential fatty acids linolcic acid (18:2(n-6),
LA), arachidonic acid (20:4(n-6), AA) and cervonic acid (22:6(n-3), CA), the sum of
the fatty acids of the n-6 family (In-6) and n-3 family (In-3), the sum of the
saturated fatty acids (ISAFA) and mono-unsaturated fatty acids (IMUFA) and the
two indices CADI and EFA status are discussed in this paper. The full data are given
in appendices Bl and B2.
The results are presented mostly in figures, showing the mean amount (± s.e.m.) of
fatty acids in maternal venous plasma phospholipids (PLs) during gestation, in
maternal (M) and umbilical (U) venous plasma PLs immediately after delivery, and in
maternal venous plasma PLs at least six months post-partum.
77»e matemaZ/affy ac/c/patterns auring pregnancy
The average total amount of fatty acids (TF) in maternal venous plasma PLs increased
significantly (p < 0.0001 ) during pregnancy (Figure 1 ), but the rise in TF became less
strong towards the end of gestation (p < 0.0001). The mean amount of TF increased
by 51% from 1238.11 mg/L at week 10 till 1867.84 mg/L at week 40 of gestation. All
the fatty acid families, when expressed as mg/L plasma, showed a similar course: the
In-6 increased by 44%, the In-3 by 41%, the ISAFA by 57% and the IMUFA by
65% from week 10 till week 40 (data not shown). When focussed on the individual
fatty acids LA, AA and CA (Figure 1), the highest increment was for CA (52%),
followed by LA (48%) and AA (23%). Six months after delivery, TF in maternal
plasma PLs had returned to levels comparable with those at the 14th week of
pregnancy. The same applied to In-6, ISAFA, IMUFA, LA and AA. The mean
absolute amounts of CA and In-3 had declined to levels even significantly (p < 0.01)
lower than at 10 weeks of gestation.
The relative amounts of the fatty acids did show a different pattern as compared to the
absolute amounts. For ISAFA and IMUFA in maternal plasma PLs, a significant (p
< 0.0001) increase was observed throughout pregnancy (Figure 2). After a slight
increase at the end of the first trimester, the In-3 decreased significantly (p < 0.0001)
during pregnancy and levelled off at the end of gestation. The mean relative amounts
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of Sn-6 steadily diminished (p < 0.0001) throughout pregnancy (Figure 2). This latter
observation was mainly due to the maternal AA status which declined from 9.6% at
week 10 till 7.8% at week 40 (Figure 3). The maternal CA status also diminished, but
only after a temporary increase until 18 weeks of gestation. In contrast, the maternal
LA status did not change throughout pregnancy (Figure 3).
While six months after delivery the In-6. XMUFA (Figure 2) and the relative
amounts of LA and AA in maternal plasma PLs (Figure 3) had returned to early
pregnancy levels, the ZSAFA had levels comparable with those of midway gestation
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(Figure 2). After delivery, the maternal CA status decreased further to 2.8% six
months post-partum, which is significantly (p < 0.0001) lower than at 10 weeks of
gestation (Figure 3). A similar pattern was observed for the £n-3 (Figure 2) which
declined to 4.5% six months post-partum.
The cervonic acid deficiency index (CADI) increased significantly (p < 0.0001)
throughout gestation (Figure 4) and levelled off towards the end of pregnancy (p <
0.0001). Six months after delivery, the CADI was equal to the CADI at 10 weeks of
gestation. The essential fatty acid status (EFA status) declined continuously
throughout the duration of pregnancy. Six months after birth, the maternal EFA status
had returned to early pregnancy levels.
éeftveew materna/ ana* /ieona/a//aM>' ac/tf"
The mean amount of TF in umbilical plasma PLs was substantially lower (p < 0.0001)
than all maternal values (Figure 1 ). This was observed for all four fatty acid families:
for ZSAFA and XMUFA the mean amount (mg/L) in umbilical plasma PLs was only
about 35% of that in maternal plasma PLs at delivery; for £n-6 and In-3 these
proportions were 32 and 47. respectively (data not shown). The mean amount (mg/L)
in umbilical plasma PLs (Figure 1) was for LA only 13% of the maternal values at
delivery, while for AA and CA the percentages were 68% and 56%, respectively (p <
0.0001 for all three fatty acids). The neonatal value for CA was not significantly
different from the maternal level six months after delivery (Figure 1 ).
In contrast to the absolute amounts for AA and CA, the mean relative amounts of AA
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Fatty acidH
TF (mg/L)
ISAFA(%ofTF)
ZMUFA(%ofTF)
In-6(%ofTF)
In-3(%ofTF)
l8:2(n-6)(%ofTF)
20:4(n-6)(%ofTF)
22:6(n-3)(%ofTF)
r
0.04
0.45
0.45
0.60
0.60
0.52
0.56
0.60
P
NS
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
< 0.0001
f: TF, sum of total fatty acids; ZSAFA, sum of saturated fatty acids; XMUFA, sum of
monounsaturatcd fatty acids; £n-6. sum of fatty acids of the (n-6) family; Ln-3. sum of fatty acids of
the (n-3) family.
and CA in umbilical plasma PLs were significantly (p < 0.0001) higher than all
maternal values (Figure 3). However, the mean relative amounts of LA in umbilical
venous plasma PLs was significantly (p < 0.0001) lower than that of the mother
(Figure 3). This resulted in a significant lower £n-6 in umbilical plasma PLs
compared to maternal plasma PLs, despite the higher neonatal AA levels (Figure 2).
The Xn-3 and XSAFA amounts in umbilical plasma PLs were significantly (p <
0.0001) higher than the maternal values. For ZMUFA no significant difference
between mother and child was observed.
The mean CADI value in umbilical venous plasma PLs was significantly (p < 0.0001)
lower than the maternal CADI, immediately after delivery, but significantly (p <
0.0001) higher than the maternal CADI six months post-partum and at 10 weeks of
gestation (Figure 4).
The neonatal EFA status did not differ significantly from the maternal value at
delivery, but was significantly (p $ 0.005) lower than the EFA status in maternal
plasma PLs six months after birth and at early pregnancy (Figure 4).
In Table 2 Pearson correlation coefficients between maternal and umbilical venous
plasma values, post-partum, are shown for the total amounts of fatty acids (TF), and
for the relative amounts of ISAFA, IMUFA, In-6, In-3, LA, AA and CA. No
significant correlation was observed for TF, but all the other fatty acids and fatty acid
combinations did show a highly significant positive correlation.
of materna/ ana" neonafa/ /âffv ana" compagnon in p/asma PLJ u-ifn
som? c/inica/ vana/iteam/.vmoAing/laftiwq/ffle mo/ner
Because of the large number of comparisons made, only those with a p £ 0.01 are
reported. For maternal values, only a significant positive correlation was observed
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between the amount of AA (% of TF) in maternal plasma PLs at 10 weeks of gestation
and binhweight (r = +0.39, p = 0.007, n = 45). This correlation did not hold for the
other time points.
The amount of LA (% of TF) in umbilical plasma PLs was negatively correlated with
gestational age (r = -0.37, p = 0.0001. n = 98). The relative as well as the absolute
amounts for CA and In-3 in umbilical plasma PLs correlated positively with
gestational age (% of TF: r = +0.38. p = 0.0001 for CA and In-3; mg/L: r = +0.42. p
< 0.0001 for CA and r = +0.43, p < 0.0001 for In-3). Significant positive correlations
were also observed between placental weight and the absolute amounts in umbilical
plasma PLs for AA (r = +0.27, p = 0.007), CA (r = +0.29, p = 0.005), In-3 (r »
+0.29, p = 0.005) and ISAFA (r = +0.28, p = 0.006, n = 96). These associations did
not change when correcting for the potential confounders parity, maternal height,
weight and age, smoking habits and educational level of the mother, sex of the
newbom and gestational age.
After adjustment for parity, a significant negative correlation was found between the
relative amounts of LA in umbilical plasma PLs and head circumference (partial r • -
0.36, p = 0.001). Introducing gestational age in the multiple regression analysis did
not alter the above conclusion.
No differences were observed between smokers (n=32) and non-smokers (n=78) for
the various fatty acids and fatty acid families in maternal and neonatal plasma PLs at
delivery.
The mean absolute amount of CA and In-3 in umbilical plasma PL were significantly
higher in girls than in boys (CA: 40 ± 2.0 vs 33 ± 1.1, p = 0.009; In-3: 46 ± 2.3 vs 38
± 1.5, p = 0.008). No significant differences in gestational age were observed between
boys and girls.
DISCUSSION
To our knowledge, this is the first report about the essential fatty acid composition of
maternal plasma phospholipids (PLs), measured longitudinally throughout normal
pregnancy, in an absolute (mg/L) and in a relative (% of total fatty acids) manner. The
decision to use the PL fraction was based on the fact that PLs are structural lipids,
which are the richest source of polyunsaturated fatty acids (PUFA). Moreover,
changes in PUFA profile are most pronounced in PLs (27) reflecting the essential fatty
acid (EFA) status best.
To correct for the, hardly avoidable, missing values, an analysis model was chosen
which estimated the means with adjustment for the missing data. The uncorrected
data, however, showed a similar course as the corrected data. Moreover, the correction
factor was never more than 2.5% of the mean value.
The increase in absolute amounts of fatty acids in maternal plasma PLs throughout
normal pregnancy (Figure 1) is a direct consequence of the enhanced PL
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concentration during gestation (28). The total fatty acid increase during pregnancy
cannot be calculated, because pre-pregnancy levels are not available. As an
approximation, maternal blood samples, taken 6 months after delivery, were analyzed.
In these samples, the amounts of most of the fatty acids were comparable with their
values at the end of the first trimester. From 18 women information was available at 8
weeks of gestation and the fatty acid concentrations in the plasma PLs of these
samples were lower than at 10 weeks. This strongly indicates that the absolute
maternal fatty acid values measured 6 months after delivery, do not yet reflect true
pre-pregnancy levels which are still appreciably lower.
During pregnancy, the increment observed for CA in maternal plasma PLs was the
highest for all polyunsaturated fatty acids, and compared to pre-pregnancy levels
(which are most probably lower than the levels 6 months after delivery - see above)
the absolute amounts doubled during gestation. This probably reflects the special
requirement for CA by the developing brain and retina (2,5,7,29).
In theory, the improved absolute maternal CA status can result from a change in
dietary habits, an increase in fish consumption in particular. However, no differences
in nutrient intake during gestation were observed (40). Another explanation can be an
increase in the activity of the enzymes involved in the synthesis of CA from its
precursors. However, this process occurs at a very low rate only (30) and, therefore, it
seems more likely that the improved maternal CA status during pregnancy is due to an
increased mobilization from maternal stores, although a metabolic re-routing (from
energy substrate to structural use) cannot be excluded.
When expressed in relative terms, the maternal CA increase lasted until 18 weeks of
gestation. Thereafter a gradual decrease is seen, which may reflect the maternal
inability to mobilize adequate amounts for optimal fetal development. This view is
supported by the fact that the maternal cervonic acid deficiency index (CADI)
increases gradually throughout pregnancy, and that the CADI value in umbilical
plasma PLs (although lower than the maternal value at delivery) is significantly higher
than the maternal value 6 months after delivery, which is the best available estimate
for the value in the non-pregnant state. These observations indicate that the present
diet of pregnant women is inadequate to guarantee an optimum CA status of the
developing fetus. This may be a rationale for considering CA supplementation during
pregnancy.
The AA status (% of total fatty acids) in umbilical venous plasma PL is, just like CA,
significantly higher than the maternal relative amounts, despite the decrease of the
maternal AA status throughout pregnancy. This might point to a high neonatal need
for AA which is the most abundant fatty acid of the (n-6) family in neural tissue and
retina (31-33).
No changes were observed for the maternal LA status throughout pregnancy. The
neonatal relative amounts of LA were almost three times less than the maternal
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plasma values. Results from a recent study demonstrated that the low fetal amounts of
LA originate early in pregnancy (34). In spite of the low LA levels in umbilical
venous plasma PLs, the neonatal EFA status did not differ from the maternal BFA
status at delivery. However, since the neonatal EFA status was significantly lower
than the maternal EFA status six months post-partum and at 10 weeks of gestation, the
question arises whether the neonatal EFA status is optimal indeed.
The capacity of the placenta and fetal liver to synthesize the long chain polyenes
(LCPs) AA and CA from their parent essential fatty acids LA and a-linolenic acid
(18:3(n-3), LnA) is very limited (35). Therefore, other mechanisms have to be
responsible for the different fatty acid profiles for LA, AA and CA between maternal
and umbilical plasma PLs. It could be due to preferential transport of LCPs across the
placenta, but selective sequestering of AA and CA. at the expense of LA, into
phospholipids on the fetal side of the placenta (36) may also be responsible. As a
consequence, AA and CA are compartmentalized into a lipid fraction which does not
recross the placental barrier (37) and therefore will remain available for the
developing tissues, like brain and retina. A possible important role in the transport of
LCPs in the fetal circulation may be reserved for a-fetoprotein (AFP). This protein is
mainly synthesized by the fetal liver and the yolk sac. Although the biological role of
AFP is not completely elucidated, it binds polyunsaturated fatty acids, mainly AA and
CA, with high affinity. Because these fatty acids are important components of
structural lipids, the transport and cell delivery of LCPs could be a major
physiological activity of AFP (38).
The placenta is, for the greater part, a fetal organ which has a fatty acid composition
more similar to that of fetal plasma than of maternal plasma (21,35). This might
explain why significant correlations were observed for placental weight with some
fetal fatty acid values, but not with maternal fatty acid levels.
A significant positive correlation between CA and £n-3 in umbilical plasma PLs and
gestational age was observed. In a preterm population (n=22), Leaf et al (39) also
observed a significant positive correlation between 22:6(n-3) in neonatal plasma
cholinephosphoglyceride and gestational age. Negative correlations were
demonstrated in the present study for linoleic acid (% of TF) with gestational age and
with head circumference. These associations were not reported by Leaf et al (39),
although she found positive correlations for birthweight and head circumference with
the sum of 20:3(n-6)+20:4(n-6) and with 22:6(n-3) (39). These latter two associations,
however, were not observed in our term population, where all infants were born
between 37 and 42 weeks of gestation, while in the preterm population the range in
gestational age was 12 weeks. This wider range in gestational age could partly explain
the difference in result. Moreover, it is known that head circumference of the
newborn, for instance, also depends on the head circumferences of the parents,
duration of expulsion, the way of delivery, method of recording head cirumference,
etc. Corrections for these possible confounders were not made.
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At the moment, the modification is discussed of the fatty acid composition of
formulas to ensure an optimal administration of AA and CA after birth. On the basis
of the results described in this paper, it can be concluded that lipid nutrition of high
quality during gestation is important also, especially with respect to CA. The
correlations between the maternal and umbilical relative amounts for LA, AA and CA
are strong and suggest that the neonatal essential fatty acid status can be influenced by
the mother.
This study has yielded data both on the course of the maternal essential fatty acid
profiles throughout normal pregnancy and on the EFA status of umbilical venous
plasma and maternal plasma, six months after delivery. In addition, the fatty acid
composition was determined absolute as mg/L and relative as percentage of total fatty
acids. These data will serve as reference values in a further comparison between
uncomplicated and complicated pregnancies which is presently being executed.
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CHAPTER 6
The essential fatty acid status of mother and child in
pregnancy-induced hypertension: a prospective
longitudinal study
Monique DM. AI, Adriana C. v. Houwelingen, Anita Badart-Smook, Tom H.M.
Hasaart, Frans J.M.E. Roumen and Gerard Hornstra
Sutom/ffetf tor pub//caf/on
ABSTRACT
To investigate the relationship between the essential fatty acid (EFA) status of
mothers and their newborns and pregnancy-induced hypertension (P1H) in a
prospective way, a longitudinal study was started. Pregnant women, healthy at the
start of the study, were asked to give a blood sample before 16 weeks, at 22 weeks
and at 32 weeks of gestation. After delivery, a blood sample from the umbilical vein,
a piece of the umbilical cord and a maternal blood sample were collected. Fatty acid
compositions were determined of the phospholipids (PLs) isolated from plasma and
from umbilical arterial and venous vessel walls. The nutrient intake of the pregnant
women was assessed with the aid of the dietary history method and using food
frequency questionnaires. The results of each woman with PIH were compared with
the results of three matched healthy controls. During pregnancy (16-32 weeks), no
significant differences were observed in nutrient intake and maternal plasma fatty acid
composition between the PIH (n=52) and the control group (n=156). After delivery,
the relative amounts of 18:2(n-6) and 18:3(n-3) in maternal plasma were significantly
lower in PIH than in normal pregnancy (NP). This was associated with significantly
higher levels of (n-6) long chain polyenes and cervonic acid (22:6(n-3),CA). As
compared to the situation at 32 weeks, the post-partum CA status increased in PIH
whereas it decreased in NP. The CA levels in umbilical plasma PLs was significantly
higher after PIH than after NP. No significant differences were observed for the
umbilical vessel walls. The results indicate that the altered EFA status in PIH is a late
phenomenon and is, therefore, unlikely to have contributed to the pathogenesis of
PIH. Moreover, the neonatal EFA status is not negatively affected by PIH.
63
INTRODUCTION I
Pregnancy-induced hypertension (PIH) is one of the most frequently occurring
disorders during pregnancy. Incidence rates of 6 to 30 % have been reported (1,2).
The etiology of PIH is still unknown, but the pathophysiological events are becoming
less enigmatic. There is considerable evidence that endothelial cell injury is involved
in the pathogenesis (3). Dysfunctional endothelium will, among other things, produce
less prostacyclin and activate platelets that subsequently release thromboxane A2
(TXA2), resulting in a disturbed balance between prostacyclin and TXA2 (4,5). It has
been suggested that administration of low-doses of aspirin could correct this
imbalance and reduce the occurrence of PIH (6). However, the results of three large
clinical trials with aspirin do not support the prophylactic or therapeutic value of the
routine administration of low-dose aspirin to women at increased risk of PIH (7-9).
Fish-oil, rich in (n-3) fatty acids, has also been considered as a remedy against PIH
(10-13) and studies in normal pregnant women have shown that fish-oil
supplementation in late pregnancy may be beneficial in the management of PIH by
correcting the prostanoid imbalance (14,15). However, we observed /i/g/ier levels of
cervonic acid (22:6(n-3), CA), one of the typical "fish fatty acids", in maternal venous
plasma phospholipids, immediately after delivery, in thirteen women with PIH
compared to fifteen women with an uncomplicated pregnancy (16). This raises the
possibility that fish-oil "treatment" may be contra-indicated in pregnancy, since CA
may theoretically be involved in the etiology of PIH. In the same study (16), lower
maternal levels of linoleic acid (18:2(n-6), LA) were observed in PIH. This was also
reported by Wang et al (17), who studied plasma polyunsaturated fatty acid (PUFA)
levels in 9 preeclamptic women. However, these studies share the disadvantage that
they are based on a retrospective design, a small number of subjects, and on material
collected in late pregnancy or post-partum. As a consequence, no information is
available whether the alterations of the essential fatty acid status took place fte/ore or
q/fer the development of PIH. Therefore, a prospective cohort study was started to
investigate the relationship between the essential fatty acid status of mother and child,
and the occurrence of PIH.
The essential fatty acid status was assessed by determining the fatty acid composition
in plasma and/or tissue phospholipids, which are the richest source of PUFAs.
Changes in PUFA profile are most pronounced in PLs, reflecting the general essential
fatty acid status of an individual best (18).
SUBJECTS, MATERIALS AND METHODS
The cohort consisted of pregnant women, who did not suffer from hypertension, or
any cardiovascular, neurological, renal or metabolic disorder at the beginning of
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pregnancy. Multiple pregnancies were excluded. At the time of entering the cohort,
the women were less than 16 weeks pregnant. After delivery, the medical records of
these women were examined and women who appeared to have developed pregnancy-
induced hypertension (cases) were selected and matched for parity and hospital with
three women who had an uncomplicated pregnancy (controls). Pregnancy-induced
hypertension (P1H) was defined as an initial diastolic blood pressure (DBP) below 90
mm Hg, an increase during pregnancy of at least 25 mm Hg or two consecutive
measurements of 90 mm Hg or more, 4 hours or more apart, or one measurement of
110 mm Hg or more suiting after 20 weeks of gestation ( 19).
Three hospitals participated in the study: University Hospital Maastricht. "De Wcvcr"
hospital Heerlen and School for Midwifery Kerkrade. The study protocol was
approved by the Ethics Committee of the University and written consent was obtained
from each participant.
Nutrient intake was assessed in the women living in the Maastricht region, only. To
estimate their fat intake during gestation, the participants filled out a food frequency
questionnaire (FFQ) each trimester. The returned FFQs were checked for
completeness by the dietitian and, if necessary, corrected after a telephone interview
with the participants concerned. Around 22 weeks of gestation, a cross-check dietary
history (20) was carried out to collect extended dietary data. The participants were
visited at home and questioned about their habitual food intake of the preceding two
months. The amounts of food eaten were estimated using portion size models or
pictures of foods. Products regularly consumed, and common household measures
were weighed afterwards on a digital scale. The food consumption data thus obtained
were encoded according to the system of the Netherlands Nutrient Databank and
converted into data on individual daily nutrient intakes, using the extended
computerized version of the Netherlands Food Table.
Maternal venous blood samples were collected into EDTA tubes before the 16th week
of pregnancy, around 22 weeks and 32 weeks of gestation. Immediately after delivery,
a maternal blood sample and a blood sample from the umbilical vein were collected as
well. Plasma was separated from the red blood cells by centrifugation and stored at -
80° C, under nitrogen, until analysis.
L/m£>i//ca/ vesse/ wa/fc
Immediately after delivery, a piece of the umbilical cord was collected, rinsed with
saline (NaCl, 0.9% w/v) and stored at -80° C until further preparation. Segments of
about 5 cm length were used to isolate the walls of both arteries and the veins. The
arterial and venous vessel walls were frozen in liquid nitrogen and pulverized in an
aluminum mortar with a stainless steel pestle, previously cooled in liquid nitrogen.
The pulverized samples were freeze-dried and weighed before fatty acid analysis.
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The fatty acid composition of phospholipids (PLs) isolated from maternal and
umbilical plasma, and from umbilical venous and arterial vessel walls was
determined. Preparation of a total lipid extract from 100 ul plasma samples was
performed with a modified Folch extraction (21,22). L-a-dinonadecanoyl lecithin was
used as an internal standard to calculate the absolute fatty acid amounts. Aminopro-
pyl bonded phase columns were used to separate phospholipids from the total lipid
extract (23). The fatty acid constituents of the phospholipids were transmethylated to
the corresponding methylesters (24), which were separated and quantified on a non-
polar CP-Sil 5 CB column (Chrompack®, Middelburg, The Netherlands). All blood
samples of a women with pregnancy-induced hypertension and her matched controls
were analysed simultaneously.
The total lipids of the umbilical vessel walls were extracted from 10-30 mg freeze-
dried tissue according to the method of Bligh and Dyer (25). Further analytical
methodology was similar as for plasma lipid extracts, except that the fatty acid
methylesters were separated on a polar capillary column (CP Sil 88, Chrompack®,
Middelburg, The Netherlands).
An aliquot of control pooled plasma was analyzed as part of every run to check the
quality of the methods.
The results were expressed in absolute (mg/L plasma or mg/g dry tissue) as well as
relative amounts (% of total fatty acids).
•Sfa//.w/ca/ ana/yrar
The type of study was a "nested" case-control study, which means that within the
cohort of pregnant women, a case-control study was conducted. Therefore, the data
were analysed according to a case-control design. Data of each case were compared
with the mean values of three controls (set). Differences between the PIH and control
group were tested with paired t-tests. Apart from an analysis of the total group, the
PIH group was divided into a group of women with an maximum DBP during
gestation of less than 105 and a group with a maximum DBP of > 105, which is
considered a critical value in the participating clinics. Paired t-tests were also used to
test the differences in fatty acid compositions of maternal plasma phospholipids
between the various sampling moments. The Chi-square test was applied to compare
categorical data, expressed as frequencies. A number of significant correlations
(Pearson correlation coefficients) was observed between fatty acids present in
umbilical venous plasma, umbilical venous vessel or arterial vessel walls and
gestational age. Therefore, multiple regression was performed to correct for
gestational age if the fatty acid composition of neonatal material in the PIH group was
compared with that of their matched controls.
Because of the many tests performed, a p-value of £ 0.01 was considered significant.
•SWecrion />/as
To study to what extent selection bias was present, women who did not want to
participate in the study and were under attendance at the University Hospital
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Variable
Number of nulliparae. at entry
(before I6wks)
Age (years)
Diastolic blood pressure, at entry
Diastolic blood pressure (maximum)
Proteinuna (%)
Smoking ('.)
Gestational age at delivery (days)
Birthwcight (grams)
Small for gestational age*
Apgar score (after 5 min.)
pH umbilical artery"
Sex (male female) (%)
NP(n=l56)
135
28.5 ± 0.35
67.4 ±0.61
76.110.50
0
31.4
279.910.59
32901 30.2
0
10 (9-10)
7.22 1 0.01
53.8/46.2
PIH (n=52)
45
27.9 1 0.54
73.7lO.94d
100.5 f 1.31**
34.6<*
23.1
273.3 12.I8C
2941 ±99.5<1
2
9.5 (9-IO)C
7.21 10.01
59.6/40.4
§: Results arc expressed as mean ± s.c.m.. except for Apgar score (median with interquartile range)
and when indicated otherwise; NP =normal pregnancy; PIH = pregnancy induced hypertension;
significant difference between NP and PIH group, b = p < 0.01, c = p < 0.005. d = p < 0.001
¥: birthwcight below 2 3rd percentile, based on the Dutch intrautcrinc growth curves, making
allowance for sex and parity (Kloostcrman GJ. On intrauterinc growth. Int J Gynaccol 1970; 8:
895-912).
#: n = 133 for NP and n =49 for PIH.
Maastricht were asked to give a blood sample once, before 16 weeks of gestation. The
fatty acid composition of their plasma phospholipids was determined and compared
with that of the women who did participate in the "nested" case-control study by
unpaired t-tests. No significant differences were observed in the maternal EFA status
of the non-participants (n=76) as compared with the participating women (n=201)
(data not shown). Although one can not exclude that the women who did agree to give
a blood sample once is a selected group, the similar EFA status at entry indicates that
selection bias, as far as the maternal EFA status is concerned, is negligible.
RESULTS
In Table 1 the clinical characteristics of the study population are shown. Fifty-two
women developed pregnancy-induced hypertension (PIH) during gestation and were
compared with three times as much women with an uncomplicated pregnancy. Of the
52 women with PIH, 45 women were nulliparous at entry (before 16 weeks of
gestation). The mean diastolic blood pressure (DBP) at entry was significantly higher
in the PIH group, but none of the women had a DBP at entry above 90 mm Hg. The
mean gestational age, birthweight and Apgar score (after 5 minutes) of the newborns
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2. Z)i//ér«ice ^/Mir/urifio/i-52 weefa o/gesfarton,) in /b/fy acia" composition o/materna/ p/osma
fmg/Ly //i rtorma/pregmjrtcy fjWV compam/ to P/// fmean ± 5.e.m., n =4 ^
Fatty acidi NP PIH
l8:2(n-6)
I(n-6)
18:3(n-3)
IPUFA
-2.6 ±
15.8 ±
-0.3 ±
I7.O±
7.23<>
IO.5C
OH*»
12.5c
-55.5
-52.1
-1.4
-54.1
± 9 . 9 0 * "
± 1 6 . 3 "
± 0 . 3 9 "
± 1 8 . 8 "
§: Significant difference between NP and PIH group. b = p < 0 . 0 1 . c = p < 0.005, d = p < 0.001;
significant different from zero, • • = p < 0.01, •• = p < 0.001.
1: Z(n-6), sum of the fatty acids of the (n-6) family; ZPUFA, sum of the polyunsaturated fatty acids.
were significantly lower in the PIH group compared with the normal group.
In 13 women (25%) of the PIH group and in 6 women (3.8%) of the control group,
labour was induced by prostaglandin-gel or oxytocin infusion (p < 0.001).
Spontaneous delivery took place in 27 women (51.9%), while in 22 of the PIH cases
delivery was either by cesarean section (23.1%), forceps (9.6%) or vacuum extraction
(9.6%). In the control group, these numbers were 113 (72.4%), 7 (4.5%), 17 (10.9%)
and 12 (7.7%), respectively. The number of women who delivered spontaneously or
by cesarean section was significantly different between the two groups.
M/rrif «/ /«rate
The first FFQ was filled out by 30 sets (each set consists of one case and three
controls) of women coming from the Maastricht region, the second by 32, the third by
25, and the dietary history was carried out on 29 sets. The nutrient intake of the
women who developed PIH was not significantly different from the women with an
uncomplicated pregnancy (see Chapter 4).
A/aff ma/ /àrfy aorf
In total 39 fatty acids were identified, but to reduce the amount of data, only those
fatty acids are reported for which significant (p £ 0.01) differences between the PIH
group and their matched controls were observed (full data are given in appendices CI
and C2).
During gestation (before 16, at 22 and 32 weeks), no significant differences in the
absolute fatty acid composition (mg/L) of maternal plasma phospholipids (PLs) were
observed between PIH and the group with a normal pregnancy (NP). Immediately
after delivery, the amount of 18:3(n-3) was significantly (p <0.01) lower in PIH (3.89
± 0.30) than in NP (4.84 ± 0.16). As compared to the situation at 32 weeks (n=42
sets), the amounts of 18:2(n-6), I8:3(n-3), I(n-6) (sum of all (n-6) fatty acids), and Z
PUFA (sum of the poly-unsaturated fatty acids) had significantly decreased after
delivery in the PIH group, whereas in the group with an uncomplicated pregnancy no
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TAe /a//y aru/ rontpasifion o/
iwnna/pregmwicy fAtfV compared /o /»/// f
tofa/ aci<M M
Fany acidl
18:2(n-6)
22:4<n-6)
I(n-6)LCPs
!8:3(n-3)
22:6(n-3)
(n-6) desatu-
ration index
NP
PIH
NP
PIH
NP
PIH
NP
PIH
NP
PIH
NP
PIH
< 16 weeks
(sets=49)
21.1 ±0.29
21.0 ±0.36
0.41 ±0.01
O.37±0.01<:
13.4 ±0 15
13.2±O.I9
0.25 ±0.01
0.25 ±0.01
4.21 ±0.08
436±O.I2
0.66 ± 0.02
0.65 ± 0.02
± 22 weeks
(sets=47)
21.0 ±0.24
21.0 ±0.46
0 41 ±0.01
0.41 ±0.01
12 8 * 0.13
13.1 ±0.24
0.29 ±0.01
0.29 ±0.02
4.22 ±0.08
4.24 ±0.12
0.63 ±0.01
0.65 ±0.02
±32 weeks
(scts=47)
21.3 ±0.20
21.2 ±0.42
0.38 ±0.01
0.40 ±0.01
12.3 * 0.13
12.6 ±0.23
0.29 ±0.01
0.28 ±0.01
4.13 ±0.07
4I8±O.II
0.59 ±0.01
0.61 ±0.02
After delivery
(sc«s=45)
20.4 ± 0.24
19.1 ± O.35C
0.39 ±0.01
0.41 ±0.01
12.7 ± 0.16
13.5 ± 0.22«:
0.26 ±0.01
0.21 ±0.0|C
4.00 ± 0.08
4.39 ± 0.1 |C
0.64 ±0.01
0.73 ± 0.02C
§: Significant difference between NP and PIH group, c = p < 0.005.
1: Z(n-6) LCPs. sum of (n-6) long chain polycnes. which arc poly-unsaturated fatty acids with 20 or
more carbon atoms and 3 or more double bonds; (n-6) desaturanon index. {[(l8:3(n-6)+20:3(n-
6)+20:4(n-6)+22:4(n-6)+22:5(n-6)]/l8:2(n-6)}.
% <* low liny l am
• Î -
0.002
1
% 01 B l « liny «CKII
0.098 0.007
0.4
18:2(n-6) (rv6)LCPs (n-6) d«sal.
index (iiO)
•oi
•0.4
0.025 <0.001 . P-VBIIM'
D Noimal
t8:3(n-3)
g i o n ^mean ± j.em., n = 42 5ett
•• = p < 0.0/. • • • = p < 0.00/. #. £>#rrence teftveenfroupj.
zero, • « /> < 0.05,
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Chapter
7aWe 4. r/ie/a/rv acia" com/7os/ft'o/i (% o/ro/a/y!irrv «ciVfe) o/pfcupAo/jpidb iso/arerf/rom
um6i7;ra/ cord' mafena/ a/ter norma/ pregnancy flV/V compared fo P// / (mean $
Fatty acid Venous plasma Venous' vessel wall Arterial vessel wall
(sets = 44) (sets = 45) (sets = 45)
22:6(n-3)
20:3(n-9)
NP
PIH
NP
PIH
6 18 ± 0.14
6.65±0.22<=
0.62 ± 0.03
0.50 ± 0.04C
5.24 ± 0.09
5.28 ±0.14
0.43 ± 0.02
0.42 ± 0.03
5.61 ±0.11
5.57 ±0.15
3.00 ±0.09
2.91 ±0.13
§: Significance was tested after correction for gcstational age. uncorrcctcd data are presented;
Significant difference between NP and PIH group, c = p < 0.005.
significant changes took place (see Table 2).
In Table 3 the fatty acid composition of maternal plasma PLs, expressed as % of total
fatty acids, is presented. The first blood sample (before 16 weeks of gestation) was
taken at a mean gestational age of 80 days in the control group and 82 days in the PIH
group. At that moment, the mean relative amount of 22:4(n-6) was significantly lower
in the PIH than in the NP group. Ai 22 and 32 weeks of gestation, no significant
differences were observed between the two groups. After delivery, the values of the
essential fatty acids l8:2(n-6) and 18:3(n-3) were significantly lower, whereas the
values of Z(n-6)LCPs (sum of (n-6) long chain polyenes, which are poly-unsaturated
fatty acids with 20 or more carbon atoms and 3 or more double bonds), 22:6(n-3) and
the (n-6) desaturation index {[(18:3(n-6)+20:3(n-6)+20:4(n-6)+22:4(n-6)+22:5(n-
6)]/18:2(n-6)} were significantly higher in PIH than in NP.
In Figure 1 the difference in fatty acid composition between the levels after parturition
and at 32 weeks of gestation are given for 18:2(n-6), I(n-6)LCPs and the (n-6)
desaturation index, and for 18:3(n-3) and 22:6(n-3) in the PIH group and the control
group (n=42 sets). The decrease in 18:2(n-6) levels was significantly stronger in the
PIH group than in the control group. The (n-6) desaturation index was significantly
more increased in PIH. The 22:6(n-3) values in the PIH group showed an increase
from 32 weeks of gestation until delivery. This pattern was significantly different
from that in the control group, where a significant decrease was observed.
There were no significant differences in the absolute amounts of fatty acids in
umbilical plasma and umbilical venous and arterial vessel wall PLs between PIH and
NP (absolute data is given in appendix C3).
Table 4 only summarizes the mean relative amounts of those fatty acids in
phospholipids of umbilical venous plasma, and umbilical venous and arterial vessel
walls, which were found to be significantly different between PIH and NP (full data is
given in appendix C4). After correction for differences in gestational age between the
groups, significantly higher levels of 22:6(n-3) and lower values of 20:3(n-9) were
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observed in umbilical plasma of the PIH group compared with their controls. The fatty
acid composition of the umbilical arterial and venous vessel wall showed no
significant differences between the PIH and control group.
Co/npamon terween severe am/ m; /</ P/W
The maximum DBP in the PIH group reached a value of 105 or more (severe PIH
group) in 17 of the 52 women. Of these 17 women. 16 women were nulliparous at
entry. Twelve women had also proteinuria. Their mean gestational age (260 ± 4.28
days) and the mean birthweight of their babies (2512 ± 223) were significantly lower
than of those in the group with a max. DBP of less than 105 mm Hg (280 ± 1.61 and
3149 ± 82, respectively). Throughout gestation (16-32 weeks) and after delivery, no
significant differences were observed in the maternal fatty acid composition of the
severe PIH group as compared with the mild PIH group. Significantly lower relative
amounts of 22:6(n-3) were observed in the umbilical plasma PLs of the severe as
compared to the mild PIH group. However, this difference was no longer significant
after correction for gestational age.
DISCUSSION
As was the case in an earlier pilot study (16), the maternal fatty acid profile of plasma
phospholipids (PLs), immediately after parturition, of women with pregnancy-induced
hypertension (PIH) is characterized by decreased levels of linoleic acid (18:2(n-6),
LA) and increased proportions of cervonic acid (22:6(n-3), CA). In addition, the
amounts of a-linolenic acid (18:3(n-3), LnA) were shown to be decreased and the
relative amounts of Z(n-6) LCPs were increased in PIH. At or before 32 weeks of
gestation, we observed no major differences in maternal plasma fatty acid compositi-
on between cases and controls. This implies that, most probably, the different fatty
acid levels in PIH developed either shortly before or possibly even after the clinical
manifestation of the disease. Only in 5 women PIH had been diagnosed before the
blood sample at 32 weeks was collected, but the fatty acid composition of these 5 sets
did not show a different pattern than the other sets. Therefore, it appears that the
observed change in fatty acid composition is rather a consequence of PIH than a
causal or contributing factor.
When comparing the post-delivery values to the situation at 32 weeks, a decrease in
the relative amounts of CA was observed in the control group, while in the PIH group
an increase took place. Because no data are available on the fatty acid composition
between 32 weeks of gestation and parturition, it is unknown at what moment in time
the maternal CA status increased in PIH. The CA status of umbilical plasma PLs in
the PIH group was also elevated while the CA status of umbilical vessel walls was not
different between cases and controls. Since the fatty acid composition of vessel wall
PLs is considered to give a longer term reflection of the essential fatty acid status than
plasma PLs, this observation also points to the fact that the increased CA status in PIH
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is a late phenomenon and is, therefore, unlikely to have contributed to the
pathogenesis of P1H.
In maternal plasma, the decreased levels of LA and LnA were associated with higher
levels of X(n-6)LCPs and CA, respectively. The (n-6) desaturation index, which is the
ratio between the desaturation and elongation products of !8:2(n-6), and 18:2(n-6),
was also elevated. The same was observed for LnA and its desaturation and
elongation products, but the (n-3) desaturation index was not calculated because the
majority of the (n-3) LCPs present in plasma PLs are likely to have been derived
directly from the diet. However, the fact that LnA levels were reduced in PI H may
imply more active desaturation and elongation of LnA also. Therefore, these
observations suggest that the parent essential fatty acids, LA and LnA, are more
actively metabolized in PIH than in an uncomplicated pregnancy.
In PIH, the process of "placentation" is disturbed (26). As a consequence, the
maternal-fetal blood flow may be reduced, which can result in an inadequate supply of
nutrients. However, this did not result in deterioration of the neonatal EFA status. On
the contrary, in PIH the overall EFA status of the neonate tends to be improved as is
indicated by a lower amount of Mead acid, 20:3(n-9), in umbilical plasma PLs. In
addition, the amount of CA in neonatal plasma PLs is even significantly higher than
after normal pregnancy (Table 4). Notwithstanding the reduced uteroplacental
perfusion and function in PIH, the more active desaturation and elongation of
maternal LA and LnA (Table 3) was obviously sufficient to guarantee an adequate
fetal supply of (n-6) and (n-3) LCPs, which are important in fetal growth and
development (27).
There may be some indications that the alterations in fatty acid composition of
maternal plasma PLs after parturition are due to stress, related to PIH. In the literature
several other stressful events have been described which were associated with
increased CA levels (28). When moderate to severe stress was induced in male rats by
repeated administration of catecholamines for 15 days, reduced LA and increased CA
levels in heart muscle PLs have been observed. Elevated CA levels have also been
reported in stressful situations like birth in rats and myocardial infarction in man (28).
All women who developed PIH in this study were hospitalized for this disorder.
During their hospital stay, which varied from a few days till more than a month, the
nutrient composition of their diet could very well be different than that at home.
Moreover, one of the common complaints of women with PIH is a reduced appetite
due to nausea and headache. So the reduced content of the parent EFAs, LA and LnA,
in maternal plasma phospholipids (mg/L and % of total fatty acids) could also be a
consequence of a change in dietary habits. However, since the derived EFAs were
higher in PIH, this seems rather unlikely.
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wa/us am/ / W
There were significant differences between the PIH and control group in the mode of
delivery and it is possible this has interfered with the results. However, in the PIH
group, women who delivered their baby by cesarean section did not differ in their
plasma levels of LA, Z(n-6) LCPs, LnA and CA from women who delivered
otherwise (data not shown). Also, if all women who gave birth by cesarean section are
excluded from the analyses, the results did not change. The same conclusions hold for
the plasma fatty acid levels of women whose labor was induced.
It has been suggested that fish-oil, rich in CA, could have a possible preventive effect
on PIH (12), because a high CA intake interferes with prostanoid metabolism (14,15).
This suggestion is supported by results from an epidemiological study performed in
Northern Canada, showing that Inuit women eating a diet rich in marine food are 2.6
times less likely to develop PIH than Inuit women whose diet contain a greater
proportion of terrestrial food (29). Whether or not CA supplementation during
pregnancy is effective in reducing the incidence of PIH remains to be seen.
In conclusion, the altered maternal EFA status, observed at delivery, in PIH is most
probably a late phenomenon, occurring after the development of PIH. Thanks to this
adaptation in maternal EFA metabolism, the neonatal EFA status is not compromised
by PIH.
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CHAPTER 7 .
The effect of linoleic acid supplementation during
pregnancy on the neonatal essential fatty acid status
Monique D.M. AI, Adriana C. v. Houwelingen, Anita Badart-Smook and Gerard
Hornstra
Subm/tted forpi/W/cahon
ABSTRACT
The essential fatty acid (EFA) status of newborns has been suggested to be marginal.
To study the effect of maternal linoleic acid (18:2(n-6), LA) supplementation on the
neonatal EFA status, pregnant women with relatively low plasma LA levels before 16
weeks of gestation (n=21 ) were supplemented with approximately 10 gram of LA per
day from the 20th week of gestation, until delivery. One of the two control groups
consisted of pregnant women with comparably low plasma LA levels at the start of
the study (LL-control group, n=22); the other consisted of women with habitual high
plasma LA levels (HL-control group, n=21 ). The neonatal EFA status was assessed by
determining the fatty acid composition of phospholipids (PLs) isolated from umbilical
plasma and umbilical vessel walls. LA supplementation resulted in significantly
higher levels of the sum of (n-6) long chain polyenes (LCPs) in umbilical plasma and
venous vessel wall PLs compared with the LL-control group. This increase was
associated with lower (n-3) LCP levels. In the HL-control group the neonatal (n-3)
LCP status was also lower as compared to the LL-control group. To improve the EFA
status of newborns, both fatty acids of the (n-6) and (n-3) family have to be supplied.
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INTRODUCTION :, •«; »-; , %
Results from earlier studies (1,2) suggest that the essential fatty acid (EFA) status of
newborns is marginal. This suggestion was based on the observation that
phospholipids (PLs) isolated from the vessel walls of the umbilical arteries (the
efferent blood vessels) contain relatively high levels of Mead acid (20:3(n-9), MA)
and its elongation product dihomoMead acid (22:3(n-9), DHMA) as compared to the
umbilical vein, the fetal supplying blood vessels. The presence of MA and DHMA are
considered to reflect a general EFA deficiency (3). The high levels of MA and DHMA
were associated with low values of linoleic acid (18:2(n-6), LA) in umbilical plasma
and vessel wall PLs (2).
Significant inverse correlations were observed between birthweight and the EFA
deficiency index (Mead acid/arachidonic acid) in the umbilical artery (4,5), and this
suggests that the presence of MA and DHMA indicates a marginal EFA status which
might have pathological consequences. This led to the question whether maternal
supplementation during pregnancy with LA could be useful to improve the fetal EFA
status.
Since a significant, positive relationship exists between the maternal and neonatal LA
status (6) and also between the neonatal LA status and the LA content of the maternal
diet (unpublished observations), maternal supplementation is likely to improve the
fetal EFA status. However, these relationships were for the greater part observed in
cross-sectional studies and, therefore, they may be the result of conditions set in early
pregnancy, already before or during the development of the placenta, the size and
function of which may be "programmed" by the nutritional conditions of that
particular period. So it is possible that LA, supplemented to pregnant women after
complete development of the placenta, may not reach the developing fetus. Therefore,
it was decided to test the efficacy of maternal LA supplementation to improve the
fetal EFA status after the placenta had fully developed.
SUBJECTS, MATERIALS AND METHODS
SM/>/VC7.V and rf/er /« r/re L4 swpp/ememed group
At their first antenatal visit to the midwife, healthy pregnant women were asked at
random to participate in the study. If they agreed, a venous blood sample was taken
before the 16th week of pregnancy to assess the linoleic acid (18:2(n-6), LA) content
of their plasma phospholipids (PLs). To prevent supplementation to result in
unnaturally high linoleic acid contents of plasma PLs, only women with plasma LA
levels not exceeding the P50 (« 22° o of total fatty acids) were accepted for supple-
mentation. This value of 22% followed from a previous study in which the EFA status
of 110 normal pregnant women was followed throughout pregnancy (6). Another
inclusion criterion was that the maternal diet had to contain sufficient saturated fat
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rich products, which could be replaced by LA rich products. Therefore, the dietary
habits of the women were assessed by a dietitian (AB-S). using the dietary history
method (7).
The supplementation period started at the 20th week of gestation and lasted until
delivery. The diet of each participant was adjusted on the basis of the results of her
dietary history. Products which were mainly used on bread (margarine, cheese,
cheesespread and chocolate paste) or used in between meals (biscuits and milk) were
substituted. The diet was adapted in such a way that an additional intake of
approximately 10 gram linoleic acid per day was accomplished, and that the total
energy intake did not change due to the substitution of products. Ten gram was the
difference in LA intake between the P50 and P90. as assessed in an earlier study
(unpublished observation), and was chosen to prevent that effects beyond the normal
range were studied.
The participants were instructed not to change their other dietary habits and to list any
deviations from their normal dietary pattern, particularly if products rich in linoleic
acid, other than those of the study, were consumed. The LA-rich products were
brought to the home of the women every week and what was left from the week
before was taken back to the research institute. The difference in weight between the
amount of products brought and taken back one week later, was recorded and the
additional intake of linoleic acid per week calculated. Twenty-five women entered the
experimental group. Two women did not complete the study: one woman did not like
the LA-rich products and one woman was admitted to the hospital after one week of
supplementation because of vaginal bleeding.
The study protocol was approved by the Ethics Committee of the University and
written consent was obtained from each participant.
Con/ro/ grou/w
There were two control groups, in which no intervention took place. These control
groups were selected from a group of women who had participated in observational
studies, which took place at our department at about the same time and which aimed
at describing the normal course of the maternal EFA status during pregnancy. One
control group consisted of women who, before 16 weeks of gestation, had plasma LA
levels at or below 22% of total fatty acids and comparable with the initial values of
the LA supplemented group (control group with low maternal LA levels: LL-control
group). The other control group was made up of women who had plasma LA levels
above 22% of total fatty acids (control group with habitual high plasma LA levels:
HL-control group). This HL-control group was included to determine if the
relationship between the maternal and neonatal EFA status in a group of women with
habitual high plasma LA levels is different from a group of women with high plasma
LA levels due to supplementation. The daily intake of linoleic acid in the control
groups was assessed with the aid of the dietary history method (7), carried out around
22 weeks of gestation. The LA supplemented group and both control groups were
matched for gestational age at birth.
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Maternal venous blood samples were collected into EDTA tubes before the 16th week
of pregnancy, at 20 weeks, and every 4 weeks thereafter, until delivery. In the HL-
control group, maternal venous blood samples were collected before 16 weeks, at 22,
32 and 40 weeks of gestation. Immediately after delivery, a blood sample from the
umbilical vein was collected. Plasma was separated from red blood cells by
centrifugation and stored at -80° C, under nitrogen, until analysis.
Immediately after delivery, a piece of the umbilical cord was collected. The umbilical
cords were rinsed with saline (NaCl, 0.9% w/v) and segments of about 5 cm length
were used to isolate the vessel wall of both arteries and the veins. The arterial and
venous vessel walls were frozen in liquid nitrogen and pulverized in an aluminum
mortar with a stainless steel pestle, previously cooled in liquid nitrogen. The
pulverized samples were freeze-dried before fatty acid analysis was performed.
Fatty ac/d awa/>w.v
The fatty acid composition of plasma phospholipids (PLs) was determined as descri-
bed earlier (6). Briefly, preparation of a total lipid extract from 100 ul samples was
,nftr.CnnTiftd .with i» .tnartififirf .Knlr.b j;xt«u\tinr /flity 1 tO- l^innnariRcauojv.l .Uxtihir was
used as an internal standard to calculate the absolute fatty acid amounts. Aminopro-
pyl bonded phase columns were used to separate phospholipids from the total lipid
extract (10). The fatty acid constituents of the phospholipids were transmethylated to
the corresponding methylesters (11), which were separated and quantified on a non-
polar CP-Sil 5 CB column (Chrompack®, Middelburg, The Netherlands). All blood
samples of a given participant were analysed simultaneously.
The total lipids of the umbilical vessel walls were extracted from 10-30 mg dry tissue
according to the method of Bligh and Dyer (12). Further analytical methodology was
similar as for plasma lipid extracts, except that the fatty acid methylesters were
separated on a polar capillary column (CP Sil 88, Chrompack, Middelburg, The
Netherlands).
The results were expressed in absolute (mg/L plasma or mg/g dry tissue) as well as
relative amounts (% of total fatty acids). In total, 39 fatty acids were identified.
However, for the sake of clarity, only the following 14 fatty acids and 8 fatty acid
combinations are reported (full data are given in appendices D1-D6): 18:2(n-6),
20:2(n-6). 20:3(n-6), 20:4(n-6), 22:4(n-6), 22:5(n-6), 24:2(n-6), 18:3(n-3), 20:4(n-3),
20:5(n-3), 22:5(n-3), 22:6(n-3). 20:3(n-9), 22:3(n-9), I(n-6)LCPs (sum of the (n-6)
long chain polyenes, which are poly-unsaturated fatty acids with 20 or more carbon
atoms and 3 or more double bonds). I(n-6) (sum of all (n-6) fatty acids), Z(n-3)LCPs
(sum of the (n-3) long chain polyenes), Z(n-3) (sum of all (n-3) fatty acids), Z(n-7)+X
(n-9) (sum of all (n-7) and (n-9) fatty acids), ISAFA (sum of all saturated fatty
acids), ZMUFA (sum of all mono-unsaturated fatty acids), and ZPUFA (sum of all
polyunsaturated fatty acids). Moreover, three indices were calculated: the EFA status
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% ot total FA in plasma PL
<16 24 28 32
gestational age
36 40
""• LL-control group * LA-suppl. group "• HL-conlrol group
(n=22) (n=21) (n-21)
L
/•Vgure /. 77ie re/arive? amou/iK o/'/ino/eir aciV/ m materna/p/a.?ma pAc>5pAo/;pia'.v OWMJ;pregnancy.
J4/ weafc 40: LL-confro/ group ^/i=/i/ I*4-5up/>/ementea' group ("/i = /i^ anrf///.-coniro/group ^/i=//^.
[(L(n-3)+I(n-6))/(I(n-7)+I(n-9))], the cervonic acid deficiency index [CADI,
22:5(n-6)/22:4(n-6)] and the classic triene/tetraene ratio [EFA deficiency index,
20:3(n-9)/20:4(n-6)](6,l3).
During the intervention period, the amount of linoleic acid in maternal plasma PLs in
the LA supplemented group was determined within one week after the blood sample
had been taken. This was done to measure compliance and to prevent the maternal LA
status from increasing above the P90. If the maternal LA status tended to raise over
the P90, the amount of LA supplied was adjusted.
All data are presented as mean ± s.e.m. Because the intake (g/day) of linoleic acid was
not normally distributed, this variable was analyzed non-parametrically. The
differences in LA intake between the three groups were tested by means of the
Kruskal Wallis test.
The effect of type of diet (LA supplemented or not) on the LA levels of maternal
plasma PLs between the LA supplemented group and the LL-control group was
evaluated by calculating the difference in fatty acid composition with regard to the
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LL-control LA supplemented HL-control
(n = 22) (n = 21) (n=21)
Age (years) 29.9 ±0.98 30.7 + 0.93 28.3 ±0.78
Gestational age at delivery (days) 281.5 ±2.53 282.8±2.58 277.7±1.64
Birthwcight (grams) 3317 ±90.3 3443 ±117.0 3260 ±91.0
Apgar score (after 5 min) 9.5 ±0.17 9.8 ±0.10 9.8 ± 0.09
Sex (boys/girls) 14/8 U/10 12/9
: Results arc expressed as mean ± s.e.m., except for sex. LL-control = control group, low in linoleic
acid; LA supplemented = linoleic acid supplemented group; HL-control = control group, high in
linoleic acid (see material and methods for details).
values at 20 weeks of gestation. Within the groups, the differences were tested by
paired t-tests and between the two groups by unpaired t-tests. In the HL-control group,
the difference in maternal LA levels was calculated with regard to the values at 22
weeks and tested with a paired t-test. The difference in LA levels between the three
groups was tested by use of Tukey's test, with p < 0.05 considered significant.
The effect of maternal LA supplementation on the neonatal EFA status was tested by
comparing the fatty acid composition of PLs isolated from umbilical plasma, and from
venous and arterial vessel walls in the three groups by means of Tukey's test.
To evaluate which other variables, apart from LA supplementation, contributed
significantly to the fatty acid composition of umbilical plasma and vessel wall PLs,
stepwise multiple regression analyses were performed in the two groups of women
with low LA levels at entry. As independent variables, the fatty acid composition of
maternal plasma PLs at the start of the intervention period, gestational age at birth,
and the type of diet (LA or control) were used. Gestational age was added as a
possible confounding factor because a significant negative correlation have been
observed with 18:2(n-6) levels and a significant positive correlation with 22:6(n-3)
levels in umbilical plasma (6).
The relationship between the maternal EFA status during gestation and the neonatal
EFA status was tested in the two control groups together by calculating the Pearson
correlation coefficient between maternal plasma fatty acid levels around 20 weeks of
gestation and the corresponding fatty acid values in umbilical plasma, venous and
arterial vessel walls. The partial correlation coefficient is calculated when gestational
age at birth appeared a significantly confounding variable.
The statistical analyses were performed by use of the SPSS-PC program (14)
RESULTS
One woman from the LA supplemented group delivered her baby at 31 weeks of
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Fatty acidi
18:2(n-6)
20:2(n-6)
20:3(n-6)
20:4(n-6)
22:4(n-6)
22:5(n-6)
24:2(n-6)
&n-6)LCPs
Kn-6)
l8:3(n-3)
20:4(n-3)
20:5(n-3)
22:5(n-3)
22:6{n-3)
I(n-3)LCPs
I(n-3)
20:3(n-9)
I(n-7)+Z(n-9)
ISAFA
IMUFA
IPUFA
EFA status
EFA def. index
CADI
TOTAL (mg/L)
LL-control
(n=22)
7.15 ±0.34
0.35 ± 0.02
4.83 ± 0.20
16.2*0.32
0.76 ± 0.02
0.83 ± 0.05
0.58 ±0.04
22.6 ± 0.30
30.8 ± 0.46
0.09 ± 0.02
0.08 ± 0.02
0.24 ± 0.02
0.50 ±0.04
6.77 ±0.33
7.59 ±0.37
7.68 ± 0.36
0.69 ±0.12
12.6 ±0.54
46.8 ±0.54
11.9 ±0.50
39.2 ± 0.46
3.18 ±0.16
0.05 ±0.01
1.08 ±0.05
606.0 ± 30.3
LA supplemented
(n=2l)
7.80 ± 0.25
0.36 ±0.01
5.05 ± 0.25
17.2 ±0.30
0.89 ±0.11
0.86 ± 0.05
0.67 ± 0.05
24.0 ± 0.29(a)
32.9 ± 0.44(a)
0.03 ±0.0l(a)
0.06 ±0.01
0.23 ± 0.03
0.40 ± 0.03(a)
5.80 ±0.26
6.50 ± 0.29(a)
6.53 ±0.29(a)
0.52 ± 0.03
12.6 ±0.28
45.8 ±0.22
12.0 ±0.25
40.0 ± 0.37
3.18 ± 0 10
0.03 ±0.00
1.06 ±0.06
660.8 ± 24.8
HL-control
(n=2l)
8.53±0.29<a)
0.40 ± 0.02
5.I2±O.19
16.1 ±0.41
0.76 ± 0.04
0.85 ± 0.05
0.75 ±0.04(a)
22.8 ± 0.36
32.5 ±O.32(a)
0.07 ±0.01
0.07 ±0.01
0.18 ±0.02
0.36±O.03(a)
5.27±0.28(a)
5.88 ± 0.3l(a)
5.95 ± 0.3l(a)
0.68 ± 0.07
13.7 ±0.57
45.6 ± 0.42
13.0 ±0.56
39.2 ±0.37
2.91 ±0.13
0.04 ±0.00
1.12 ±0.05
592.4 ± 33.3
§: LL-control = control group, low in linoleic acid; LA supplemented = linoleic acid supplemented
group; HL-control = control group, high in linoleic acid (sec material and methods for details).
1: LCPs, long chain polyenes (poly-unsaturatcd fatty acids with 20 or more carbon atoms and 3 or
more double bonds); ZSAFA. sum of all saturated fany acids; LMUFA, sum of all mono-
unsaturated fatty acids; LPUFA, sum of all polyunsaturated fatty acids; EFA status. [Z(n-6)+Kn-
3)]/[I(n-7)+I(n-9)]; EFA def. index, 20:3(n-9)/20:4(n-6); CADI. 22:5(n-6)/22:4(n-6).
a: significantly different from the LL-control group, p < 0.05.
gestation, and from another participant material of the umbilical cord was missing.
The data from these women were excluded from the data analyses. Clinical characte-
ristics of the three groups are given in table 1. No significant differences were
observed in age of the mother, gestational age at delivery, birthweight and Apgar
score after 5 minutes, between the three groups.
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Fany acidj
18:2(n-6)
20:2(n-6)
20:3(n-6)
20:4(n-6)
22:4(n-6)
22:5(n-6)
24:2(n-6)
I(n-6)LCPs
I(n-6)
I(n-3)LCPs
20:3(n-9)
22:3(n-9)
I(n-7)+Z(n-9)
ISAFA
IMUFA
ZPUFA
EFA status
EFA dcf. index
CADI
TOTAL (mg/g)
LL-control
(n=22)
1.80 ±0.10
0.37 ±0.03
1.76 ±0.06
19.0 ±0.35
5.48 ± 0.20
2.85 ±0.14
0.64 ± 0.03
29.1 ±0.41
32.0 ±0.44
6.26 ±0.16
0.50 ±0.07
0.43 ± 0.05
15.8 ±0.46
45.9 ± 0.24
14.8 ±0.36
39.2 ±0.37
2.48 ± 0.09
0.03 ± 0.00
0.54 ±0.04
17.0 ±0.78"
LA supplemented
(n=21)
1.96 ±0.08
0.39 ±0.02
2.09 ± 0.09(a)
19.9±0.23(b)
5.71 ±0.21
3.08 ±0.13
0.74 ± 0.04
30.7 ± O.33(a,b)
33.9±0.33(a.b)
5.59±0.15(a.b)
0.41 ±0.04
0.38 ± 0.03
15.1 ±0.30
45.4±0.23(b)
14.4 ± 0.27
40.3±0.27(b)
2.63±0.07(b)
0.02 ±0.00
0.56 ±0.04
16.8 ±0.47
HL-control
(n=2l)
2.26±0.12(a)
0.46 ± 0.03
1.89 ±0.06
18.1 ±0.35
5.36 ±0.19
2.97 ±0.15
0.64 ± 0.05
28.3 ±0.44
31.8 ± 0.44
4.63 ± 0.20(a)
0.39 ±0.04
0.32 ±0.03
15.7 ±0.31
47.9 ± 0.37(a)
15.0 ±0.29
37.1 ±0.52(a)
2.35 ±0.08
0.02 ± 0.00
0.58 ±0.04
15.0 ±0.62*
#:
LL-control = control group, low in linolcic acid; LA supplemented = linolcic acid supplemented
group; HL-control = control group, high in linolcic acid (sec material and methods for details).
LCPs. long chain polyencs (poly-unsaturatcd fatty acids with 20 or more carbon atoms and 3 or
more double bonds); ISAFA. sum of all saturated fany acids; LMUFA. sum of all mono-
unsaturatcd fatty acids; EPUFA. sum of all polyunsaturatcd fatty acids; EFA status. [L(n-6)+Z(n-
3)]/[I(n-7)+I(n-9)]; EFA dcf. index. 20:3(n-9)/20:4(n-6); CADI. 22:5(n-6)/22:4(n-6).
n = 2 l ;¥:n= 18.
a: significantly different from the LL-control group, p < 0.05.
b; significantly different from the HL-control group, p < 0.05.
«faring gesfa
The mean relative amount (% of total fatty acids) of linoleic acid in maternal plasma
phospholipids (PLs), before 16 weeks of gestation, was 20.2 ± 0.36 in the LL-control
group (n = 22). 20.5 ± 0.50 in the LA supplementation group (n = 21 ) and 24.5 ± 0.51
in the HL-control group (n = 21). which was significantly higher than in the former
two groups.
According to the dietary history, the mean linoleic acid intake before supplementation,
was significantly lower in the LL-control group (13.5 ± 1.52 g/day. n = 22) and the
LA supplementation group (14.0 ± 1.03, n = 21 ) than in the HL-controlgroup (23.5 ±
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Fatty acid]
l8:2(n-6)
20:2(n-6)
20:3(n-6)
20:4<n-6)
22:4(n-6)
22:5(n-6)
24:2(n-6)
I(n-6)LCPs
Kn-6)
Kn-3)LCPs
20:3(n-9)
22:3(n-9)
I(n-7)+I(n-9)
ISAFA
IMUFA
IPUFA
EFA status
EFA def. index
CADI
TOTAL (mR/K)
LL-comrol
(n=22)
1.22 ±0.06
0.17 ±0.02
1.27 ±0.05
15.1 ±0.51
3.36±O.I6
3.28 ±0.13
0.21 ±0.02
23.0 ± 0.63
24.6 ± 0.66
6.48 ± 0.25
2.66 ± 0.24
1.37 ±0.09
22.4 ±0.87
46.5 ± 0.34
18.3 ±0.59
35.1 ±0.59
1.47 ± 0.10
0.19 ±0.02
1.03 ±0.07
16.4 ±1.03*
LA supplemented
(n=2l)
l.27±004(b)
0.18±0.01(b)
1.41 ±0.06
15.4 ±0.44
3.57 ±0.16
3.49 ±0.13
0.24 ± 0.02
23.9 ±0.55
25.6 ±0.58
5.74 ± 0.16(a.b)
2.94 ±0.23
1.59 ± 0.12
22.8 ±0.75
45.9 ± 0.25
18.3 ±0.46
35.9±O.38(b)
1.43 ± 0.08
0.20 ± 0.02
1.02 ±0.06
16.6 ±0.34
HL-control
(n=2l)
1 60 ±0 1 l(a)
O.27±O.O3(a)
1.34 ±0.05
14.3 ± 0.43
3.10*0.12
3.50 ±0.12
0.20 ± 0.02
22.2 ±0.57
24.4 ±0.61
4.99 ±0.22(8)
2 87 ± 0.18
1 44 ± 0 10
23.7 ±0.70
47.0 ± 0.40
19.3 ±0.50
33.7 ±0.59
1.28 ±0.07
0.21 ±0.02
1.16 ± 0.06
14.6 ±0.71*
§: see for legends Table 3.
1.98 g/day, n = 19). The mean additional intake of linoleic acid in the LA
supplemented group during the supplementation period was 10.7 ± 0.11 g/day, which
is almost similar to the difference between the LL- and HL-control group.
In figure 1 the mean relative amounts of linoleic acid in maternal plasma PLs of the
three groups during pregnancy is given. After 4 weeks of supplementation, the LA
levels in the LA supplemented group had significantly (p < 0.001 ) increased to 23.3 ±
0.33 % and remained significantly higher than in the LL-control group, but were not
significantly different from the HL-control group. In the LL-control and HL-control,
the relative amounts of LA did not change significantly from 20, respectively 22
weeks of gestation until delivery.
The mean total amount of fatty acids in umbilical plasma, and in venous and arterial
vessel wall PLs was not significantly different between the three groups and
therefore, only the relative amounts of the fatty acids are presented (absolute amounts
are given in appendices Dl, D3 and D4).
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Dependent variable^! Independent variables"
tested.
Significant explanatory variables
B§ (p-value)
18:2(n-6)-up
I(n-6) LCPs-up
I(n-3) LCPs-up
diet, gcstational age.
l8:2(n-6)-m20
diet, gcstational age.
I(n-6)LCPs-m20
diet, gcstational age.
I(n-3)LCPs-m2O
18:2(n-6)-m20:+0.30 (0.001)
gestational age: -0.05 (0.0006)
diet:+1.50 (0.0007)
diet:-1.16 (0.009)
I(n-3)LCPs-m20:+0.32 (0.03)
gestational age: +0.04 (0.025)
!8:2(n-6)-ua
I(n-6) LCPs-ua
I(n-3) LCPs-ua
20:3(n-9)-ua
diet, gcstational age.
IK:2(n-6)-m20
diet, gcstational age.
I(n-6)LCPs-m20
diet, gcstational age.
diet, gcstational age,
18:2(n-6)-m20. -up, -uv, -ua
gestational age: +0.008 (0.01)
gestational age: +0.10 (0.005)
diet:-0.75 (0.01)
Z(n-3)LCPs-/n20.+0.25 (0.0J)
NS
l8:2(n-6)-uv
I(n-6) LCPs-uv
I(n-3) LCPs-uv
diet, gcstational age.
l8:2(n-6)-m20
diet, gcstational age,
I(n-6)LCPs-m20
diet, gcstational age.
I(n-3)LCPs-m20
NS
diet:+1.65 (0.003)
gcstational age: +0.05 (0.05)
diet: -0.67 (0.003)
1: up = umbilical plasma; ua = umbilical artery; uv = umbilical vein.
¥: diet =LA supplemented or LL-control; gcstational age in days; m20 = maternal plasma values (%
of total fatty acids) at week 20.
§: B regression coefficient.
In table 2 the fatty acid composition of umbilical venous plasma PLs are given.
Although maternal LA supplementation did not result in significantly higher LA
values in umbilical venous plasma, it caused significantly higher relative amounts of
I(n-6) LCPs compared with the LL-control group. The I(n-6) levels were
significantly higher both in the LA supplemented group and in the HL-control group
than in the LL-control group. In the HL-control group this was mainly due to
significantly higher values of 18;2(n-6) compared with the LL-control group. The £
(n-3) LCP and X(n-3) values were significantly reduced in the LA supplemented and
HL-control groups. The indices 'EFA status", 'EFA deficiency index" and 'CADI" were
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V " / / 1/1 u/n/>i/;a2/p/<umû. vt-nou5 a/id" ar/t-na/ w&sW «oWs /T.*. ar dc/rucry fit*<I>£
Fatty acid Umbilical plasma Venous vessel wall Arterial vessel wall
l8:2(n-6) 40.51^ +0.33" +0.35"
I(n-6)LCPs +0.33» +0.16 +0.10
%n-3) LCPs +0.S4b +0.65^ +0.51^
§: Partial correlation coefficient (after correction for gcstational age ai birth) is given for l8:2(n-6) in
umbilical plasma, for L(n-6) LCPs in umbilical venous and ancrial vessel walls and for L(n-3)
LCPs in umbilical plasma, venous and arterial vessel walls.
a: p < 0.05; b: p < 0.001.
not significantly affected by maternal LA supplementation, nor were they significantly
different in the HL-control group compared to the LL-control group.
The fatty acid compositions of the umbilical venous and arterial vessel wall PLs are
shown in table 3 and 4, respectively. LA supplementation was again associated with a
significantly higher Z(n-6) LCP content (umbilical vein) and lower X(n-3) LCP
amount, and not with significantly higher LA levels as compared with the LL-control
group. In the HL-control group, in which the habitual LA intake is comparable to the
total daily LA intake in the LA supplemented group, LA levels were significantly
higher than in the LL-control group. The LA content in the arterial vessel walls was
even in the HL-control group significantly higher as compared with the LA
supplemented group. The Z(n-3) LCP levels in the HL-control group were, however,
significantly lower than in the other two groups.
The significantly higher Z(n-6) LCPs and Z(n-3) LCPs in the LA supplemented group
as compared with the HL-control group, resulted in a significantly higher EFA status
in the venous vessel walls. Compared with the LL-control group, however, the
difference in EFA status was not significant. The relative amounts of Mead acid
(20:3(n-9), MA) and dihomoMead acid (22:3(n-9), DHMA) were not significantly
different between the three groups, nor were the EFA deficiency index and CADI.
In table 5 the results of the multiple regression analyses for the relative values (% of
total fatty acids) are shown. LA supplementation was a significant positive
explanatory variable for the relative amounts of £(n-6)LCPs in umbilical plasma and
venous vessel wall, and a significant negative explanatory variable for the £(n-3) LCP
levels in umbilical plasma, and in the arterial and venous vessel wall. The maternal
LA status at 20 weeks of gestation explained in a significant and positive way the
variation in the relative amounts of LA in umbilical plasma at delivery. The maternal
Z(n-3) LCP status at 20 weeks of gestation contributed significantly and in a positive
way to the L(n-3) LCP levels in umbilical plasma as well as in arterial vessel walls.
The high relative amounts of 20:3(n-9) in the umbilical artery were not associated
with diet, gestational age, nor did they correlate significantly with the 18:2(n-6) levels
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in maternal plasma, umbilical plasma, artery and vein.
In the control groups (n=43), the fatty acid values in maternal plasma at week 20 were
positively and significantly related to the fatty acids levels in umbilical plasma for
18:2(n-6), Z(n-6) LCPs and Z (n-3) LCPs, and in umbilical venous and arterial vessel
walls for 18:2(n-6) and Z(n-3) LCPs (see table 6). The (partial) correlation coefficient
ranged from +0.33 (p < 0.05) for E(n-6) LCPs in umbilical plasma to +0.65 (p <
0.001 ) for L(n-3) LCPs in umbilical venous vessel wall PLs.
DISCUSSION
There are two families of fatty acids, the (n-6) and (n-3), known to be essential for
normal mammalian cell function (for a recent review: see ref. 15). Linoleic acid
(18:2(n-6), LA) is the parent essential fatty acid of the (n-6) family and serves an
essential function in the maintenance of the epidermal water barrier and as an ultimate
dietary precursor fatty acid of eicosanoids, which include leukotrienes, prostaglandins,
thromboxanes and related compounds. Because LA cannot be synthesized by man, it
must be taken up by the diet. Clearly, the fetus must derive all LA from the maternal
circulation by placenta! transfer.
The present study demonstrated that a linoleic acid enriched diet, used by pregnant
women from 20 weeks of gestation until delivery, did not result in higher neonatal LA
levels, but in higher amounts of the Z(n-6) LCPs in umbilical plasma and venous
vessel wall PLs. This was associated with lower (n-3) fatty acid levels in umbilical
plasma and in venous and arterial vessel wall PLs compared with the LL-control
group. This opposite effect on (n-6) and (n-3) fatty acids may explain why LA supple-
mentation had no significant effect on the neonatal overall EFA status and the
essential fatty acid deficiency indicators Mead acid (20:3(n-9), MA) and dihomoMead
acid (22:3(n-9), DHMA) in the umbilical artery.
Tinoco et al (16) found that changes in fatty acid composition of retina, brain tissue
and muscle PLs from linolenic acid deficient rats were most marked when the experi-
mental diet was given to the mother from the time of mating or even earlier. So, it is
possible that in the present study the maternal LA supplementation started too late to
have an effect on the neonatal LA status. Indeed, in the HL-control group with a
habitual daily LA intake (23.5 ± 1.98) comparable with the total intake in the LA
supplemented group (24.7 ± 0.96), the neonatal LA status did show significantly
higher LA values than in the LL-control group. The LA levels in umbilical arteries of
the HL-control group were also significantly higher when compared with the LA
supplemented group. This suggests that the maternal LA status early in pregnancy, or
even before conception, has a greater influence on the neonatal LA status than the
increased maternal LA status later in pregnancy due to LA supplementation. This is
supported by the significant positive association between the neonatal LA status and
the maternal LA plasma levels at 20 weeks of gestation (table 5 and 6). Moreover, the
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observation that, apart from diet, the maternal X(n-3) LCP status at 20 weeks of
gestation (that is before the start of the supplementation period) already significantly
and positively contributed to the levels of these fatty acids in umbilical plasma and
arterial vessel wall PLs (table 5) points in the same direction.
Other factors which could have influenced the results, are the degree of compliance
and the amount of LA supplemented. The increment of maternal plasma LA levels in
the LA supplemented group was higher than expected on basis of the known relation
between LA intake and LA levels in plasma PLs (17, unpublished observation),
demonstrating that the dietary compliance of the women was good. The decision to
supplement the diet with approximately 10 gram LA per day was based on previous
studies (6, unpublished observation) in a group of healthy pregnant women, so that we
were sure that effects were studied within a normal range.
Recently, it was observed that the LCP status at birth is a major determinant of the
post-natal LCP status about 8 weeks after birth (18). This implies that, in order to
ensure an optimal post-natal LCP status, the pre-natal LCP status should be optimal as
well. Our present study demonstrates that maternal LA supplementation can result in a
higher neonatal (n-6) LCP status. This may have beneficial effects, especially for
children born prematurely, for which significant positive correlations have been
described between the (n-6) long chain polyene 20:4(n-6) in plasma phosphatidyl
choline, and growth in the first year of life ( 19).
In the LA supplemented group, the elevated (n-6) LCP status at birth was
accompanied by a decreased (n-3) LCP status. It is known that high intakes of LA
suppress the incorporation of (n-3) fatty acids in phospholipids (20-22). The (n-6) and
(n-3) fatty acids compete for the same desaturase and elongase enzyme systems. So,
increasing LA levels can result in a competitive inhibition of (n-3) LCP synthesis.
Cervonic acid (22:6(n-3), CA), the major (n-3) fatty acid, is an important constituent
of cell membranes, especially in brain and retina tissue and data are accumulating that
CA is an essential fatty acid for a normal development of brain and retina functions
(23-25). Hence, it is important that the maternal and neonatal (n-3) LCP status arc
optimal. Therefore, the lower (n-3) LCP content in umbilical plasma and tissue after
LA supplementation may be a matter of some concern. In the group of women with
habitual high plasma LA levels (HL-control group) the (n-3) LCP status of umbilical
plasma and vessel walls was also lower. For the umbilical vessel walls, this effect was
even more pronounced than in the LA supplemented group. However, these high LA
consumptions did not significantly affect the/uncft'ana/ CA status, since the cervonic
acid deficiency index was not significantly altered. Nevertheless, the reduced (n-3)
LCP content in neonatal tissue after LA supplementation should be prevented and,
therefore, not only the intake of LA, but also that of (n-3) LCPs during gestation
deserves consideration.
The effect of an additional intake of (n-3) fatty acids during gestation was recently
87
C/repter 7
described by Houwelingen et al. (26). An increased neonatal CA status was observed,
which was accompanied by a decrease in the neonatal (n-6) LCP status. So, again a
competition between the (n-6) and (n-3) LCPs was evident. Therefore, if the general
LCP status of the newborn needs to be improved, fatty acids of the (n-6) as well as of
the (n-3) family have to be supplied. Further research should aim at finding the
optimal fatty acid mixture of both families. Moreover, the time-period of
supplementation should be considered. There is evidence that the maternal nutritional
status during ovum maturation and early embryonic development has more effect on
the fetus than the maternal nutritional status during the last two trimesters of
pregnancy (27). This may be due, among other things, to the development of the
placental barrier in early pregnancy. Events occurring at the time of placental
implantation play a role in determining the ultimate size attained by the placenta (28).
So it is possible that the nutritional status of the mother of that particular period has a
significant influence on the composition and function of the placenta. The higher
neonatal LA status in the HL-control group and the significant positive contribution of
the maternal fatty acid levels (before supplementation) to the corresponding fatty
acids in umbilical plasma and/or vessel wall PLs provide indications that the pre-
conceptional maternal HFA status does have a significant influence on the neonatal
EFA status. Therefore, as one might expect that early intervention will be more
efficient in improving the neonatal EFA status than supplementation after complete
development of the placenta, supplementation has to start very early in pregnancy, or
even before conception.
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CHAPTER 8
General discussion
The focus of this thesis is on the relationships between the essential fatty acid (EFA)
composition of the maternal diet, and on the maternal and neonatal EFA status in
normal pregnancy and in pregnancy-induced hypertension (PIH).
Main findings
EFAs are important structural components of all cell membranes. During pregnancy,
accretion of maternal, placental and fetal tissue occurs and, consequently, the HFA
requirements of pregnant women and their developing fetus are increased. Brain tissue
is one of the tissues which contains relatively high levels of (n-3) and (n-6) long chain
polyenes (LCPs), particularly cervonic acid (22:6(n-3), CA) and arachidonic acid
(20:4(n-6), AA) (1,2). The last trimester of pregnancy is the most active period of
EFA accumulation in the brain (1,2), which is consistent with the rapid synthesis of
brain tissue during this period (3). Therefore, it is important to guarantee an adequate
EFA supply to the fetus. The fetus is mainly dependent on placental transfer to obtain
EFAs and thus on the EFA status and/or supply of the mother (4,5). Data concerning
the maternal and neonatal EFA status in normal pregnancy are, however, surprisingly,
limited. Homstra et al (6) suggested that the neonatal EFA status at birth is marginal,
if not insufficient. This view is supported by the results of the fatty acid analyses of
phospholipids (PLs) from umbilical plasma and blood cells, and from umbilical
arterial and venous vessel walls as described in the results of the first initial study
reported in this thesis (Chapter 2). In this study, the neonatal EFA status was
characterized by low linoleic acid (18:2(n-6), LA) levels in all analyzed material and
relatively high amounts of the essential fatty acid deficiency marker Mead acid
(20:3(n-9), MA) in the walls of the umbilical arteries. Moreover, the CA status, as
reflected by the cervonic acid deficiency index (22:5(n-6)/22:4(n-6), CADI), was
significantly higher in the walls from umbilical arteries (efferent blood vessel) as
compared to umbilical veins (afferent blood vessel), which may point to a relative
shortage of fetal CA.
A second initial study (Chapter 3) showed that in PIH, where the placental function
may be reduced, the neonatal EFA status was not different from that of babies born
after a normal pregnancy. However, the serum PLs of the mothers with PIH,
contained significantly lower LA, and higher CA levels as compared with
uncomplicated pregnancies. This led to the question whether an altered maternal EFA
status is involved in the etiology of PIH. The results of the study were based on a
cross-sectional design using material collected immediately after delivery and,
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therefore, do not allow any conclusion with respect to a possible cause and effect
relationship. Such a conclusion would require a prospective longitudinal comparison
of the maternal EFA courses during normal and complicated pregnancies. As hardly
any information is presently available with respect to the course of the maternal EFA
status throughout gestation, a prospective longitudinal study was performed to
describe the maternal EFA status in relation to the maternal diet during normal
pregnancy and in PIH (Chapters 4-6). Immediately after delivery, the neonatal EFA
status was assessed also. In a second study (Chapter 7), the efficacy of maternal LA
supplementation to improve the neonatal EFA status at birth was investigated.
77ie ma/erna/ £F/4 /«fate and £7vf ,9/afw.ç «faring «orma/ pregnancy ana" ite
First, the maternal EFA intake and EFA status during normal pregnancy were studied
(Chapters 4 and 5, respectively). In contrast to the stable EFA intake, the maternal
EFA status was shown to change substantially throughout normal pregnancy, both
absolute (mg fatty acid present in PLs per L plasma) as well as relative (% of total
fatty acids of plasma PLs). A continuing increase was observed for the absolute
amounts of all (n-6) and (n-3) fatty acids; the increment observed for CA was the
highest, and compared to "pre-pregnancy" levels the absolute amounts almost doubled
during pregnancy. When expressed in relative terms, the maternal LA status did not
change significantly during pregnancy. The maternal AA and CA status, however,
decreased significantly (for CA after an initial increase). This was associated with a
decrease of the overall EFA status (ratio between [I(n-6)+Z(n-3)] and [Z(n-7)+Z(n-
9)]) and an increase of the cervonic acid deficiency index. At the end of gestation, the
maternal overall EFA status was significantly lower and the CADI significantly higher
as compared to the non-pregnant state. These changes in the maternal EFA patterns
during pregnancy may be normal physiological phenomena, characteristic of being
pregnant. However, the continuous increase of the CADI may point to a progressive
deterioration of the maternal CA status as well, suggesting that under the prevailing
dietary conditions, the maternal capacity to meet the high fetal requirement for CA (5)
is working on its limits or may even be inadequate. The significantly higher CADI
values in umbilical plasma as compared to the maternal non-pregnant values also
indicates that the mother is unable to provide an optimum CA status of the developing
fetus.
At delivery, highly significant correlations were observed between umbilical venous
and maternal venous plasma PLs for all EFAs, which suggests that the neonatal EFA
status can be influenced by maternal dietary intervention. Whether mother and/or
child would functionally benefit from such an intervention require further studies on
the clinical relevance of an altered maternal and fetal EFA status.
mar?ma/ ana" neonara/ £F<4 sfafttf in pregnanowna'ucea' nyper
The observation in the second initial study (Chapter 3). regarding the higher maternal
CA levels at delivery in PIH. could theoretically mean that CA is involved in the
etiology of PIH. In that case, CA supplementation during pregnancy is probably
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contra-indicated. Whether the higher maternal CA status, at delivery, was a
consequence of or a contributing factor to P1H, was studied in a longitudinal "nested"
case-control study (Chapter 6). The results demonstrated that the higher maternal CA
status in PIH is a late phenomenon, occurring after the clinical manifestations of the
disease and, therefore, most probably is not causally related to the onset of PIH.
Supplementing pregnant women with CA will thus most probably not contribute to
the development of PIH. This suggestion is supported by results from an
epidemiological study performed in Northern Canada, showing that Inuit women
eating a diet rich in marine food are 2.6 times less likely to develop PIH than Inuit
women whose diet contain a greater proportion of terrestrial food (7). Whether or not
CA supplementation during pregnancy is effective in reducing the incidence of PIH
remains to be investigated.
In the same study (Chapter 6), it was also investigated whether the lower maternal LA
status in PIH preceded the clinical manifestations of the disease and could therefore,
be involved in its etiology. Again no significant differences were observed between
cases and controls during pregnancy. After delivery the LA levels in maternal plasma
PLs were reduced in PIH. This was associated with significantly higher amounts of
total (n-6) LCPs. In addition, the content of a-linolenic acid (18:3(n-3), LnA) was
significantly decreased. In PIH, the EFA status of umbilical vessel wall PLs was not
different from normal. Since the fatty acid composition of these PLs gives a longer
term reflection of the fetal EFA status, this observation supports the suggestion that
the altered EFA status in mothers with PIH is a late phenomenon and, therefore, rather
a consequence than a cause of this disease.
The decreased levels of the parent EFAs, LA and LnA, in combination with the higher
levels of Z(n-6) LCPs and CA suggest that the parent EFAs are more actively
metabolized in PIH than in an uncomplicated pregnancy, most probably to guarantee
an adequate LCP supply to the fetus in spite of the compromised placental circulation.
As a consequence, the neonatal EFA status in PIH is not significantly different from
that in a normal pregnancy. On the contrary, the neonatal EFA status tends to be
improved as is indicated by lower relative amounts of the EFA deficiency marker
Mead acid (20:3(n-9), MA). Moreover, the levels of CA in neonatal plasma PLs arc
even significantly higher than after a normal pregnancy.
Maternal LA supplementation during pregnancy had no effect on the neonatal LA
status (Chapter 7). A well known (and possibly the only) direct physiological function
of LA is to control the permeability of the skin to water (8). A low fetal LA status will
probably not be harmful, as during intra-uterine life, the fetus is surrounded by
amniotic fluid and, therefore, this function of LA will probably be of minor
importance during fetal life. Consequently, low LA levels in fetal life (9) will
probably have no consequences, as far as this function of LA is concerned.
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Maternal LA supplementation did increase the (n-6) LCP status of the neonate, but at
the expense of its (n-3) LCP status (Chapter 7). An intervention study, in which
pregnant women were supplemented with (n-3) fatty acids (10) showed that an
increased neonatal CA status is accompanied by a decreased (n-6) LCP status. So,
again a competition between (n-6) and (n-3) fatty acids was evident. Therefore, if the
general EFA status of the newborn needs to be improved, it is important to use diets
or supplements containing balanced amounts of (n-6) and (n-3) fatty acids.
Some methodological considerations
" ari</ co»i/?o.v///o« o/fAe um6i/ira/ vesse/ wa//j as a /onger term re/7ecfzon 0 /
To assess the neonatal EFA status, the fatty acid composition was determined of
phospholipids (PLs) isolated from umbilical plasma and blood cells, and from
umbilical venous and arterial vessel walls. The EFA composition of the umbilical
vessel wall PLs is considered to give a longer term reflection of the neonatal EFA
status than that of plasma or blood cells (6). This view is based on the fact that
umbilical vessel walls have no vasa vasorum and, therefore, have to obtain their
essential fatty acids from the blood they contain. Moreover, the turnover of vessel
wall PLs may be expected to be slower than that of plasma or blood cells.
The PLs of the umbilical arterial vessel walls contain relatively high levels of the EFA
deficiency markers Mead acid (20:3(n-9), MA) and dihomoMead acid (22:3(n-9),
DUMA). This observation led to the suggestion that the fetal need for EFAs may not
be adequately covered. Since data on fetal fatty acid biochemistry is limited, the
results from umbilical material are all interpreted on the basis of biochemical
relationships in adult material, which may be different in fetal cells and tissues. For
instance, the fetal desaturase system could be much more active than the adult
desaturase system, resulting in the formation of MA and DHMA even if adequate
amounts of EFAs are available. However, even then, it still remains to be explained
why these fatty acids are only present in high amounts in the umbilical artery and not
in the umbilical vein, while the (n-6) desaturation index [(18:3(n-6)+20:3(n-
6)+20:4(n-6)+22:4(n-6)+22:5(n-6)/l8:2(n-6)] is not significantly different between
these two types of vessel walls. An alternative explanation for the high MA and
DHMA levels in the umbilical artery could be that the arterial vessel walls serve as
the "dustbin" for the baby, to get rid of substances (MA and DHMA) it does not need.
The question whether the EFA status of newborns is insufficient, marginal or adequate
cannot be answered properly as long as there is no more information available on fetal
fatty acid biochemistry.
a/i</ re/ar/ve /âf/v aci</ rfa/a
In most of our studies, we expressed the fatty acid composition in absolute (mg fatty
acid present in PL per L plasma or per g dry weight tissue) and relative (% of total
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fatty acids of plasma PLs) amounts. Different results were observed between both
methods. Whereas the relative amounts of AA and CA are significantly higher in
umbilical than in maternal plasma PLs, the absolute amounts are significantly lower,
because the PL concentration is considerably lower in cord blood than in maternal
blood at delivery (see also Figure 1 ). So when pool sizes are different (as is the case in
mother/fetal comparisons) or when pool sizes are changing considerably over time (as
happens in maternal blood during pregnancy), it may be preferable to base a
comparison on absolute fatty acid amounts. However, one has to be careful when
comparing absolute fatty acid amounts between mother and child and between
pregnant women and non-pregnant women, because the (physiological) state of
hyperlipidemia in pregnancy is likely to exaggerate the differences.
Since metabolic reactions of fatty acids occur in a lipid environment, it is the amount
of a given fatty acid relative to the other fatty acids present that determines the rate of
this reaction in that environment. Therefore, from a metabolic perspective, relative
fatty acid compositions are just as important as absolute values. An additional
advantage of relative fatty acid data above absolute amounts is that the measurement
error of the analytical procedure when determining relative concentrations is, usually,
smaller.
versas /«/jcr/ona/ parameters
In this thesis, the studies were restricted to biochemical endpoints. It is, however, also
essential to know whether an altered EFA status is associated with functional changes.
Studies in premature infants have shown that their CA status is positively associated
with cognitive indicators derived from tests like the Baley Mental Development Index
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and Baley Psychomotor Developmental Index (11) and with visual functions, like
visual-evoked-potential and forced-choice preferential looking (12,13). Carlson et al
(14) observed in premature children a significant positive correlation between
arachidonic acid (20:4(n-6), AA) levels in plasma phosphatidyl choline and growth in
the first year of life. Because premature children often experience conditions (chronic
illness, intrauterine malnutrition) that could have adversely affected growth and/or
development, studies in term infants should be carried out as well. The results of the
few preliminary studies performed so far in term infants, support the evidence for an
essential role of CA in visual function (13,15). It will be very important to extend our
biochemical data with functional parameters, so that conclusions can be drawn on
aspects relating to human development.
The EFA composition of the maternal diet during pregnancy: the pros and cons
of EFA supplementation
The studies reported in Chapters 2, 4, 5 and 7 represent for a great part observational
research, among women with an uncomplicated pregnancy. Therefore, one can
assume that the fatty acid data of these women and their newborn infants are
representing the average normal fatty acid patterns in pregnancy. However, the
question whether or not these data also represent the o/wmia/ situation for pregnant
women and their children is yet unanswered. Based on the results from the studies
described in this thesis in combination with indications from the literature, in my
opinion, supplementation of (n-6) and (n-3) LCPs to the maternal diet may have
potential benefits.
During the last trimester of pregnancy, fetal CA demands are high due to rapid
accumulation of CA in neural (1,2) and retinal tissue (2). As shown in figure 2, fetal
phospholipids show an increasing content of CA with increasing gestational age.
Studies in preterm and term infants have shown that their CA status is positively
associated with visual (2.12,13) and cognitive functions (11), indicating the relevance
of an optimal CA status. During normal pregnancy the maternal CA status was shown
to decrease (Chapter S). It is possible that this results from the maternal attempt to
meet the high fetal requirement for CA. The maternal CA status seems to decrease
even further with each following pregnancy (16), which may imply that the maternal
CA status does not fully normalize after the first pregnancy. We observed no
significant differences in the neonatal CA status of infants from primigravida as
compared to that of multigravida after a normal pregnancy (Unpublished observation).
Carlson et al (17), however, found in preterm children that birth order is a significant
negative predictor of their red blood cell CA content, which suggests also that the CA
supply to the fetus is depleted by repeated pregnancies. Although the functional
implications of this "exhaustion-effect" of pregnancy on the maternal CA status is not
yet known, it may be prudent to prevent this. As the neonatal CA status is
significantly and positively correlated with the maternal CA status (Chapter 2 and 5),
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the CA status of the fetus will benefit from an improved maternal CA status.
Premature children are prematurely deprived from their CA source in utero, and are
thus dependent on artificial formula or breast-milk for their CA supply. This supply
may not be as adequate as during intra-uterine life (18). Therefore, it is reasonable to
expect that the premature infant will benefit from an improved CA status, at delivery
already. This seems the more so, as the post-natal CA status, about eight weeks after
birth, is still for a great part determined by the neonatal CA status at birth (19).
It has been shown that an increased maternal CA intake is associated with a reduced
neonatal (n-6) LCP status (10). The major (n-6) LCP arachidonic acid (20:4(n-6), AA)
is also one of the predominant fatty acids in the central nervous system (5), and
therefore a reduced (n-6) LCP should be prevented. Since the AA status of premature
infants positively predicts growth and cognitive development (Baley MDI, Fagan
Infantest) in the first year of life ( 14,17), an adequate maternal supply of both C A and
AA should be considered.
The EFAs in the diet of the pregnant women participating in our studies consisted
largely of linoleic acid (more than 80% of the total polyunsaturated fat intake, Chapter
4). The amount of other polyunsaturated fatty acids, like arachidonic acid (20:4(n-6),
AA) and cervonic acid (22:6n-3), CA), could not be calculated because the
Netherlands Nutrient Databank does not contain information on the content of these
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fatty acids in food(s). Collecting and analyzing duplicate food portions will have to
provide us with this important information. Dietary data from Crawford et al (20)
showed that the AA plus CA content present in the diet of British pregnant women
was less than one percent of the total fat intake. So, although there may be some AA
and CA present in the maternal diet, it may, perhaps, not be enough to meet the need
for these fatty acids by the developing fetus and to prevent the deterioration of the
maternal CA status. The optimal EFA composition of the maternal diet - if there is
such an optimum - can only be established by controlled clinical intervention studies.
These studies have not yet been performed and, therefore, at this moment one can
only speculate on this.
Some years ago, Eaton & Konner (21 ) suggested that man should consume a diet
more in accordance with the diet of its paleolithic ancestors, since this is the diet to
which humans are genetically programmed for and on which they have developed
during 4 million years of evolution. The diet of our remote ancestors included more
structural fat and less depot fat with a P/S ratio (ratio between polyunsaturated fat and
saturated fat) of approximately 1.4 (21). This figure differs considerable from the P/S
ratio of 0.4 in our present diet (Chapter 4). The difference in P/S ratio is, among other
things, due to the higher content of (n-6) and (n-3) LCPs present in meat of wild
animals (consumed by our ancestors), as compared to that present in domestic
livestock (21,22). The lower P/S ratio in our current diet is also explained by the high
consumption of cooking fats and dairy products nowadays, which are rich in saturated
fat (23). The paleolethic diet contained no dairy products whatsoever (21 ).
The changes in human genetic constitution have been relatively small over the last
40,000 years (21), whereas, due to developments in producing and processing food,
major changes in the dietary patterns have occurred in the last few millenia (transition
from a hunter-gatherer society to an agricultural society). During the last century,
major developments in the food industry took place, allowing too short a time span to
enable men to adapt genetically to the changed dietary patterns. Differences between
the nutrient composition of our diet and of the diet to which our remote ancestors
became accustomed to through evolution could very well account for at least part of
the diet-related health problems we have nowadays. Therefore, it is perhaps better to
raise the proportion of (n-3) and (n-6) long chain polyenes in our diet. This may be of
special importance in the diet of pregnant women because of the high fetal
requirements for these fatty acids.
The theory of Eaton & Konner is in line with that put forward by Crawford (24,25),
regarding the availability of structural fats like AA and CA being a limiting factor in
brain development and evolution. Crawford's theory of nutrient dependency supposes
that man evolved at the land-water interface, which provided him with the appropriate
nutrients to enable brain evolution to keep pace with increasing body size. As
mentioned earlier, our diet contains hardly any (n-6) and (n-3) LCPs. As human brain
growth largely takes place during intra-uterine life (3). it may have potential benefits
to supplement (n-6) and (n-3) LCPs to the maternal diet. Because of the competition
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between these two fatty acid families, one should try to find the optimal balance
between them.
The ratio between (n-6) and (n-3) fatty acids in brain tissue varies between 1.5:1 to
2.8:1 (26,27). The mean (n-6)/(n-3) ratio in the diet of 24 British pregnant women
from higher social classes, as assessed by direct analysis of the foods which the
mother were using, has been estimated at 7:1 (20). Fatty acid analyses of muscle and
adipose fat of wild animals revealed a ratio of 1:1 to 4:1 (22). If the ideal dietary ratio
should be more in accordance to that found in brain tissue, it should be closer to one
(24). However, more research is necessary to determine the ideal dietary ratio, before
making any recommendations.
The most active period of cell divisions is within the first weeks after conception. At
this stage, nutrition of the embryo is exclusively dependent on its mother's health,
nutrition and metabolism because the placenta has not yet been formed (25). It is
therefore not unlikely that maternal nutrition in that particular period will have a great
influence on pregnancy outcome. This view is supported by results from the "Dutch
famine studies" as reported by Wynn & Wynn (28) who stated that "if a woman was
short of food before or around that she conceived, the risks to her baby (like
congenital malformations or neural tube defects) were much more serious than if she
was well fed at conception but short of food during pregnancy". We observed that the
neonatal EFA status at birth (umbilical plasma) is positively correlated with the EFA
status of maternal plasma at 14 weeks of gestation already. Correlation coefficients
were +0.44 for LA, +0.41 for AA and +0.45 for CA (n = 85 , p < 0.001 for all three
correlation coefficients given). Since the maternal fatty acid values at that time are
significantly and positively related to their non-pregnant relative amounts (LA: r =
+0.53; AA: r = +0.52; CA: r = + 0.67; n = 38, p < 0.001 ), one may assume that the
maternal EFA status early in pregnancy or even before conception is also positively
associated with the neonatal EFA status. In the LA intervention study (Chapter 7) it
was shown that maternal LA supplementation after the placenta had fully developed
had no significant effect on the LA status. These observations suggest that when the
EFA status of the developing fetus needs to be improved, supplementation very early
in pregnancy or preferably before conception may have the most beneficial effects.
Future research
As already mentioned, the effect of maternal supplementation with (n-6) and (n-3)
LCPs on the maternal and neonatal EFA status should be studied. This holds
particularly for CA, since the maternal CA status decreases during gestation and
seems to be lower with each following pregnancy. Therefore, supplementing CA may
assist the mother in providing sufficient CA to the fetus without depleting her own
stores. It will be important to extend the biochemical data with clinical and functional
parameters to study how infant development is affected. Since polyunsaturated fatty
acids are easily peroxidized, an increased PUFA intake could cause more peroxidation
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in the body which could present some major health risks (29). Therefore, special
attention has to be given to the anti-oxidant status of mother and child.
To further elucidate the processes and mechanisms responsible for the differences
between the EFA profile of mothers and of their newborn infants, more research has
to be done on fetal fatty acid metabolism and placental fatty acid transfer in humans.
The use of fatty acids labelled with stable isotopes combined with gas
chromatography/mass spectometry (GC/MS) techniques will greatly expand the
oppurtunities for /« v/vo research. Stable isotope studies in pregnant women will
provide us with essential data required for designing optimal nutritional strategies for
mother and fetus.
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SUMMARY
Essential fatty acids (EFAs) are important constituents of all cell membranes. During
pregnancy, when processes like fetal brain development and organogenesis are taking
place in a limited time period, fetal EFA demand is high. The EFA status of babies
born after a normal pregnancy seems not to be adequate, if not insufficient (see
Chapter 1 ). The studies presented and discussed in this thesis were intended to obtain
more information on the relationships between the neonatal and maternal EFA status
in normal pregnancy and pregnancy-induced hypertension. In addition, the EFA
composition of the maternal diet was studied.
First, the neonatal EFA status was compared with that of their mothers at delivery by
determining the fatty acid compositions of phospholipids (PLs). isolated from
umbilical arterial and venous vessel walls, blood cells (BC) and plasma, and from
maternal venous plasma and BC. The fatty acid content of non-infarcted placental
tissue was determined also (Chapter 2). The PLs of umbilical arterial tissue (efferent
fetal vessels) contained fewer fatty acids of the (n-6) family and more of the (n-9)
family than umbilical venous tissue (afferent fetal vessel). The relative amounts of (n-
6) and (n-3) fatty acids were less in arterial than in venous plasma. Mead acid. 2O:3(n-
9), the presence of which indicates a poor EFA status, was 5 times higher in the
efferent than in afferent cord vessels. In neonatal plasma and BC it was twice as high
as compared with maternal levels. In general, the fatty acid composition of the
placenta PLs showed a pattern comparable with neonatal venous plasma PLs. These
findings indicate that the biochemical EFA status of neonates, born after a normal
pregnancy may not be optimal. The significant correlations between neonatal and
maternal EFAs indicate that the neonatal EFA status depends on the EFA content of
the maternal diet.
In situations where the placental function is impaired, the transfer of nutrients from
mother to fetus may be insufficient. To what extent the neonatal EFA status is
affected by such an event was studied in cases with pregnancy-induced hypertension
(PIH), which is, in a high percentage, characterized by a reduced placental perfusion
(Chapter 3). The fatty acid composition was determined from PLs, triglycérides (TG)
and cholesterolesters (CE) of umbilical cord serum and maternal serum. Relative
contents of linoleic acid of serum PL and CE were significantly lower in mothers with
PIH (n=13) compared to normal pregnancies (n=15). Most other (n-6) polyencs in PL
tended to be higher under hypertensive conditions. Total maternal (n-3) polyenes of
serum PL were significantly higher in PIH. mainly due to clupanodonic acid, 22:5(n-
3), and cervonic acid, 22:6(n-3). Total maternal (n-7) and (n-9) fatty acids were also
significantly higher in PIH (PL and CE). The results indicate that PIH is associated
with a relative increased unsaturalion of maternal serum PL, which might facilitate the
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placental transfer of long-chain, polyunsaturated fatty acids. As a result, the neonatal
EFA status after PIH only slightly differs from normal.
The altered maternal EFA status in PIH could theoretically mean that these fatty acids
are involved in the etiology of PIH. The results of the study are based on a cross-
sectional design using material collected immediately after delivery and, therefore, do
not allow any conclusion with respect to a possible cause and effect relationship. Such
a conclusion would require a prospective longitudinal comparison of the maternal
EFA courses during normal and complicated pregnancies. Therefore, a prospective
longitudinal study was performed to describe the maternal EFA status in relation to
the maternal diet during normal pregnancy and in PIH. Immediately after delivery, the
neonatal EFA status was assessed also (Chapters 4-6).
The nutrient intake of 176 women throughout a normal pregnancy with special
emphasis on the amount and type of fat consumed is described in Chapter 4. The
subjects completed a food frequency questionnaire (FFQ) before 13, at 22, and at 32
weeks of gestation. At 22 weeks of gestation a diet history (DH) was carried out and a
maternal blood sample was taken. No significant changes in the mean daily intake of
saturated fat.mono-unsaturated fat, polyunsaturated fat, and linoleic acid during
pregnancy were observed. Less than 30 % of the women met the recommendations for
amount and type of dietary fat. The intakes of linoleic acid and polyunsaturated fatty
acids (% of total fat intake) of pregnant women assessed with the FFQ and DH
correlated well with the amounts of these fatty acids in plasma phospholipids. It is
concluded that the fat content and composition of the maternal diet does not change
during a normal pregnancy. In addition, the individual dietary composition with
respect to these nutrients seems consistent during gestation.
Chapter 5 reports on maternal EFA patterns during normal pregnancy. Moreover, its
relationship to the neonatal EFA status at birth is described. One-hundred-ten
pregnant women gave repeatedly a blood sample from the 10th week of gestation until
delivery. After birth, a blood sample from the umbilical vein and a maternal venous
blood sample were collected as well, and six months after delivery a final blood
sample from the mother was taken. The absolute (mg/L) and relative (% of total fatty
acids) amounts of the fatty acids in plasma phospholipids were determined. The total
amounts of fatty acids increased significantly during pregnancy. This pattern was
similar for the individual fatty acids and fatty acid families. The relative amounts of
linoleic acid [18:2(n-6)| did not change during pregnancy, whereas the relative
amounts of arachidonic acid (20:4(n-6)] decreased. Despite a maternal mobilization of
cervonic acid (22:6(n-3). CA). suggested by a temporarily increase in the CA status
until 18 weeks of gestation, the CA status steadily declined thereafter. This was
associated with an increase of the cervonic acid deficiency index (22:5(n-6V22:4(n-6),
CADI) in maternal blood throughout pregnancy. The overall maternal EFA status
(ratio between [X(n-6)+X(n-3)) and [X(n-7)+X(n-9)]) also declined during pregnancy.
These changes in the maternal EFA patterns during pregnancy may be normal
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Summary
physiological phenomena. However, the continuous increase of the CADI may point
to a progressive deterioration of the maternal CA status, suggesting that under the
prevailing dietary conditions, the maternal capacity to meet the high fetal requirement
for CA is working on its limits or may even be inadequate. The significantly higher
CADI values in umbilical plasma as compared to the maternal non-pregnant values
also indicates that the mother is unable to provide an optimum CA status of the
developing fetus.
In Chapter 6 the maternal and neonatal EFA status in PIH is compared with that in
uncomplicated pregnancies. Pregnant women, healthy at the start of the study, were
asked to give a blood sample before 16 weeks, at 22 weeks and at 32 weeks of
gestation. After delivery, a blood sample from the umbilical vein, a piece of the
umbilical cord and a maternal blood sample were collected. Fatty acid compositions
were determined of the PLs isolated from plasma and from umbilical arterial and
venous vessel walls. The nutrient intake of the pregnant women was assessed with the
aid of the dietary history method and using food frequency questionnaires. The results
of each woman with PIH were compared with the results of three matched healthy
controls. During pregnancy (16-32 weeks) no significant differences were observed in
nutrient intake and maternal plasma fatty acid composition between the PIH (n=52)
and the control group (n=156). After delivery, the relative amounts of 18:2(n-6) and
18:3(n-3) in maternal plasma were significantly lower in PIH than in normal
pregnancy (NP). This was associated with significantly higher levels of (n-6) long
chain polyenes and cervonic acid (22:6(n-3),CA). As compared to the situation at 32
weeks, the post-partum CA status increased in PIH whereas it decreased in NP. The
CA levels in umbilical plasma PLs were significantly higher after PIH than alter NP.
No significant differences were observed for the umbilical vessel walls. These results
indicate that the altered EFA status in PIH is a late phenomenon and is, therefore,
unlikely to have contributed to the pathogenesis of PIH. Moreover, the neonatal EFA
status is not negatively affected by PIH.
Finally, the effect of maternal linoleic acid (18:2(n-6), LA) supplementation on the
neonatal EFA status was studied and the results are described in Chapter 7. Pregnant
women with relatively low plasma LA levels before 16 weeks of gestation (n=21)
were supplemented with approximately 10 gram of LA per day from the 20th week of
gestation until delivery. One of the two control groups consisted of pregnant women
with comparably low plasma LA levels at the start of the study (LL-control group,
n=22); the other consisted of women with habitual high plasma LA levels (HL-control
group, n=21). The neonatal EFA status was assessed by determining the fatty acid
composition of PLs isolated from umbilical plasma and umbilical vessel walls. LA
supplementation resulted in significantly higher levels of the sum of (n-6) long chain
polyenes (LCPs) in umbilical plasma and venous vessel walls compared with the LL-
control group. This increase was associated with lower (n-3) LCP levels. In the HL-
control group the neonatal (n-3) LCP status was also lower as compared to the LL-
control group. It is concluded that if the EFA status of newborns needs to be
improved, fatty acids of both the (n-6) and (n-3) family have to be supplied.
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In Chapter 8 the main findings and some methodological considerations of the studies
in this thesis are discussed. Furthermore, the pros and cons of EFA supplementation
during pregnancy is evaluated and some suggestions for future research are given.
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SAMENVATTING
Essentiële vetzuren ('essential fatty acids', EFAs) zijn belangrijke bouwstenen van aile
celmembranen. Tijdens de zwangerschap is de behoefte van de foetus aan EFAs hoog
omdat veel nieuw weefsel wordt gevormd. Biochemisch onderzoek suggereert dat de
EFA status van gezonde pasgeborenen niet optimaal is en missehien zelfs wel
onvoldoende (zie hoofdstuk 1). De in dit proefschrilt beschreven onderzoeken zijn
uitgevoerd om meer inzicht te krijgen in de relatte tussen de essentiële vctzuurstatus
van het kind en die van de moeder. Dit is onderzocht bij normale zwangerschap en bij
zwangerschapshypertensie. Bovendien is de essentiële vetzuursamenstelling van dc
voeding van vrouwen tijdens de zwangerschap bestudeerd.
Allereerst werd de EFA status van gezonde pasgeborenen vergeleken met die van hun
moeders vlak na de bevalling. De EFA status werd vastgesteld door de
vetzuursamenstelling van fosfolipiden ('phospholipids', PL) geïsoleerd uit arterieel en
veneus vaatwandweefsel, erytrocyten en plasma van de navelstreng en uit vencus
plasma en erytrocyten van de moeder te bepalen. De vetzuursamenstelling van niet
geïnfarceerd placentaweefsel werd ook bepaald (Hoofdstuk 2). De PI. van arterieel
vaatwandweefsel (afvoerende vaten) bevatte minder vetzuren van de (n-6) familic en
meer van de (n-9) familie dan veneus vaatwandweefsel (aanvoerende vaten). De
relatieve hoeveelheden van de (n-6) en (n-3) vetzuren in arterieel navclstrengplasma
waren lager dan in veneus navelstrengplasma. De aanwezigheid van relatief grote
hoeveelheden Meadzuur, 20:3(n-9). wijst in de richting van een ongunstige EFA
status. In de afvoerende vaten van de navelstreng was Meadzuur vijfmaal meer
aanwezig dan in de aanvoerende vaten; in plasma en erytrocyten van de navelstreng
was de hoeveelheid Meadzuur tweemaal zo hoog dan in plasma en erytrocyten van de
moeder. De vetzuursamenstelling van placenta PL vertoonde over het algemeen cen
beeld vergelijkbaar met die in veneus navelstrengplasma PL. Deze resultatcn
bevestigen dat de biochemische EFA status van kinderen, geboren na een normale
zwangerschap, niet optimaal lijkt te zijn. De significante correlaties tussen de EFAs
van moeder en kind suggereren dat de EFA status van het kind afhankelijk is van de
EFA samenstelling van de voeding van de moeder.
Wanneer de placentafunktie verminderd is kan de overdracht van voedingsstoffen van
moeder naar kind onvoldoende zijn. Zo'n verminderde placentafunktie komt veel voor
bij zwangerschapshypertensie. Welke gevolgen dit heeft voor de EFA status van het
kind is onderzocht bij vrouwen en hun kinderen, waarvan de zwangerschap
gecompliceerd werd door zwangerschapshypertensie (Hoofdstuk 3). De
vetzuursamenstelling werd bepaald van PL, triglyceriden (TG) en cholesterolesters
(CE), geïsoleerd uit veneus serum van de navelstreng en van de moeder. Relatieve
hoeveelheden van linolzuur in serum PL en CE waren significant lager bij vrouwen
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met zwangerschapshypertensie (n=13) dan bij vrouwen met een normale
zwangerschap (n=15). De meeste andere (n-6) vetzuren in PL hadden de neiging
hoger te zijn bij zwangerschapshypertensie (pregnancy-induced hypertension', PIH).
De totale som van de (n-3) vetzuren in serum PL was significant hoger in PIH,
voornamelijk door clupanodonzuur, 22:5(n-3), en cervonzuur, 22:6(n-3). De totale
som van de (n-7) en (n-9) vetzuren was ook significant hoger in PIH (PL en CE).
Deze rcsultaten geven aanwijzingen voor een toegenomen onverzadiging in de serum
PL van vrouwen met PIH. Dit zou de overdracht van langketen meervoudig
onverzadigde vetzuren ('long chain polyenes', LCPs) over de placenta kunnen
vergemakkclijkcn. Dientengevolge verschilde de EFA status van de pasgeborenen van
mocdcrs met PIH niet significant van die van moeders met een normale
zwangerschap.
De verandcrde EFA status van vrouwen met PIH op het moment van de bevalling kan
theoretisch betekenen dat deze vetzuren een rol spelen in het ontstaan van PIH. De
resultatcn zijn echter gebaseerd op materiaal dat direkt na de bevalling was verzameld.
Op dat moment hadden de vrouwen al PIH en daarom kan geen uitspraak gedaan
worden over een mogelijke oorzaak-effekt relatie. Om een antwoord te krijgen op de
vraag of de gewijzigde EFA status een oorzaak of een gevolg is van PIH dient de EFA
status van vrouwen tijdens de zwangerschap prospectief en longitudinaal te worden
gevolgd, zowcl tijdens normale zwangerschappen als bij PIH. In hoofdstuk 4 tot en
met 6 wordt een dergelijk prospectief longitudinaal onderzoek beschreven. Bovendien
is nageguan hoe de relatie is tussen de EFA status van de moeder en de EFA
samenstelling van hun voeding. Na de bevalling is ook de EFA status van het kind
bepaald.
De nutrientinncming van 176 vrouwen gedurende een normale zwangerschap is
beschreven in hoofdstuk 4. Hierbij is vooral aandacht besteed aan de hoeveelheid en
het soon vet dat werd geconsumeerd. De deelnemers vulde vôôr 13 weken, en rond 22
en 32 weken van de zwangerschap een voedselfrequentielijst ('food frequency
questionnaire'. FFQ) in. Omstreeks de 22e week van de zwangerschap werd ook een
dietary history (DH) uitgevoerd en een bloedmonster van de moeder verzameld. De
inneming van (otaal vet, verzadigd vet, enkelvoudig onverzadigd vet, meervoudig
onver/adigd vet en linol/.uur veranderde niet significant tijdens de zwangerschap.
Minder dan 3O9f van de vrouwen voldeden aan de aanbevolen hoeveelheden voor
hoeveelheid en soort voedingsvet. De inneming van linolzuur en meervoudig
onver/adigd vet (% van totaal vet inneming) volgens de FFQ en de DH correleerde
goed met do hoeveelheid van deze velzuren in de plasma fosfolipiden. Dit onderzoek
liet zien dat de hoeveelheid en soort vet in de voeding van zwangere vrouwen niet
significant veranderen gedurende een normale zwangerschap. De individuele
vetsamcnstclling van de voeding lijkt ook constant tijdens de zwangerschap.
Hoofdstuk 5 rapporteert over het verloop van de EFA status van moeders tijdens een
normale /wangerschap. Tevens is de relalie tussen de EFA status van de moeder en
die van het kind op het moment van geboorte onderzocht. Honderdtien zwangere
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vrouwen gaven vanaf de tiende week van de zwangerschap tot aan de bevulling
regelmatig een bloedmonster. Na de bevalling werd een bloedmonster uit de
navelstrengvene en van de moeder verzameld. Ongeveer een half jaar na de bevalling
werd bij een aantal vrouwen nog een bloedmonster afgenomcn. De hoevcclheid
vetzuren in plasma PL werd zowel absoluut (mg/L) als relatiel" ('7r van lotaal vetzuur)
berekend. De totale hoeveelheid vetzuren steeg significant tijdens de /.wungcrschap.
Dit beeld was vergelijkbaar voor de afzonderlijke vetzuren en vct/uuilamilies. De
gemiddelde relatieve hoeveelheid linolzuur [(18:2(n-6)] veranderde niet significant
tijdens de zwangerschap. De relatieve hoeveelheden arachidonzuur [20:4(n-6)],
daarentegen. daalde significant. De cervonzuurstatus (22:6(n-3), CA) van de moeder
steeg tot ongeveer de 18e week van de zwangerschap (mogelijk vanwege een
mobilisatie van opgeslagen cervonzuur). om vervolgens gestadig af te nemen. Dit was
geassocieerd met een toename in de cervonzuur deficiCntie index (22:5(n-6)/22:4(n-6),
CADI) in het plasma van de moeder. De "totale" EFA status (ratio tussen |X(n-6)+£
(n-3)] en [Z(n-7)+X(n-9)]) van de moeder daalde ook tijdens de zwangerschap. De
waargenomen veranderingen in het verloop van de EFAs in het plasma van dc moeder
tijdens de zwangerschap kunnen normale fysiologische aanpassingen zijn. Echter, de
continue toename van de CADI wijst in de richting van een verslechterde CA status
van de moeder. Dit zou kunnen betekenen dat bij het huidige voedingspatroon, de
moeder veel moeite heeft om tegemoet te komen aan de grote CA behoefte van de
foetus. Dit wordt bevestigd door de significant hogere CADI waarde in het
navelstrengplasma vergeleken met de waarde in het plasma van de moeder, ses
maanden na de bevalling.
In hoofdstuk 6 is de EFA status van moeder en kind bij PI H vergeleken met die
tijdens normale zwangerschap. Zwangere vrouwen, die gezond waren bij aanvang van
het onderzoek, werden gevraagd een bloedmonster te geven voor 16 wcken, rond 22
en 32 weken van de zwangerschap en direkt na de bevalling. Ook werd een
bloedmonster uit de navelstreng en een stukje navelstreng verzameld. De
vetzuursamenstelling van de fosfolipiden, geïsoleerd uit plasma en
navelstrengweefsel. werd bepaald. De nutnenteninneming van de zwangere vrouwen
werd geschat met behulp van voedselfrequentievragenlijsten en de dietary history
méthode. De resultaten van een vrouw die PIH had gekregen werd vergeleken met dc
resultaten van drie gezonde zwangere vrouwen. Matching vond plaats op de
parameters pariteit en bevallingscentrum. Tijdens de zwangerschap (16-32 weken)
werden geen significante verschillen in de nutrientinneming en de
vetzuursamenstelling van het moederlijke plasma tussen de PIH groep (n=52) en de
contrôle groep (n=156) waargenomen. Na de bevalling waren de relatieve
hoeveelheden van 18:2(n-6) en 18:3(n-3) in het plasma van de moeder significant
lager in de PIH dan in de normale groep (normal pregnancy', NP). Dit was
geassocieerd met significant hogere hoeveelheden van de (n-6) LCPs en cervonzuur
(22:6(n-3), CA). Na 32 weken zwangerschap nam de CA status toe bij PIH, terwijl
deze afnam bij NP. De hoeveelheden CA in navelstrengplasma waren significant
hoger bij PIH dan in NP groep. Tussen de PIH en NP groep werden geen significante
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verschillen gevonden in de vetzuursamenstelling van het navelstrengvaatweefsel. De
resultaten tonen aan dat de veranderde EFA status bij PIH een laat fenomeen is en
daarom hoogstwaarschijnlijk niet heeft bijgedragen aan het ontstaan van PIH. De
resultaten geven ook aan dat de EFA status van het kind niet verslechtert ten gevolge
van PIH. ,
Tenslotte is het effect van linolzuursuppletie (18:2(n-6), LA) tijdens de zwangerschap
onderzocht op de EFA status van het kind en de resultaten zijn beschreven in
hoofdstuk 7. Zwangere vrouwen (n=21) die minder dan 16 weken zwanger waren en
een relatief lage LA status hadden werden gesupplementeerd met ongeveer 10 gram
LA per dag vanaf de 20ste week van de zwangerschap tot aan de bevalling. Eén van
de twee contrôle groepen bestond uit zwangere vrouwen met een vergelijkbare LA
status aan het begin van het onderzoek (LL-controle groep, n=22); de andere contrôle
groep bestond uit zwangere vrouwen met een habitueel hoge LA status (HL-controle
groep, n=21). Dc EFA status van het kind werd vastgesteld middels het bepalen van
de vetzuursamenstelling van fosfolipiden uit navelstrengplasma en -vaatwandweefsel.
Het supplementeren van zwangere vrouwen met linolzuur resulteerde in significant
hogere hoeveelheden van de (n-6) LCPs in navelstrengplasma en veneus
vaatwandweefsel in vergelijking met de LL-controle groep. Deze toename was
geassocieerd met lagere hoeveelheden van de (n-3) LCPs. De gemiddelde hoeveelheid
(n-3) LCPs in het navelstrengplasma en het -vaatwandweefsel van de HL-controle
groep was ook significant lager dan in de LL-controle groep. Mocht het wenselijk
worden geacht dc EFA status van pasgeborenen te verbeteren, dan moeten zowel
vetzuren van de (n-6) als de (n-3) familie worden gesupplementeerd.
Hoofdstuk 8 bevat de discussie van de belangrijkste resultaten die in dit proefschrift
beschreven zijn, samen met een bespreking van een aantal methodologische
ovcrwegingen.
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Fatty acid daU of Chapter 5: Appendix B1-B2 . • -—•
Fatty acid data o f Chapter 6: Appendix C1-C4.
Fatty acid data of Chapter 7: Appendix D1-D6.
if Ï
Fatty acids present less than 0.195- of total fatty acids arc not reported.
ZSAFA: sum of all saturated fatty acids
ZMUFA: sum of all mono-unsaturated fatty acids
Z(n-7)+I(n-9): sum of all fatty acids of the (n-7) and (n-9) family
X(n-6): sum of all fatty acids of the (n-6) family
Z(n-3): sum of all fatty acids of the (n-3) family
dma: dimethyl acetal (tentative identification)
nd: not detectable
Appendix B1. The absolute fatty acid composition (mg/L) of phospholipids from maternal venous plasma during pregnancy
(gestational age in weeks), from maternal (M) and umbilical (U) venous plasma at delivery, and from maternal venous plasma
six months after delivery (> 0.5 yr). Results are given as mean ± s.e.m. (n=l 10, after correction for missing values).
Fatty acid
14:0
15:0
16:0
IH:0
20:0
22:0
23:0
24:0
ISAFA
l6:l(n-7)
18:l(n-7)
IS l<n-9)
2W fin-*)
24:l(n-9)
IMUKA
IhOdma
IK:0dma
IX 1 ilnm
10
3.56 ±0.21
2.39 ±0.16
326.7 ± 7.53
147.9 ±2.86
6.37 ±0.17
18.8 ±0.51
6.39 ± 0.20
11.3 ±0.36
523.6 ±10.7
2.74 ±0.41
27.3 ±0.75
97.2 ± 3.85
1 99 ±0.08
16 4 ±0 62
146.1 ±4.82
8.16 ±0.25
6.36 ± 0.22
2 07 ± 0.08
14
3.98 ±0.17
2.84 ±0.14
371.9 ±6.62
154.7 ±2.49
6.79 ±0.15
20.3 ± 0.47
7.25 ±0.18
12.4 ±0.33
580.0 ± 9.44
3.18 ±0.33
30.4 ±0.61
107.5 * 3.02
2.36 ± 0.06
18.2 ±0.56
162.3 ± 3.80
8.39 ±0.22
6.25 ±0.19
2.15 ±0.07
18
4.59 ±0.17
3.19 ± 0.14
410.8 ±6.58
160.3 ±2.48
7.35 ±0.15
21.8 ±0.47
8.03 ±0.18
13.3 ±0.32
629.4 ± 9.39
3.74 ± 0.32
31.9 ±0.61
118.1 ±2.99
2.56 ± 0.06
20 5 ± 0.56
177.6 ±3.77
8.46 ±0.22
6.32 ±0.19
2.22 ± 0.07
22
5.33±O.I7
3.19 ±0.14
446.1 ±6.61
164.3 ±2.49
7.84 ±0.15
23.5 ± 0.47
8.80 ±0.18
14.3 ±0.32
673.4 ± 9.42
4.76 ±0.33
32.8 ±0.61
130.3 ±3.03
2.64 ± 0.06
21.7 ±0.56
192.9 ±3.81
8.39 ±0.22
6.54 ±0.19
2.21 ±0.07
26
5.83 ±0.17
3.34 ±0.14
476.5 ± 6.60
168.9 ±2.49
8.33 ±0.15
25.0 ± 0.47
9.33 ±0.18
15.2 ±0.32
712.5 ±9.41
5.46 ± 0.33
34.4 ±0.61
138.1 ±3.02
2.73 ± 0.06
23.1 ±0.56
204.6 ± 3.79
8.38 ±0.22
6.48 ±0.19
2.16 ±0.07
30
5.77 ±0.17
3.40 ±0.14
500.4 ± 6.56
172.7 ±2.47
8.74 ±0.15
25.8 ± 0.46
9.55 ±0.18
15.4 ±0.32
741.9 ±9.35
5.88 ±0.32
34.4 ± 0.60
145.6 ±2.96
2.67 ± 0.06
24.0 ± 0.56
213.4 ±3.73
8.IO±O.21
6.65 ±0.19
2.04 ± 0.07
32
5.55 ±0.17
3.45 ±0.14
505.5 ± 6.57
171.8 ±2.47
9.05 ±0.15
26.1 ±0.47
9.65 ±0.18
15.3 ±0.32
746.4 ± 9.37
5.77 ±0.32
34.0 ± 0.60
146.4 ± 2.98
2.65 ± 0.06
24.7 ± 0.56
214.4 ±3.75
7.99 ±0.21
6.71 ±0.19
2.03 ± 0.07
2O:3(n-9) 3.22 ±0 21 3.56 ±0.18 3.95 ±0.18 4.39±O.I8 4.73 ±0.18 4.96±0.18 5.10±0.18
I(n-7)+I(n-9) 149.7 ±4.95 166.4 ±3.91 182.0 ±3.88 197.8 ± 3.92 209.8 ± 3.90 218.9 ±3.84 220.0 ±3.86
l8:2(n-6)
2O:2(n-6)
20:3(n-6)
20:4(n-6)
22:4(n-6)
22:5(n-6)
24:2(n-6)
I (n-6)
274.2 ± 6.66
5.50 ±0.18
36.3 ±1.35
119.4 ± 2.91
4.84 ±0.16
4.06 ±0.26
2.39 ±0.11
446.3 ± 8.85
301.5 ±5.78
6.65 ±0.15
41.6 * 1.17
127.2 ±2.68
5.28 ±0.14
5.14 ±0.23
2.68 ± 0.09
490.7 ± 7.84
322.4 ± 5.75
7.57 ±0.15
45.9 ±1.16
131.8 ±2.67
5.65 ±0.14
6.17 ±0.23
2.93 ± 0.09
523.1 ±7.80
338.3 ±5.77
8.30 ±0.15
50.8 ±1.17
133.3 ±2.68
6.11 ±0.14
6.90 ± 0.23
3.17 ±0.09
547.5 ± 7.82
357.7 ± 5.77
8.67 ±0.15
54.3 ±1.17
137.0 ±2.67
6.25 ±0.14
7.50 ±0.23
3.38 ± 0.09
575.5 ±7.81
371.4 ±5.72
8.62 ±0.15
56.5 ±1.16
138.5 ±2.66
6.29 ±0 14
7.76 ± 0.23
3.52 ± 0.09
593.3 ± 7.77
373.8 ± 5.74
8.39 ±0.15
56.0 ±1.16
138.5 ±2.67
6.19 ±0.14
7.81 ±0.23
3.59 ± 0.09
595.1 ±7.78
Appendix B1 continued.
Fatty acid
14:0
15:0
16:0
18:0
20:0
22:0
23:0
24:0
ISAFA
16:l(n-7)
18:l(n-7)
18:l(n-9)
20:l(n-9)
24:l(n-9)
IMUFA
16:0 dma
18:0 dma
18:1 dma
34
5.53 ±0.17
3.32 ±0.14
516.0 ±6.59
173.9 ±2.48
9.08 ± 0 15
26.1 ±0.47
9 58 ±0.18
15.4 ±0.32
758.9 ± 9.40
6.38 ± 0.32
34.6 ±0.61
152.2 ±3.00
2.57 ± 0.06
25.2 ± 0.56
221.8 ±3.78
8.01 ±0.22
6.40 ±0.19
2.05 ± 0.07
36
5.89*0.17
3.33 ±0.14
535.0 ± 6.59
179.5 ±2.48
9.23 ±0.15
26.4 ± 0.47
9.62 ±0.18
15.6 ±0.32
784.5 ± 9.40
7.66 ±0.32
34.8 ±0.61
163.7 ± 3.00
2.63 ± 0.06
25.3 ± 0.56
235.0 ± 3.77
8.48 ± 0.22
6.68 ±0.19
2.12 ±0.07
38
6.06 ± 0 17
3.31 ±0.14
549.6 ± 6.73
185.4 ±2.54
9.40 ±0.16
26.5 ± 0.47
9.67 ±0.18
15.7 ±0.33
805.6 ± 9.60
7.49 ± 0.34
33.9 ±0.63
163.0 ±3.13
2.63 ± 0.06
26.1 ±0.57
234.0 ± 3.94
8.62 ± 0.22
6.80 ± 0.20
2.13 ±0.07
40
5 91 ±0.22
3 30*0.16
561.8 ±7.81
187.8 ±2.97
9.65 ±0.17
27.0 ± 0.53
9 92 ± 0.20
16.1 ±0.37
821.6*11.1
7.73 ± 0.43
34.8 ±0 78
167.4 ±4.06
2.73 ± 0.08
26.9 ± 0.64
240.9 ± 5.09
8.57 ± 0.26
6.84 ± 0.23
2.08 ± 0.08
M
5 13*018
3.23 ±0.16
528.2 ± 8 00
165.7 ± 2.90
9 14*0 18
25.8 ± 0.57
9 48 ±0.21
15.3 ±0.36
761.4 ±11.4
7.40 ± 0.39
32.9 ±0.65
154.4 ±3.26
2.43 ± 0.06
25.6 ± 0.63
223.6 ±4.10
7.74 ± 0.20
5.58 ±0.18
1 82 ±0.06
U
1.34 ±0.08
0.55 ± 0.04
163.1*3.57
85.2 ±1.96
5.10*0.15
8.59 ± 0.25
1.20 ±0.05
8.24 ± 0.24
273.4 ± 5.95
3.15 ±0.19
15.7 ±0.47
44.2 ±2.38
0.30 ± 0.03
12.2 ±0.35
75.6 ±3.17
3.83 ±0.16
1.31 ±0.10
0.19 ±0.02
> 0.5 yr
387 ± 0 26
2.29*014
356.0 ± 10 6
162.2 ±4.09
6.62 ±0.22
21.6 ±0.80
7.30 ±0 29
14.6 ±0.54
575.1 * 14.5
3 4 5 * 0 4 2
28.3*0.73
105.2 * 3.75
2.03 ± 0.08
19.1 ±0 75
158.6 ±4.99
8.33*0.25
5.80*0.23
2.17*0.09
2O:3(n-9) 5.43*0.18 5.96±0.18 6 I2±O. I8 6.I9±O.22 6.07±0.24 3.93*0.20 4.92*0.28
I(n-7)+I(n-9) 227.7 ± 3.89 241.5 ±3.88 240.6 ±4.05 247.6 ±5.22 230.0 ±4.24 79.8*3.26 163.7*5.21
18:2(n-6)
20:2(n-6)
20:3(n-6)
20:4(n-6)
22:4(n-6)
22:5(n-6)
24:2(n-6)
I (n-6)
377.1*5.76
8.22 ±0.15
56.7 ±1.17
138.0*2.67
6.26 ±0.14
8.15 ±0.23
3.63 ± 0.09
598.9 ± 7.80
390.7 ± 5.76
8.25 ±0.15
58.6 ±1.17
142.3 ± 2.67
6.50*0.14
8.72 ± 0.23
3.58 ± 0.09
619.5*7.80
400.8 ± 5.90
8.28 ±0.15
596 ±1 20
144.9 ±2.71
6.52*0.14
8.90 * 0.24
3.68*0.10
633.5 * 7.98
407.9*6.91
8.54*0.18
61 8*1.41
147.4*2.97
6.65*0.17
9.17*0.27
3.82*0.11
644.6*9.14
358.6 * 6.69
7.58*0.17
57.9*1.39
141.1 ±3.13
6.09*0.15
8.72*0.31
3.60*0.10
584.8 * 9.67
45.3 ±1.49
2.22 * 0.07
29.5 * 0.83
95.7*2.21
4.56*0.13
5.09*0.18
3.67*0.14
186.7*4.33
302.3*6.35
5.32 * 0.25
39.0*2 01
121.8*3.74
4.27*0.14
3.43*0.17
1.87*0.09
476 9*10.6
Appendix Bl continued
Fatty acid
18:3(n-3)
20:4(n-3)
2O:5(n-3)
22:5(n-3)
22:6(n-3)
&n-3)
10
3.31 ±0.21
1.75 ±0.14
6.31 ±0.59
9.31 ±0.29
47.1 ± 1.69
68.4 ± 2.35
14
3.82 ±0.17
1.99 ±0.11
6.84 ± 0.48
9.28 ± 0.24
55.8 ±1.48
78.4 ± 2.00
18
4.20 ±0.17
2.27 ±0.11
6.80 ± 0.47
9.42 ± 0.24
61.3 ±1.47
84.5 ±1.99
22
4.63 ±0.17
2.59 ±0.11
6.92 ±0.48
9.83 ±0.24
63.8 ± 1.48
88.3 ± 2.00
26
4.78 ±0.17
2.62 ±0.11
7.20 ± 0.48
9.99 ± 0.24
66.8 ± 1.48
91.9 ±2.00
30
4.98 ±0.17
2.64 ±0.10
6.69 ± 0.47
9.92 ± 0.24
69.1 ± 1.47
93.7 ± 1.98
32
4.89 ±0.17
2.59 ±0.11
6.28 ± 0.47
9.58 ± 0.24
67.9 ± 1.47
91.7 ±1.99
.ft * *':
\ppendix B1 continued
34 36 38 40 M U >0.5yr
5.17*0.17
2.85 ±0.11
6.44 * 0.47
9.45 * 0.24
67.8*1.48
92 1*199
5.26 ±0.17
2.78 ±0.11
6.13 ±047
9.63 ± 0.24
68.2*1.47
92.4 ±1.99
5.26 ±0.18
2.91 ±0 11
6.72 ± 0.50
9 74 ± 0.25
69.8± 1.51
94.8 ± 2.05
5.13 ±0.22
2 89 ±0.14
6.44 ± 0.62
9.96 ± 0 30
71.7 ±1.75
96 1 ±2.45
4.60 ±0.20
2.65 ±0.11
5.95 ± 0.34
9.11 ±0.26
65.0*1.50
87.7 * 2.00
0.61 ±0.03
0.65 * 0.04
1.31 ±0.06
2.71 ±0.12
36 1*1.21
41.4*1.35
4.10*0.18
2.07 ±0 15
8.10 ±0.70
9.19*0.34
38.6 ± 1.61
62.3 ± 2.35
vlfi * «
; • ' • » ' '
< . l . E »
Appendix B2. The relative fatly acid composition (% of total fatty acids) of phospholipids from maternal venous plasma during
pregnancy (gestational age in weeks), from maternal (M) and umbilical (U) venous plasma at delivery, and from maternal
venous plasma six months after delivery (> 0.5 yr). Results are given as mean ± s.e.m. (n=l 10, after correction for missing
values).
Fatly acid
14:0
15:0
16:0
18:0
20:0
22:0
23:0
24:0
ISAFA
16:l(n-7)
!8:l(n-7)
!8:l(n-9)
20:l(n-9)
24:l(n-9)
IMUFA
16:0 dm*
18:0 dmu
18:1 dma
10
0.28 ±0.01
0.19 ±0.01
26.3 ±0.14
11.9 ±0.09
0.52 ±0.01
1.52 ±0.03
0.51 ±0.01
0.91 ±0.02
42.2 ±0.13
0.22 ± 0.02
2.21 ±0.04
7.91*0 16
0.16 ±0.00
1.33 ±0.04
II 9 ±0.19
0.66 ±0.01
0.30 ±0.01
0 16 ±0.00
14
0.29 ± 0.01
0.21 ±0.01
27.0 ±0.12
11.3 ±0.07
0.49 ±0.01
1.49 ±0.03
0.53 ±0.01
0.91 ±0.02
42.2 ±0.11
0.23 ± 0.02
2.22 ± 0.03
7.R6J-D.U
0.17 ±0.00
1.33 ±0.03
11.9±0.15
0.61 ±0.01
0.46 ± 0.01
0.16 ±0.00
18
0.31 ±0.01
0.21 ±0.01
27.7 ±0.12
10.9 ±0.07
0.50 ±0.01
1.48 ±0.03
0.54 ±0.01
0.90 ± 0.02
42.6 ±0.11
0.25 ± 0.02
2.17 ±0.03
Ji.flP.ifi!.'J»
0.17 ±0.00
1.38 ±0.03
12.0*0.15
0.57 ± 0.01
0.43 ±0.01
0.15 ±0.00
22
0.34 ± 0.01
0.20 ± 0.01
28.4 ±0.12
10.5 ±0.07
0.50 ± 0.01
1.51 ±0.03
0.56 ± 0.01
0.91 ±0.02
43.0 ±0.11
0.30 ± 0.02
2.11 ±0.03
0.17 ±0.00
1.39 ±0.03
12.3±0.15
0.54 ±0.01
0.42 ±0.01
0.14 ±0.00
26
0.35 ±0.01
0.20 ±0.01
28.9 ±0.12
10.2 ± 0.07
0.51 ±0.01
1.53 ±0.03
0.57 ±0.01
0.93 ± 0.02
43.2 ±0.11
0.32 ±0.02
2.10 ±0.03
O.I7±0.00
1.40 ±0.03
12.4 ±0.15
0.51 ±0.01
0.40 ±0.01
0.13 ±0.00
30
0.34 ±0.01
0.20 ±0.01
29.3 ±0.12
10.1 ±0.07
0.51 ±0.01
1.52 ±0.03
0.56 ±0.01
0.91 ±0.02
43.5 ±0.11
0.34 ± 0.02
2.03 ± 0.03
<P./i'± tfiT"
0.16 ±0.00
1.41 ±0.03
12.5 * 0.15
0.48 ±0.01
0.39 ±0.01
0.12 ±0.00
32
0.32 ±0.01
0.20 ±0.01
29.5 ±0.12
10.0 ±0.07
0.53 ± 0.01
1.53 ±0.03
0.56 ±0.01
0.90 ± 0.02
43.6 ±0.11
0.33 ±0.02
1.99 ±0.03
if.*»- ±tf.r.r
0.15 ±0.00
1.45 ±0.03
12.5 ±0.15
0.47 ± 0.01
0.39 ± 0.01
0.12 ±0.00
2O:3(n-9) 0.26 ±0.01 0.26 ±0.01 0.27 ±0.01 0.28 ±0.01 0.29 ±0.01 0.29 ±0.01 0.30 ±0.01
I(n-7)+I(n-9) 12.1*0.19 12.2 ±0.16 12.3*0.16 12.6*0.16 12.7 ±0.16 12.8*0.16 12.9*0.16
l8:2(n-6)
20:2(n-6)
2O:3(n-6)
20:4(n-6)
22:4(n-6)
22:3(n-6)
24:2(n-6)
I(n-6)
22.1*0.29
0.44 ± 0.01
2.91*0.06
9.63*0.13
0.39*0.01
0.33*0.01
0.19*0.01
36.0*0.24
22.0 * 0.25
0.48 * 0.01
3.01 ±0.05
9.26*0.12
0.38 * 0.01
0.37*0.01
0 19*0.01
35.7 * 0.20
21.9*0.25
0.51 ±001
3.09 * 0.05
8.89*0.11
0.38*0.01
0.42*0.01
0.20 * 0.01
35.4 * 0.20
21.7*0.25
0.53*0.01
3.22 * 0.05
8.51 ±0.11
0.39*0.01
0.44*0.01
0.20*0.01
35.0*0.20
21.7*0.25
0.53*0.01
3.28 * 0.05
8.29*0.11
0.38 * 0.01
0.46*0.01
0.21*0.01
34.9 * 0.20
21.8*0.25
0.51 ±0.01
3.30 * 0.05
8.10*0.11
0.37 * 0.01
0.46*0.01
0.21 ±0.01
34.8 * 0.20
21.9 ±0.25
0.49 ±0.01
3.27 ± 0.05
8.08 ±0.11
0.36 ±0.01
0.46 ±0.01
0.21 ±0.01
34.8 ±0.20
Appendix B2. The relative fatty acid composition (% of total fatty acids) of phospholipids from maternal venous plasma during
pregnancy (gestational age in weeks), from maternal (M) and umbilical (If) venous plasma at delivery, and from maternal
venous plasma six months after delivery (> 0.5 yr). Results are given as mean ± s.e.m. (n=l 10, after correction for missing
values).
Fatly acid
14:0
15:0
16:0
18:0
20:0
22:0
23:0
24:0
ISAFA
!6:l(n-7)
IK:l(n-7)
l8:l(n-9)
20:l(n-9)
24:l(n-9)
IMUFA
16:0 dma
18:0 dma
18:1 dma
20:3(n-9)
Z(n-7Hl(n-9)
l8:2(n-6)
2O:2(n-6)
2O:3(n-6)
20:4(n-6)
23:4(n-6)
22:S(n-6)
24:2(n-6)
I(n-6)
10
0.28 ±0.01
0.19*0.01
26.3*0.14
11.9*0.09
0.52*0.01
1.52*0.03
0.51 ±0.01
0.91*0.02
42.2 ±0.13
0.22 ± 0.02
2.21 ±0 04
7.91 ±0 16
0.16*0.00
1.33 ±0.04
119*019
0.66 ±0.01
0.50*0.01
0.16 ±0.00
0.26 ±0.01
12.1 ±0.19
22.1*0.29
0.44 ±0.01
2.91 ±0.06
9.63 ±0.13
0.39 ±0.01
0.33 ±0.01
0.19 ±0.01
36.0 ±0.24
14
0.29*0.01
0.21*0.01
27.0*0.12
11.3*0.07
0.49 * 0.01
1.49*0.03
0.53*0.01
0.91 ±0.02
42.2 ±0.11
0.23 * 0.02
2.22 * 0.03
7.R6.*.0.U
0.17*0.00
1.33*0.03
11 9*0.15
0.61 ±0 01
0.46*0.01
0.16*0.00
0.26*0.01
12.2*0.16
22.0*0.25
0.48 * 0.01
3.01 *0.05
9.26*0.12
0.38*0.01
0.37 ±0.01
0 19*0.01
35.7 * 0.20
18
0.31 ±0.01
0.21*0.01
27.7*0.12
10.9*0.07
0.50*0.01
1.48*0.03
0.54*0.01
0.90 * 0.02
42.6*0.11
0.25 * 0.02
2.17*0.03
0.17*0.00
1.38 ±0.03
12.0*0.15
0.57*0.01
0.43*0.01
0.15*0.00
0.27*0.01
12.3*0.16
21.9*0.25
0.51 ±001
3 09 * 0.05
8.89*0.11
0.38 ±0.01
0.42 ± 0.01
0.20 ± 0.01
35.4 ± 0.20
22
0.34 * 0.01
0.20 ± 0.01
28.4*0.12
10.5*0.07
0.50*0.01
1.51*0.03
0.56*0.01
0.91 ±0.02
43.0*0.11
0.30 * 0.02
2.11 *0.03
0.17*0.00
1.39*0.03
12.3*0.15
0.54*0.01
0.42*0.01
0.14 ±0.00
0.28 ±0.01
12.6*0.16
21.7*0.25
0.53 * 0.01
3.22 * 0.05
8.51*0.11
0 39 * 0.01
0.44*0.01
0.20 ±0.01
35.0 ±0.20
26
0.35*0.01
0.20*0.01
28.9*0.12
10.2*0.07
0.51*0.01
1.53*0.03
0.57*0.01
0.93 * 0.02
43.2*0.11
0.32 * 0.02
2.10*0.03
*.?i*d!i'.?
0.17*0.00
1.40*0.03
12.4*0.15
0.51*0.01
0.40*0.01
0.13*0.00
0.29 * 0.01
12.7*0.16
21.7*0.25
0.53 * 0.01
3.28 * 0.05
8.29*0.11
0.38 * 0.01
0.46 ± 0.01
0.21 ±0.01
34.9 ±0.20
30
0.34*0.01
0.20*0.01
29.3*0.12
10.1*0.07
0.51 tO.01
1.52*0.03
0.56*0.01
0.91 ±0.02
43.5*0.11
0.34*0.02
2.03 * 0.03
(P./rivf.iV
0.16*0.00
1.41 ±003
12.5*0.15
0.48*0.01
0.39*0.01
0.12*0.00
0.29*0.01
12.8*0.16
21.8*0.25
0.51 ±0.01
3.30 ± 0.05
8 10*0 11
0.37 ± 0.01
0.46 ± 0.01
0.21 ±0.01
34.8 ±0.20
32
0.32*0.01
0.20*0.01
29.5*0.12
10.0*0.07
0.53*0.01
1.53*0.03
0.56*0.01
0.90 * 0.02
43.6 ±0.11
0.33 * 0.02
1.99*0.03
<r.iv*«j:ri"
0.15*0.00
1.45 ±0.03
12.5*0.15
0.47 ± 0.01
0.39 ±0.01
0.12*0.00
0.30*0.01
12.9*0.16
21.9*0.25
0.49*0.01
3.27 * 0.05
8.08*0.11
0.36*0.01
0.46*0.01
0.21*0.01
34.8 * 0.20
Append)* B2 continued.
Fatty acid
14:0
15:0
16:0
18:0
20:0
22:0
23.0
24:0
ISAFA
I6:l(n-7)
l8:l(n-7)
18:l(n-9)
20:l(n-9)
24:l(n-9)
IMUFA
16:0 dma
18:0 dma
18:1 dma
34
0.32 * 0.01
0.19 ±0.01
29.7 ±0.12
10.0 ±0.07
0.53 ± 0.01
1.51 ±0.03
0.55 ± 0.01
0.89 ± 0.02
43.7 ±0.11
0.36 ± 0.02
2.00 ± 0.03
8.75 ±0.13
0.15 ±0.00
1.45 ±0.03
12 8 ± 0 15
0.46 ±0.01
0.37*0.01
0.12 ±0.00
36
0.32 ±0.01
0.18 ±0.01
29.8 ±0.12
10.0 ±0.07
0.52 ±0.01
1.48 ±0.03
0.54 ±0.01
0 87 ± 0.02
43.7 ±0.11
0.42 ± 0.02
1.94 ±0.03
9.05 ±0.13
0.15 ±0.00
1.41 ±0.03
13.0 ±0.15
0.47 ±0.01
0.38 ±0.01
0.12 ±0.00
38
0.33 ±0.01
0.18 ±0.01
29.9*0.12
10.1 ±0.07
0.51 ±001
1.45*0.03
0 53*0.01
0.86 * 0.02
43.9*0.12
0.41 ±0.02
1.86*0.03
8.91 ±0.13
0.15 ±0.00
1.43*0.03
12 8 ± 0 16
0.47 ±0.01
0.37 ±0.01
0.12 ±0.00
40
0.32 * 0.01
0.17*0.01
30.0*0.14
10.0 * 0.09
0.52*001
1.45*0.03
0.53 ± 0.01
0.87 * 0.02
43.9*0.14
0.41*0.02
188*004
9.02*0.17
0.15*0.00
1.45*0.04
13.0*0.20
0.46*0.01
0.37 * 0.01
Oil ±001
M
0.30*0.01
0.19*0.01
30.7*0.13
9.65 * 0.08
0 53 * 0 01
1.50*0.03
0.55*0.01
0.90 * 0.02
44.4*0.11
0.43 ± 0.02
1.92 ±0.03
8.98 ±0.13
0.14*0.00
1 50*0.03
13.0*0.15
0.45 ± 0.01
0.33 ±0.01
Oil ±0.00
u
0.22*0.01
0.09 ±0.01
27.6 ±0.15
14.4*0.12
0.86 * 0.02
1.44*0.03
0.20*0.01
1.39*0.03
46.2*0.21
0.52 * 0.02
2.63 * 0.05
7.26 * 0.24
0.05 * 0.00
2.06 * 0.04
12.6*0.29
0.64 ± 0.02
0.22*0.01
0.03 * 0.00
> O.Syr
0.28*0.01
0.16 ±0.01-;
26.6*0.2?
12.3*0 18
049*001
163*0.03
0.53 * 0.02
1 11*0.04
43 1*0 16
0 25*0.02
2 14*005
7.90*0.15
0.16*0.01
1.45*0.05
11.9*0.19
0.63 * 0.01
0.44 * 0.02
0.16*0.01
20:3(n-9) 0.31*0.01 0.33*0.01 0.33 ±0.01 0.33*0.01 0.35*0.01 0.67*0.03 0.37*0.02
I(n-7)+I(n-9) 13.1*0.16 13.4*0.16 13.2*0.16 13.3*0.20 13.4*0.15 13.3*0.30 12.3*0.20
18:2(n-6)
20:2(n-6)
20:3(n-6)
20:4(n-6)
22:4{n-6)
22:5(n-6)
24:2(n-6)
I(n-6)
21.8*0.25
0.47 ±0.01
3.26 ± 0.05
7.95 ±0.11
0.36 ±0.01
0.47 ±0.01
0.21 ±0.01
34.5 * 0.20
21.8*0.25
0.46*0.01
3.26 * 0.05
7.93*0.11
0.36 ± 0.01
0.49 * 0.01
0.20*0.01
34.5 * 0.20
21.9*0.26
0.45 * 0.01
3.23 * 0.05
7.88*0.12
0.36*0.01
0.48*0.01
0.20*0.01
34.6*0.21
21.8*0.30
0.46 * 0.01
3.30 ± 0.06
7.84*0.13
0.35 * 0.01
0.49*0.01
0.21*0.01
34.5 * 0.25
20.9 * 0.23
0.44*0.01
3.35 * 0.06
8.18*0.13
0.35*0.01
0.51*0.02
0.21*0.01
34.0*0.19
7.53 ±0.12
0.37*0.01
5.01*0.09
16.2*0.14
0.77 * 0.01
0.86 * 0.02
0.62 * 0.02
31.5*0.18
22.8 * 0.32
0.40 * 0 01
2.84*0.09
9.07*0.17
0.32 * 0.01
0.26 * 0.01
0.14*0.01
36.0 * 0.25
Appendix B2 continued
Fatty acid
18:3(n-3)
2O:4(n-3)
2O:5(n-3)
22:5(n-3)
22:6(n-3)
Kn-3)
10
0.27 ± 0.01
0.14 ±0.01
0.50 ± 0.04
0.75 ± 0.01
3.79 ± 0.09
5.50 ±0.12
14
0.28 ±0.01
0.14 ±0.01
0.51 ±0.03
0.68 ± 0.01
4.07 ± 0.08
5.72 ±0.10
18
0.29 ±0.01
0.15 ±0.01
0.46 ± 0.03
0.64 ±0.01
4.16 ±0.08
5.73 ±0.10
*" •• 1 ' ' - . ; •'"•' '
, - , ' 1/ -
22
0.30 ±0.01
0.16 ±0.01
0.44 ± 0.03
0.63 ±0.01
4.09 ± 0.08
5.65 ±0.10
. • M . ) - " • . :
26
0.29 ±0.01
0.16 ±0.01
0.44 ± 0.03
0.61 ±0.01
4.06 ± 0.08
5.59 ±0.10
; ' • ' . > • . * • . - " ; •
30
0.29 ±0.01
0.15 ±0.01
0.39 ± 0.03
0.58 ±0.01
4.05 ± 0.08
5.49 ±0.10
32
0.29 ±0.01
0.15 ±0.01
0.36 ± 0.03
0.56 ±0.01
3.97 ± 0.08
5.35 ±0.10
Appendix B2 continued
Fatty acid
18:3(n-3)
20:4(o-3)
2O.5 (D-3 )
22:5(n-3)
22:6(n-3)
Kn-3)
34
0.30*0.01
0.16*0.0)
0.37*0.03
0.54 * 001
3.90*0.08
5.30*0.10
36
0.29*0.01
0.15 ±001
0.34 ± 0.03
0.54 ±0.01
3.80 ±0.08
5.14*0.10
38
0.29 ±0.01
0 16 ±0.01
0.37 ± 0 03
0.53*0.01
3.80 ± 0.08
5 16*011
40
0.28*0.01
0 15*001
0.35 ± 0.04
0.53 ± 0.02
3.84 * 0.09
5.16*0.12
M
0.27*0.01
0.15*0.01
0.35 * 0.02
0.53*0.01
3.79 * 0.07
5.10*0.10
U
0.11*0.01
Oil ±001
0.23 ± 0.01
0.46 * 0.02
6.10*0.14
6.99*0.16
> O.Syr
0.30 ±0.01
0.15 ±0.01
0 57 * 0.05
0.68 * 0.02
2.84 * 0.08
4.50*0.10
<Hf v «'X <Vi- :
!&*!
Appendix Cl. The fatty acid composition of maternal plasma phospholipids (mg/L) in normal
pregnancy (NP) and pregnancy-induced hypertension (PIH) (mean ± s.e.m.).
Fatty acid
14:0 NP
PIH
15:0
16:0
18:0
20:0
22:0
23:0
24:0
ISAFA
l8:l(n-9)
20:l(n-9)
24:l(n-9)
IMUFA
16:0 dma
18:0 dma
18:1 dma
< 16 weeks
(sets=49)
4.01 ±0.14
4.41 ±0.24
2.57 ± 0.08
2.81 ±0.13
362.2 ± 6.34
373.4 ± 10.1
155.8 ±2.28
158.8 ±3.89
6.73 ±0.19
6.96 ± 0.28
20.6 ± 0.36
21.3 ±0.70
7.32 ±0.16
7.97 ± 0.33
13.9 ±0.35
14.1 ±0.54
573.1 ±9.08
589.7 ± 14.5
3.21 ±0.19
3.34 ± 0.20
29.8 ± 0.55
29.8 ± 0.97
104.7 ±2.10
106.8 ± 3.58
2.20 ± 0.06
2.34 ±0.12
21.3 ±0.64
22.4 ± 0.90
161.9 ±2.91
165.5 ±4.97
9.02 ± 0.23
8.96 ± 0.29
6.30 ± 0.20
6.07 ± 0.30
2.43 ± 0.08
2.42 ±0.12
± 22 weeks
(sets=47)
5.94 ±0.18
6.34 ±0.41
3.34 ± 0.09
3.53 ±0.19
472.4 ± 7.44
497.4 ±15.2
170.0 ±2.35
183.3 ±4.96
8.12 ±0.16
8.12 ±0.27
24.8 ± 0.43
25.2 ± 0.80
9.26 ±0.19
9.70 ± 0.43
16.4 ±0.38
16.5 ± 0.77
710.3 ± 10.3
750.0 ±21.3
5.66 ± 0.35
6.16 ±0.64
35.6 ±0.84
36.7 ± 1.22
138.9 ±3.02
144.0 ±6.67
2.68 ± 0.07
2.84 ±0.11
25.2 ±0.75
26.7 ± 1.12
208.8 ±4.17
217.3 ±8.73
9.09 ± 0.23
9.51 ±0.34
6.05 ±0.19
6.57 ± 0.28
2.51 ±0.08
2.46 ±0.12
± 32 weeks
(sets=47)
5.96 ±0.15
6.44 ± 0.36
3.28 ± 0.07
3.41 ±0.17
524.4 ± 6.55
561.7 ±14.0
175.6 ±2.13
190.4 ± 4.54
9.15 ±0.21
9.11 ±0.31
26.8 ± 0.49
26.7 ± 0.83
9.82 ± 0.20
10.2 ±0.37
17.1 ±0.37
16.7 ± 0.63
772.1 ±9.14
824.7 ± 18.9
6.44 ±0.31
8.23 ±0.91
36.2 ± 0.72
37.4 ±1.10
150.9 ± 2.52
163.0 ± 6.53
2.66 ± 0.07
2.72 ± 0.08
27.5 ± 0.86
28.3 ±1.04
224.6 ± 3.34
240.7 ± 8.48
8.62 ±0.19
9.45 ± 0.30
5.85 ±0.18
6.07 ± 0.29
2.26 ± 0.06
2.28 ±0.11
After delivery
(sets=45)
5.45 ±0.18 ..,-.
5.07 ± 0.36
3.11 ±0.08
2.89 ±0.17
564.5 ± 9.07
567.0 ± 20.5
173.9 ±3.04
174.3 ±6.32
9.37 ±0.21
8.71 ±0.32
27.2 ± 0.58
23.9 ± 0.99
10.1 ±0.22
9.03 ± 0.42
17.0 ±0.39
14.5 ±0.67
810.6 ± 12.6
805.4 ± 27.9
8.63 ± 0.44
9.84 ± 0.93
35.2 ± 0.78
35.6 ±1.47
161.7 ±3.44
163.8 ±8.10
2.62 ±0.12
2.43 ± 0.09
28.5 ±0.81
29.2 ±1.23
237.8 ± 4.47
242.2 ± 10.7
8.55 ± 0.22
8.20 ± 0.28
5.05 ±0.18
4.36 ± 0.24
2.05 ± 0.07
1.76 ±0.11
Appendix Cl continued
Fatty acid
20:3(n-9)
Kn-7)+ï(n-9)
18:2(n-6)
20:2(11-6)
20:3(n-6)
20:4(n-6)
22:4{n-6)
22:5(n-6)
24:2(n-6)
I(n-6)
18:3(n-3)
20:4(n-3)
2O:5(n-3)
22:5(n-3)
22:6(n-3)
KD-3)
< 16 weeks
(sets=49)
3.69 ±0.13
3.82 ±0.19
166.2 ± 3.00
169.8 ± 5.08
283.2 ±5.38
291.0 ± 10.0
6.31 ±0.16
6.67 ± 0.32
41.0± 111
43.3 ± 1.58
129.1 ±2.51
129.4 ±3.73
5.55 ±0.15
5.17 ±0.19
5.00 ±0.19
4.75 ± 0.24
2.41 ±0.10
2.51 ±0.13
473.3 ±7.61
483.5 ±13.4
3.32 ±0.12
3.51 ±0.22
1.89 ±0.09
2.00 ±0.11
7.32 ± 0.45
7.97 ± 0.59
10.4 ±0.23
10.2 ±0.36
57.0 ± 1.51
60.2 ± 2.04
80.4 ± 1.94
84.6 ±2.53
± 22 weeks
(sets=47)
4.94 ± 0.20
5.08 ± 0.35
214.3 ±4.28
222.9 ± 9.00
345.0 ±5.40
364.7 ± 12.0
8.76 ± 0.20
9.21 ±0.36
54.7 ± 1.40
62.2 ± 2.89
142.3 ±2.64
150.9 ±4.99
6.75 ±0.16
7.21 ±0.33
7.82 ±0.21
7.89 ± 0.43
2.73 ±0.12
3.15 ±0.19
568.9 ± 7.74
606.1 ± 16.1
4.82 ±0.14
5.10 ±0.34
2.61 ±0.12
2.94 ± 0.25
7.25 ± 0.45
8.16 ±0.69
10.9 ±0.33
11.7 ± 0.63
69.8 ± 1.70
73.3 ± 2.70
96.0 ±2.41
101.9 ±4.04
± 32 weeks
(sels=47)
5.69 ± 0.20
6.46 ± 0.44
230.8 ± 3.42
247.7 ± 8.84
375.8 ±4.81
396.1 ±9.56
8.58 ±0.16
9.31 ±0.31
58.8 ± 1.32
67.3 ± 2.98
144.0 ±2.41
153 8 ±5.54
6.80 ±0.14
7.59 ±0.32
8.86 ± 0.26
9.72 ± 0.58
3.15 ±0.16
3.38 ±0.16
606.9 ± 6.65
648.2 ± 13.9
5.09 ±0.18
5.37 ±0.30
2.60 ±0.11
3.02 ± 0.22
6.57 ±0.33
6.86 ± 0.59
10.4 ± 0.26
11.1 ± 0.48
73.1 ±1.62
78.3 ± 2.56
98.3 ±2.17
105.3 ± 3.47
After delivery
(sets»45)
6.61 ±0.27
7.35 ± 0.62
244.8 ±4.64
250.0 ± 11.2
372.7 ±7.62 '
343.8 ± 12.1
8.13 ±0.19
7.90 ±0.41
63.0 ± 1.59
69.1 ± 4.03
152.9 ±3.00
158.0 ±6.40
7.10±0.19
7.51 ±0.42
9.97 ± 0.33
11.0 ±0.74
3.29 ±0.15
3.60 ±0.19
618.0 ± 10.4
602.0 ± 20.8
4.84 ±0.16
3.89 ± 0.30
2.67 ±0.12
2.63 ± 0.25
6.96 ± 0.69
5.87 ± 0.44
10.6 ± 0.30
10.8 ± 0.69
73.2 ± 1.70
78.3 ± 2.74
98.7 ± 2.50
101.9 ±3.83
Appendix C2. The fatty acid composition of maternal plasma phospholipids (% of total fatty acids) in
normal pregnancy (NP) and pregnancy-induced hypertension (PIH) (mean ± s.e.m.).
Fatty acid
14:0 NP
PIH
15:0
16:0
18:0
20:0
22:0
23:0
24:0
ISAFA
l6:l(n-7)
l8:l(n-7)
l8:l(n-9)
20:l(n-9)
24:l(n-9)
IMUFA
16:0 dma
l8:0dma
18:1 dma
< 16 weeks
(sets=49)
0.29 ±0.01
0.31 ±0.01
0.19 ±0.00
0.20 ±0.01
26.8 ±0.13
26.9 ± 0.20
11.6 ± 0.09
11.5 ± 0.15
0.50 ±0.01
0.50 ± 0.02
1.54 ± 0.02
1.55 ±0.04
0.54 ±0.01
0.58 ± 0.02
1.03 ± 0.02
1.03 ±0.03
42.5 ±0.12
42.7 ±0.17
0.23 ±0.01
0.24 ±0.01
2.23 ± 0.03
2.16 ±0.05
7.77 ±0.10
7.68 ±0.13
0.16 ±0.00
0.17 ±0.01
1.58 ±0.04
1.63 ± 0.05
12.0 ±0.11
11.9 ±0.16
0.67 ± 0.02
0.65 ± 0.02
0.47 ±0.01
0.44 ± 0.02
0.18 ±0.01
0.18 ±0.01
± 22 weeks
(sets=47)
0.36 ±0.01
0.35 ±0.01
0.20 ± 0.00
0.20 ±0.01
28.6 ±0.12
28.5 ± 0.20
10.3 ± 0.07
10.6 ±0.11
0.50 ±0.01
0.47 ±0.01
1.51 ±0.02
1.46 ± 0.04
0.56 ±0.01
0.56 ± 0.02
0.99 ± 0.02
0.95 ± 0.04
43.0 ±0.12
43.0 ±0.17
0.33 ± 0.02
0.33 ± 0.03
2.16 ±0.04
2.11 ±0.05
8.39 ±0.11
8.13 ±0.18
0.16 ±0.00
0.17 ±0.01
1.53 ±0.04
1.54 ±0.06
12.6 ±0.13
12.3 ±0.21
0.55 ± 0.01
0.55 ±0.01
0.37 ±0.01
0.38 ± 0.02
0.15 ±0.01
0.14 ±0.01
± 32 weeks
(sets=47)
0.33 ±0.01
0.34 ±0.01
0.19 ±0.00
0.18 ±0.01
29.6 ±0.11
29.8 ±0.16
9.94 ± 0.07
10.1 ±0.12
0.52 ±0.01
0.49 ± 0.02
1.52 ±0.02
1.43 ±0.04
0.56 ±0.01
0.54 ± 0.02
0.97 ± 0.02
0.90 ± 0.04
43.7 ±0.11
43.7 ±0.12
0.36 ± 0.02
0.42 ± 0.04
2.05 ± 0.04
1.99 ± 0.04
8.53 ±0.10
8.55 ±0.18
0.15 ±0.00
0.15 ±0.00
1.56 ±0.04
1.52 ±0.06
12.7 ±0.11
12.7 ±0.22
0.49 ±0.01
0.50 ±0.01
0.33 ±0.01
0.32 ± 0.02
0.13 ±0.00
0.12 ±0.01
After delivery
(sets=45)
0.29 ±0.01
0.27 ±0.01
0.17 ±0.00
0.16 ±0.01
30.9 ±0.10
31.3 ±0 .16
9.51 ±0.09
9.65 ±0.13
0.52 ±0.01
0.49 ± 0.02
1.49 ±0.02
1.34 ±0.05
0.55 ±0.01
0.50 ± 0.02
0.93 ± 0.02
0.81 ±0.03
44.4 ± 0.09
44.5 ±0.14
0.47 ± 0.02
0.52 ± 0.04
1.93 ±0.03
1.97 ±0.04
8.83 ±0.11
8.93 ±0.21
0.14 ±0.01
0.14 ±0.00
1.58 ±0.04
1.65 ±0.07
13.0 ±0.13
13.3 ±0.25
0.47 ± 0.01
0.46 ±0.01
0.28 ±0.01
0.24 ±0.01
0.11 ± 0.00
0.10 ±0.01
Appendix C2 continued
Fatty acid
2O:3(n-9)
Kn-7Hl(n-9)
18:2(n-6)
20:2(n-6)
20.3(n-6)
20:4(n-6)
22:4(n-6)
22:5(n-6)
24:2(n-6)
Kn-6)
18:3(n-3)
20:4(n-3)
2O:5(n-3)
22:5(n-3)
22:6(n-3)
Kn-3)
< 16 weeks
(sets=49)
0.27 * 0.01
0.28*0.01
12.3*0.12
12.2*0.16
21.1 *0.29
21.0*0.36
0.46*0.01
0.48*0.01
3.02 * 0.06
3.12*0.08
9.58*0.11
9.39*0.17
0.41*0.01
0.37 * 0.01
0.37 * 0.01
0.34*0.01
0.18*0.01
0.18*0.01
35.1 ±0.20
34.9 * 0.25
0.25*0.01
0.25*0.01
0.14*0.01
0.14*0.01
0.55 * 0.03
0.59 * 0.49
0.77 * 0.02
0.74 * 0.02
4.21 * 0.08
4.36*0.12
5.95*0.11
6.14*0.14
* 22 weeks
(sets=47)
0.30*0.01
0.29 * 0.02
13.0*0.13
12.7*0.21
21.0*0.24
21.0*0.46
0.53*0.01
0.53 * 0.02
3.30*0.06
3.54*0.11
8.63*0.12
8.71*0.20
0.41 ±0.01
0.41 *0.0l
0.47*0.01
0.45 ± 0.02
0.17*0.01
0.18*0.01
34.5*0.18
34.9 * 0.30
0.29*0.01
0.29 * 0.02
0.16*0.01
0.16*0.01
0.43 * 0.02
0.46 ± 0.03
0.65*0.01
0.66 * 0.02
4.22 * 0.08
4.24*0.12
5.80*0.10
5.85*0.16
* 32 weeks
(sets=47)
0.32 * 0.01
0.34 * 0.02
13.1*0.12
13.0*0.23
21.3*0.20
21.2*0.42
0.49*0.01
0.49 * 0.01
3.31 *0.06
3.54*0.11
8.14*0.11
8.14*0.19
0.38*0.01
0.40*0.01
0.50*0.01
0.51 *0.02
0.18*0.01
0.18*0.01
34.4*0.15
34.5 * 0.29
0.29*0.01
0.28*0.01
0.15 ±0.01
0.16 ±0.01
0.37 ± 0.02
0.37 * 0.03
0.59*0.01
0.58 * 0.02
4.13* 0.07
4.18*0.11
5.55*0.10
5.59*0.14
After delivery
(sets-45)
0.36*0.01
0.39*0.03 >;
13.4*0.13
13.7*0.27
• 0 -rH
20.4 * 0.24
19.1 *0.35 <i
0.44*0.01
0.43*0.01 M
3.43 * 0.06
3.74*0.13
8.37 * 0.12
8.80*0.22
0.39*0.01
0.41 ±0 01
0.54 * 0.02
0.60 * 0.03
0.18*0.01
0.20*0.01
33.8*0.16
33.3*0.30
0.26*0.01
0.21 ±0.01
0.14*0.01
0.14*0.01
0.38 * 0.04
0.32 * 0.02
0.57*0.01
0.59 * 0.02
4.00 * 0.08
4.39*0.11
5.39*0.11
5.67*0.12
Appendix C3. The fatty acid composition (mg/L plasma or mg/g dry tissue) of phospholipids isolated
from umbilical cord in normal pregnancy (NP) and pregnancy-induced hypertension (PIH) (mean ±
s.e.m.).
Fatty acid
14:0 NP
PIH
15:0
16:0
17:0
18:0
20:0
22:0
23:0
24:0
ISAFA
l6:l(n-7)
18:l(n-7)
18:l(n-9)
20:l(n-9)
24:l(n-9)
IMUFA
16:0 dma
18:0 dma
Venous plasma
(sets = 44)
1.39 ±0.09 ••'''"
1.32 ±0.09
0.61 ±0.05 "
0.65 ± 0.06
165.7 ±3.13
164.5 ±5.05
nd
nd
84.8 ±1.53 •
85.0 ± 2.77
5.01 ±0.15
4.70 ±0.23
8.87 ± 0.22
8.08 ± 0.40
1.19 ±0.06
1.25 ±0.08
8.90 ± 0.24
8.17 ±0.42
276.4 ± 4.94
272.6 ± 8.30
2.86 ±0.13
2.94 ±0.27
15.9 ±0.36
16.2 ±0.67
39.3 ± 1.09
38.3 ± 1.61
0.31 ±0.01
0.29 ± 0.02
13.1 ±0.32
12.5 ±0.59
71.8 ± 1.67
70.4 ± 2.79
4.29 ±0.17
4.09 ±0.21
1.24 ±0.10
1.00 ±0.11
Venous vessel wall
(sets = 43)
0.17 ±0.01
0.17 ±0.01
0.11 ±0.00
0.12 ±0.00
4.30 ± 0.06
4.37 ± 0.08
0.16 ±0.00
0.17 ±0.01
2.12 ±0.03
2.04 ± 0.04
0.06 ± 0.00
0.07 ± 0.00
0.17 ±0.01
0.16 ±0.01
nd
nd
0.32 ± 0.01
0.30 ± 0.01
7.41 ±0.11
7.40 ±0.13
0.07 ± 0.00
0.08 ± 0.00
0.36 ±0.01
0.38 ±0.11
1.21 ±0.02
1.27 ±0.04
0.05 ± 0.00
0.05 ± 0.00
0.59 ± 0.02
0.58 ± 0.03
2.29 ± 0.04
2.38 ± 0.07
ad
nd
nd
nd
Arterial vessel wall
(sets = 43)
0.18 ±0.01
0.20 ±0.01 ^ ^ r - n i i
0.10 ±0.00
0.11 ± 0.00
3.76 ± 0.07
3.83 ±0.09 -vr-n.iiH:
0.14 ±0.00
0.14 ±0.00 <! ? £ » :
2.06 ± 0.04
2.05 ±0.05 ; * .
0.07 ± 0.00
0.07 ±0.00
0.22 ±0.01
0.22 ±0.01
nd
nd
0.40 ±0.01
0.40 ± 0.02
6.93 ±0.13
7.03 ±0.17
0.06 ± 0.00
0.07 ± 0.00
0.41 ±0.01
0.42 ±0.01
1.58 ±0.04
1.69 ±0.06
0.07 ± 0.00
0.08 ±0.00
0.64 ± 0.02
0.63 ± 0.03
2.78 ± 0.06
2.89 ± 0.09
nd
nd
nd
nd
Appendix C3 continued
Fatty acid Venous plasma
(sets = 44)
Venous vessel wall
(sets = 43)
Anehal vessel wall
(sets « 43)
2O:3(n-9)
22:3(n-9)
Kn-7Hl(n-9
l8:2(n-6)
2O:2(n-6)
20:3(n-6)
20:4(n-6)
22:4(n-6)
22:5(n-6)
24:2(n-6)
Kn-6)
20:5(n-3)
22:5(n-3)
22:6(n-3)
Kn-3)
3.71 ±0.16
2.93 ± 0.25
0.18 ±0.02
0.14 ±0.02
) 75.7 ±1.77
73.5 ± 2.96
45.3 ±1.23
45.0 ± 1.89
2.20 ± 0.06
1.95 ± 0.08
30.1 ±0.59
2.7»±.0,%
98.4 ±1.59
98.6 ±3.32
4.76 ±0.12
4.46 ± 0.20
4.94 ±0.17
4.44 ± 0.27
3.83 ±0.13
3.75 ±0.18
190.0 ±3.28
186.6 ±5.82
1.35 ±0.07
1.40±0.10
2.79 ±0.12
3.11 ±0.23
36.9 ±1.04
39.3 ±1.76
42.0 ± 1.19
44.8 ± 2.01
0.07 ± 0.00
0.07 ± 0.01
0.06 ± 0.00
0.06 ± 0.00
2.41 ±0.05
2.50 ± 0.08
0.32 ± 0.07
0.34 ±0.15
0.06 ± 0.00
0.06 ± 0.00
0.29 ±0.01
Q..17 tftflV
2.94 ± 0.06
2.87 ± 0.07
0.80 ± 0.02
0.79 ± 0.02
0.43 ± 0.01
0.43 ± 0.02
0.10 ±0.00
0.10 ±0.01
4.95 ± 0.09
4.87 ±0.11
nd
nd
nd
nd
0.82 ± 0.02
0.83 ± 0.03
0.82 ± 0.02
0.83 ± 0.03
0.44 ± 0.02
0.43 ± 0.02
0 21 ±0.01
0.21 ±0.01
3.43 ± 0.08
3.54 ±0.12
0.20 ± 0.06
0.20 ± 0.09
0.03 ± 0.00
0.03 ± 0.00
0.19 ±0.01
2.13 ±0.05
2.07 ± 0.07
0.45 ±0.01
0.45 ± 0.02
0.48 ±0.01
0.51 ±0.02
0.03 ± 0.00
0.03 ± 0.00
3.51 ±0.08
3.46 ±0.11
nd
nd
nd
nd
0.82 ± 0.02
0.84 ± 0.04
0.82 ± 0.02
0.84 ± 0.04
Appendix C4. The fatty acid composition (% of total fatty acids) of phospholipids isolated from
umbilical cord in normal pregnancy (NP) and pregnancy-induced hypertension (PIH) (mean ± s.e.m.).
Fatty acid
14:0 NP
PIH
15:0
16:0
17:0
18:0
20:0
22:0
23:0
24:0
ISAFA
I6:l(n-7)
l8:I(n-7)
18:l(n-9)
20:l(n-9)
24:l(n-9)
IMUFA
16:0 dm»
18:0 dim
Venous plasma
(sets = 44)
0.23 ± 0.01
0.22 ±0.01
0.10 ±0.01
0.11 ±0.01
27.7 ±0.15
27.9 ±0.21
nd
nd
14.2 ±0.11
14.2 ±0.17
0.84 ± 0.02
0.79 ± 0.03
1.48 ±0.03
1.36 ±0.05
0.20 ±0.01
0.21 ±0.01
1.49 ±0.03
1.38 ±0.06
46.3 ±0.14
46.2 ±0.21
0.48 ± 0.02
0.49 ± 0.04
2.66 ± 0.04
2.74 ± 0.07
6.59 ±0.13
6.55 ± 0.27
0.05 ± 0.00
0.05 ± 0.00
2.19 ±0.03
2.10 ±0.07
12.0 ±0.16
12.0 ±0.33
0.71 ±0.02
0.68 ± 0.03
0.20 ±0.01
0.17 ±0.02
Venous vessel wall
(sets =45)
1.09 ±0.04
1.11 ±0.05
0.73 ± 0.02
0.75 ± 0.02
27.7 ±0.17
28.1 ±0.22
1.06 ±0.02
1.07 ±0.03
13.6 ±0.10
13.1 ±0.14
0.41 ±0.01
0.44 ± 0.04
1.08 ±0.03
1.05 ± 0.03
nd
nd
2.04 ± 0.05
1.94 ±0.06
47.7 ±0.21
47.6 ± 0.29
0.46 ±0.01
0.52 ± 0.03
2.34 ± 0.03
2.44 ± 0.05
7.72 ± 0.08
8.09 ±0.15
0.30 ±0.01
0.31 ±0.02
3.75 ± 0.09
3.72 ±0.12
14.7 ±0.14
15.2 ±0.25
8.8
.
nd
nd
Arterial vessel wall
(sets = 45)
1.26 ±0.03
1.37 ±0.07 is- s) i)i
0.71 ±0.01
0.74 ±0.02 i^nsfAl
25.6 ±0.11
25.9 ±0.22 :.;•>, .•• ,.i
0.97 ± 0.02
0.95 ± 0.03
14.0 ±0.09
13.8 ±0.13
0.48 ± 0.02
0.50 ±0.03
1.46 ± 0.03
1.45 ±0.04 •-
nd
nd
2.70 ± 0.06
2.70 ± 0.08
47.2 ±0.17
47.4 ±0.33
0.43 ±0.01
0.47 ±0.03 '
2.81 ±0.04
2.83 ± 0.06
10.7 ±0.16
11.3 ±0.28
0.50 ±0.01
0.52 ± 0.02
4.33 ±0.10
4.21 ±0.13
18.9 ±0.22
19.4 ±0.38
8.8
.
nd
nd
Appendix C4 continued
Fatty acid
2O:3(n-9)
22:3(n-9)
I(n-7)+}>-9)
18:2(n-6)
20:2(n-6)
20:3(n-6)
20:4(n-6)
22:4(n-6)
22:5(n-6)
24:2(n-6)
I(n-6)
20:5(n-3)
22:5(n-3)
22:6(n-3)
ÏC-3)
Venous plasma
(sets = 44)
0.62 ± 0.03
0.50 ± 0.04
0.03 ± 0.00
0.02 ± 0.00
12.7 ±0.18
12.5 ±0.36
7.55 ±0.11
7.66 ±0.22
0.37 ±0.01
0.33 ±0.01
5.05 ± 0.07
4.74 ±0.13
16.5 ±0.13
16.7 ±0.18
0.80 ± 0.02
0.76 ± 0.03
0.82 ± 0.02
0.75 ± 0.04
0.64 ± 0.02
0.64 ± 0.03
31.8 ±0.16
31.7 ±0.28
0.23 ± 0.01
0.24 ± 0.02
0.47 ± 0.02
0.52 ± 0.03
6.18*0.14
6.65 ± 0.22
7.05 ±0.16
7.59 ±0.25
Venous vessel wall
(sels = 45)
0.43 ± 0.02
0.42 ± 0.03
0.35 ±0.01
0.36 ±0 03
15.4 ±0.16
16.0 ±0.29
2.04 ± 0.04
2.18 ±0.09
0.38 ±0.01
0.41 ±0.02
1.86 ±0.03
1.76 ±0.05
18.8 ±0.18
18.4 ±0.24
5.16 ±0.08
5.08 ±0.13
2.73 ± 0.06
2.75 ±0.10
0.62 ± 0.02
0.62 ± 0.03
31.6 ±0.23
31.2 ±0.28
nd
nd
nd
nd
5.24 ± 0.09
5.28 ±0.14
5.24 ± 0.09
5.28 ±0.14
Anerial vessel wall
(sets = 45)
3.00 ± 0 09
2.91 ±0.13
1.46 ± 0.04
1.40 ±0.07
23.3 ± 0.32
23.7 ± 0.53
1.37 ±0.04
1.33*0.06
0 20 ±0.01
0.19 ±0.01
1.30 ±0.02
1.23 ± 0.04
14.5 ±0.20
13.9 ±0.32
3.02 ± 0.06
3.01 ±0.10
3.25 ± 0.06
3.40 ±0.10
0.18 ±0.01
0.18 ±0.01
23.9 ± 0.30
23.3 ± 0.45
nd
nd
nd
nd
5.61 ±0.11
5.57 ±0.15
5.61 ±0.11
5.57 ±0.15
: >: S
I . - :
Appendix Dl. The fatty acid composition of umbilical plasma phospholipids (mg/L)*.
Fatty acid
14:0
15:0
16:0
18:0
20:0
22:0
23:0
24:0
ISAFA
16i l(n-7)
18: l(n-7)
18:l(n-9)
24:l(n-9)
IMUFA
16:Odma
l8:Odmu
20:3(n-9)
Kn-7Hl(n-9)
l8:2(n-6)
20:2(n-6)
20:3(n-6)
20:4(n-6)
22:4(n-6)
22:5(n-6)
24:2(n-6)
Kn-6)
2O:5(n-3)
22:5(n-3)
LL-control
(n=22)
1.35 ±0.15
0.43 ±0.10
169.9 ±8.11
87.8 ±4.56
5.11 ±0.27
8.54 ± 0.46
1.18±0.11
8.21 ±0.51
282.5 ± 13.3
2.91 ±0.31
14.7 ± 1.41
43.2 ± 3.68
11.6 ±0.61
72.8 ± 5.20
3.95 ± 0.42
1.60 ±0.25
4.00 ± 0.64
76.9 ± 3.29
43.8 ± 3.33
2.12±O.I3
28.8 ± 1.55
98.7 ± 5.83
4.66 ± 0.30
5.05 ± 0.42
3.44 ± 0.26
186.9 ±10.23
1.43 ±0.14
3.00 ± 0.24
LA supplemented
(n=21)
1.62 ±0.11 *~
0.66 ± 0.05
181.4 ±7.23
92.4 ±3.14
5.20 ± 0.30
9.23 ± 0.49
1.30 ±0.10
10.6 ± 1.63
302.4 ± 11.2
3.48 ± 0.27
17.6 ±0.85
42.8 ± 2.38
14.9 ± 0.95
79.8 ±4.01
5.32 ± 0.67
2.46 ± 1.01
3.51 ±0.28
83.7 ± 4.28
51.4 ±2.52
2.38 ±0.10
33.0 ±1.77
113.1 ±4.22
6.04 ±1.06
5.63 ± 0.36
4.46 ± 0.39
216.7 ± 7.69
1.53 ±0.26
2.63 ± 0.24
HL-control
(n=21)
1.04 ±0.17
0.41 ±0.07
163.7 ± 9.20
81.3 ±3.70
5.15 ±0.40 ,;,,
8.33 ± 0.62
1.21 ±0.14
8.12 ±0.43
269.2 ± 13.7
3.54 ± 0.47
16.4 ± 1.06
45.4 ± 5.79
13.0 ±0.85
78.8 ±7.83
4.24 ± 0.24
1.36 ±0.24
4.10 ±0.48
83.1 ±8.05
51.6 ±4.36
2.39 ±0.18
30.3 ± 1.98
94.3 ± 4.68
4.38 ±0.19
4.95 ± 0.34
4.49 ± 0.43
192.9 ± 10.8
1.03 ±0.10
2.04 ±0.12
fu
Appendix Dl continued
Fatty acid LL-control LA supplemented HL-control
(n=22) (n=21)
22:6(n-3) 41.2 ±3.19 38.2 ±2.31 30.3 ±1.49 '
I(n-3) 46.7 ±3.42 43.1 ±2.66 34.2 ±1.58 *i
V: LL-control = control group, low in linoleic acid: LA supplemented « linoleic acid supplemented
group; HL-control = control group, high in linoleic acid.
' " { , ï - - • • ' . . . • • - : • • • : • • * . . < * * >
Appendix D2. Fatty acid composition (% of total fatty acids) of umbilical plasma PLs*.
Fatty acid
14:0
15:0
16:0
18:0
20:0
22:0
23:0
24:0
ISAFA
16: l(n-7)
18:l(n-7)
18:l(n-9)
24:l(n-9)
IMUFA
16:0 dma
l8:0dma
20:3(n-9)
I(n-7Hl(n-9)
18:2(n-6)
20:2(n-6)
20:3(n-6)
20:4(n-6)
22:4(n-6)
22:5(n-6)
24:2(n-6)
Kn-6)
2O:5(n-3)
22:5(n-3)
LL-control
(n=22)
0.22 ± 0.02
0.07 ± 0.02
28.1 ±0.34
14.5 ± 0.34
0.86 ± 0.04
1.43 ±0.06
0.19 ±0.02
1.37 ±0.07
46.8 ± 0.54
0.49 ± 0.05
2.38 ±0.18
7.06 ± 0.39
1.93 ±0.07
11.9 ±0.50
0.64 ± 0.05
0.26 ± 0.04
0.69 ±0.12
12.6 ±0.54
7.15 ±0.34
0.35 ± 0.02
4.83 ± 0.20
16.2 ± 0.32
0.76 ± 0.02
0.83 ± 0.05
0.58 ± 0.04
30.8 ± 0.46
0.24 ± 0.02
0.50 ± 0.04
LA supplemented
(n=21)
0.24 ± 0.01
0.10 ±0.01
27.4 ± 0.24
14.1 ±0.28 ' * ^ "
0.79 ± 0.04
1.40 ± 0.05
0.20 ±0.01
1.55 ±0.17
45.8 ±0.22
0.52 ± 0.03
2.67 ± 0.07
6.42 ±0.17
2.24 ± 0.08
12.0 ±0.25
0.79 ± 0.07
0.34 ±0.12
0.52 ± 0.03
12.6 ±0.28
7.80 ± 0.25
0.36 ±0.01
5.05 ± 0.25
17.2 ±0.30
0.89 ±0.11
0.86 ± 0.05
0.67 ± 0.05
32.9 ± 0.44
0.23 ± 0.03
0.40 ± 0.03
HL-control
(n=21)
0.17 ±0.02
0.07 ±0.01
27.6 ±0.41
13.9 ±0.28
0.86 ± 0.04
1.41 ±0.08
0.20 ± 0.02
1.40 ±0.07
45.6 ±0.42
0.57 ± 0.05
2.76 ± 0.08
7.38 ±0.50
2.19 ±0.07
13.0 ±0.56
0.74 ± 0.04
0.23 ± 0.03
0.68 ± 0.07
13.7 ±0.57
8.53 ± 0.29
0.40 ± 0.02
5.12 ±0.19
16.1 ±0.41
0.76 ± 0.04
0.85 ± 0.05
0.75 ± 0.04
32.5*0.32
0.18 ±0.02
0.36 ± 0.03
Appendix D2 continued
Fatty acid
22:6(n-3)
Kn-3)
V: see appendix Dl.
LL-control
(n=22)
6.77 ± 0.33
7.68 ± 0.36
LA supplemented
(n=21)
5.80 ± 0.26
6.53 ± 0.29
HL-control
(n=2I)
5.27 ±0.28
5.95 ±0.31
Appendix D3. Fatty acid composition (mg/g dry tissue) of umbilical venous vessel wall PLs*.
Fatty acid
14:0
15:0
16:0
17:0
18:0
20:0
22:0
24:0
ISAFA
16:l(n-7)
!8:l(n-7)
!8:l(n-9)
20:l(n-9)
24:l(n-9)
IMUFA
20:3(n-9)
22:3(n-9)
Kn-7Hl(n-9)
l8:2(n-6)
20:2(n-6)
20:3(n-6)
20:4(n-6)
22:4(n-6)
22:5(n-6)
24:2(n-6)
Kn-6)
22:6(n-3)
LL-control
(n=21)
0.15 ±0.01
0.10 ±0.01
4.47 ± 0.23
0.17 ±0.01
2.25 ± 0.09
0.07 ± 0.00
0.22 ± 0.01
0.39 ± 0.02
7.82 ± 0.36
0.08 ± 0.00
0.38 ± 0.02
1.29 ±0.09
0.05 ± 0.00
0.74 ± 0.06
2.56 ±0.17
0.09 ± 0.02
0.08 ±0.01
2.73 ± 0.20
0.31 ±0.02
0.06 ± 0.00
0.30 ± 0.02
3.23 ±0.14
0.92 ± 0.04
0.49 ± 0.04
0.10 ±0.01
5.43 ±0.21
1.06 ±0.05
LA supplemented
(n=21)
0.14 ±0.01
0.11 ±0.01
4.28 ±0.12 """•
0.16 ±0.01
2.29 ± 0.07
0.07 ± 0.00
0.21 ±0.01
0.38 ± 0.02
7.64 ± 0.23
0.08 ± 0.00
0.37 ±0.01
1.23 ±0.05
0.04 ± 0.00
0.69 ± 0.04
2.42 ± 0.09
0.07 ±0.01
0.06 ±0.01
2.56 ±0.10
0.33 ± 0.02
0.07 ± 0.00
0.35 ± 0.02
3.33 ± 0.08
0.96 ± 0.04
0.52 ± 0.02
0.12 ±0.01
5.68 ±0.14
0.94 ± 0.04
HL-control
(n=18)
0.20 ± 0.02
0.12 ±0.01
4.21 ±0.17
0.18 ±0.01
1.98 ±0.08
0.06 ± 0.01
0.15 ±0.01
0.28 ± 0.03
7.19 ±0.30
0.07 ± 0.00
0.39 ± 0.02
1.20 ±0.06
0.05 ±0.01
0.56 ± 0.04
2.28 ±0.11
0.06 ± 0.01
0.05 ± 0.01
2.38 ±0.12
0.35 ±0.02
0.07 ± 0.01
0.29 ± 0.02
2.72 ±0.12
0.80 ± 0.04
0.44 ± 0.03
0.10 ±0.01
4.78 ± 0.20
0.69 ± 0.05
.,:-)»* ¥
V: see appendix Dl.
Appendix D4. Fatty acid composition (mg/g dry tissue) of umbilical arterial vessel wall PLs".
Fany acid
M*
15.0
16.O
17:0
18.O
20K)
22.-0
24:0
ISAFA
16:l(n-7)
18:l(n-7)
18:l(n-9)
20:l(n-9)
24:l(n-9)
IMUFA
2O:3(n-9)
22:3(n-9)
I(n-7HKn-9)
18:2(n-6)
20:2(n-6)
20:3(n-6)
20:4(n-6)
22:4(n-6)
22:5(n-6)
24:2(n-6)
X(n-6)
22:6(n-3)
LL<ontrol
(n=21)
0.17 ±0.01
0.10 ±0.01
4.03 ± 0.25
0.16 ±0.01
4* 2.31 ±0.15
0.08 ±0.01
0.28 ± 0.02
0.51 ±0.04
7.64 ± 0.47
0.07 ± 0.00
0.43 ± 0.03
1.67 ±0.14
0.08 ±0.01
0.80 ± 0.07
3.06 ± 0.24
0.44 ± 0.05
0.22 ± 0.02
3.72 ± 0.30
0.20 ± 0.01
0.03 ± 0.00
0.21 ±0.02
2.44 ±0.17
0.54 ± 0.04
0.55 ± 0.04
0.03 ± 0.00
4.01 ± 0.25
1.01 ±0.08
LA supplemented
(n=21)
0.16 ±0.01
0.10 ±0.01
3.99 ±0.10
0.16 ±0.01
2.32 ± 0.04
0.08 ± 0.00
0.29 ±0.01
0.52 ± 0.03
7.61 ±0.17
0.07 ± 0.00
0.44 ± 0.01
1.62 ±0.07
0.07 ± 0.00
0.82 ± 0.04
3.04 ±0.12
0.48 ± 0.04
0.26 ± 0.02
3.78 ±0.15
0.21 ±0.01
0.03 ± 0.00
0.23 ±0.01
2.56 ± 0.09
0.59 ± 0.03
0.58 ± 0.02
0.04 ± 0.00
4.24 ±0.12
0.95 ± 0.04
HL-control
(n-18)
0.21 ±0.02
Oi l ±0.00
3.70 ±0.16
0.16 ±0.01
1.98 ±0.10
0.07 ± 0.00
0.20 ± 0.02
0.37 ± 0.03
6.79 ± 0.32
0.07 ± 0.00
0.44 ± 0.02
1.63 ± 0.09
0.08 ±0.01
0.61 ±0.05
2.84 ±0.16
0.42 ± 0.03
0.21 ±0.02
3.47 ± 0.20
0.24 ± 0.02
0.04 ± 0.00
0.20 ± 0.02
2.10±0.12
0.46 ± 0.04
0.51 ±0.03
0.03 ± 0.00
3.59 ± 0.20
0.73 ± 0.06
V: see appendix 0 1 .
Appendix DS. Fatty acid composition (% of total fatty acids) of umbilical venous vessel wall PLs*.
Fatty acid
14:0
15:0
16:0
17:0
18:0
20:0
22:0
24:0
ISAFA
16:.(n-7)
!8:l(n-7)
l8:l(n-9)
2O:l(n-9)
24:l(n-9)
IMUFA
20:3(n-9)
22:3(n-9)
I(n-7HKn-9)
l8:2(n-6)
20:2(n-6)
2O:3(n-6)
20:4(n-6)
22:4(n-6)
22:5(n-6)
24:2(n-6)
Kn-6)
22:6(n-3)
LL-control
(n=22)
0.87 ± 0.04
0.59 ± 0.02
26.1 ±0.27
0.99 ± 0.04
13.3 ±0.12
0.44 ±0.01
1.31 ±0.04
2.34 ± 0.08
45.9 ± 0.24
0.46 ± 0.02
2.23 ±0.06
7.46 ±0.18
0.30 ± 0.02
4.28 ±0.13
14.8 ±0.36
0.50 ± 0.07
0.43 ± 0.05
15.8 ±0.46
1.80 ±0.10
0.37 ± 0.03
1.76 ±0.06
19.0 ±0.35
5.48 ± 0.20
2.85 ±0.14
0.64 ± 0.03
32.0 ± 0.44
6.26 ±0.16
LA supplemented
(n=21)
0.80 ± 0.04
0.64 ± 0.04
25.4 ± 0.23
0.97 ± 0.03
13.6*0.18
0.44 ± 0.02
1.27 ±0.04
2.22 ±0.11
45.4 ± 0.23
0.45 ±0.01
2.21 ±0.04
7.30 ±0.18
0.24 ± 0.02
4.07 ±0.16
14.4 ± 0.27
0.41 ±0.04
0.38 ± 0.03
15.1 ±0.30
1.96 ±0.08
0.39 ± 0.02
2.09 ± 0.09
19.9 ± 0.23
5.71 ±0.21
3.08 ±0.13
0.74 ± 0.04
33.9 ± 0.33
5.59 ±0.15
HL-control
(n=21)
1.38±0.12
0.83 ± 0.06
28.0 ± 0.26
1.17 ±0.04
13.3 ±0.16
0.41 ±0.02
1.01 ±0.06
1.90±0.11
47.9 ± 0.37
0.47 ± 0.02
2.55 ± 0.07
7.89 ±0.16
0.31 ±0.03
3.67 ±0.18
15.0 ±0.29
0.39 ± 0.04
0.32 ± 0.03
15.7 ±0.31
2.26 ±0.12
0.46 ± 0.03
1.89 ±0.06
18.1 ±0.35
5.36 ±0.19
2.97 ±0.15
0.64 ± 0.05
31.8 ±0.44
4.63 ± 0.20
;; t-l
{ j r l <
• ' ; • - ' !
V: see appendix Dl.
Appendix D6. Fatty acid composition (% of total fatty acids) of umbilical anerial vessel wall PLs*.
Fatty acid
14:0
ISA
16.-0
17A
ISA
20A
22A
24:0
ISAFA
16:l(n-7)
18:l(n-7)
l8:l(n-9)
20:l(n-9)
24:l(n-9)
IMUFA
20:3(n-9)
22:3(n-9)
I(n-7Hl(n-9)
18:2(n-6)
20:2(n-6)
20:3(n-6)
20:4{n-6)
22:4{n-6)
22:5(n-6)
24:2(n-6)
Kn-6)
22:6(n-3)
LL-control
(n=22)
1.04 ±0.05
0.61 ±0.02
24.6 ± 0.34
0.96 ± 0.03
14.1 ±0.18
0.49 ±0.01
1.67 ± 0.05
3.10 ±0.10
46.5 ± 0.34
0.44 ± 0.02
2.58 ± 0.09
9 % ± 0.42
0.44 ± 0.03
4.81 ±0.15
18.3 ±0.59
2.66 ± 0.24
1.37 ±0.09
22.4 ± 0.87
1.22 ±0.06
0.17 ±0.02
1.27 ±0.05
15.1 ±0.51
3.36 ±0.16
3.28 ±0.13
0.21 ±0.02
24.6 ± 0.66
6.48 ± 0.25
LA supplemented
(n=21)
0.94 ± 0.03
0.62 ± 0.03
24.0 ± 0.23
0.91 ±0.02
14.0 ±0.12
0.50 ± 0.02
1.72 ±0.05
3.10 ±0.12
45.9 ± 0.25
0.41 ±0.01
2.64 ± 0.06
9.75 ± 0.30
0.45 ± 0.03
4.90 ±0.18
18.3 ±0.46
2.94 ± 0.23
1.59 * 0.12
22.8 ± 0.75
1.27 ±0.04
0.18 ±0.01
1.41 ±0.06
15.4 ±0.44
3.57 ±0.16
3.49 ±0.13
0.24 ± 0.02
25.6 ± 0.58
5.74 ±0.16
HL-control
(n=21)
1.52 ±0.11
0.79 ± 0.06
25.7 ± 0.29
1.07 ±0.04
13.6 ±0.17
0.48 ± 0.02
1.36 ±0.07
2.52 ±0.12
47.0 ±0.40
0.45 ± 0.02
3.00 ± 0.08
11.0 ±0.37
0.55 ± 0.06
4.21 ±0.17
19.3 ± 0.50
2.87 ±0.18
1.44 ±0.10
23.7 ± 0.70
1.60* 0.11
0.27 ± 0.03
1.34 ± 0.05
14.3 ± 0.43
3.10*0.12
3.50 ±0.12
0.20 ± 0.02
24.7 ± 0.63
4.99 ± 0.22
V: see appendix Dl.

